The	O
cellular	B-DNA
oncogene	I-DNA
c-myb	B-DNA
can	O
interact	O
synergistically	O
with	O
the	O
Epstein-Barr	B-protein
virus	I-protein
BZLF1	I-protein
transactivator	I-protein
in	O
lymphoid	B-cell_type
cells	I-cell_type
.	O

Regulation	O
of	O
replicative	O
functions	O
in	O
the	O
Epstein-Barr	B-DNA
virus	I-DNA
(	I-DNA
EBV	I-DNA
)	I-DNA
genome	I-DNA
is	O
mediated	O
through	O
activation	O
of	O
a	O
virally	B-protein
encoded	I-protein
transcription	I-protein
factor	I-protein
,	O
Z	B-protein
(	O
BZLF1	B-protein
)	O
.	O

We	O
have	O
shown	O
that	O
the	O
Z	B-protein
gene	I-protein
product	I-protein
,	O
which	O
binds	O
to	O
AP-1	B-DNA
sites	I-DNA
as	O
a	O
homodimer	O
and	O
has	O
sequence	O
similarity	O
to	O
c-Fos	B-DNA
,	O
can	O
efficiently	O
activate	O
the	O
EBV	B-DNA
early	I-DNA
promoter	I-DNA
,	O
BMRF1	B-DNA
,	O
in	O
certain	O
cell	O
types	O
(	O
i.e.	O
,	O
HeLa	B-cell_line
cells	I-cell_line
)	O
but	O
not	O
others	O
(	O
i.e.	O
,	O
Jurkat	B-cell_line
cells	I-cell_line
)	O
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
c-myb	B-protein
proto-oncogene	I-protein
product	I-protein
,	O
which	O
is	O
itself	O
a	O
DNA-binding	B-protein
protein	I-protein
and	O
transcriptional	B-protein
transactivator	I-protein
,	O
can	O
interact	O
synergistically	O
with	O
Z	B-protein
in	O
activating	O
the	O
BMRF1	B-DNA
promoter	I-DNA
in	O
Jurkat	B-cell_line
cells	I-cell_line
(	O
a	O
T-cell	B-cell_line
line	I-cell_line
)	O
or	O
Raji	B-cell_line
cells	I-cell_line
(	O
an	O
EBV-positive	B-cell_line
B-cell	I-cell_line
)	O
,	O
whereas	O
the	O
c-myb	B-protein
gene	I-protein
product	I-protein
by	O
itself	O
has	O
little	O
effect	O
.	O

The	O
simian	B-DNA
virus	I-DNA
40	I-DNA
early	I-DNA
promoter	I-DNA
is	O
also	O
synergistically	O
activated	O
by	O
the	O
Z/c-myb	B-protein
combination	I-protein
.	O

Synergistic	O
transactivation	O
of	O
the	O
BMRF1	B-DNA
promoter	I-DNA
by	O
the	O
Z/c-myb	B-protein
combination	I-protein
appears	O
to	O
involve	O
direct	O
binding	O
by	O
the	O
Z	B-protein
protein	I-protein
but	O
not	O
the	O
c-myb	B-protein
protein	I-protein
.	O

A	O
30-bp	B-DNA
sequence	I-DNA
in	O
the	O
BMRF1	B-DNA
promoter	I-DNA
which	O
contains	O
a	O
Z	B-DNA
binding	I-DNA
site	I-DNA
(	O
a	O
consensus	B-DNA
AP-1	I-DNA
site	I-DNA
)	O
is	O
sufficient	O
to	O
transfer	O
high-level	O
lymphoid-specific	O
responsiveness	O
to	O
the	O
Z/c-myb	B-protein
combination	I-protein
to	O
a	O
heterologous	B-DNA
promoter	I-DNA
.	O

That	O
the	O
c-myb	B-protein
oncogene	I-protein
product	I-protein
can	O
interact	O
synergistically	O
with	O
an	O
EBV-encoded	B-protein
member	I-protein
of	O
the	O
leucine	B-protein
zipper	I-protein
protein	I-protein
family	I-protein
suggests	O
c-myb	B-DNA
is	O
likely	O
to	O
engage	O
in	O
similar	O
interactions	O
with	O
cellularly	B-protein
encoded	I-protein
transcription	I-protein
factors	I-protein
.	O

MoLECULAR	NULL
anp	NULL
CELLULAR	NULL
BioLOGY	NULL
,	NULL
Jan.	NULL
1992	NULL
,	NULL
p.	NULL
136-146	NULL
0270-7	NULL
Vol	NULL
.	NULL

12	NULL
,	NULL
No	NULL
.	NULL

1	NULL
The	NULL
Cellular	NULL
Oncogene	NULL
c-myb	NULL
Can	NULL
Interact	NULL
Synergistically	NULL
with	NULL
the	NULL
Epstein-Barr	NULL
Virus	NULL
BZLF1	NULL
Transactivator	NULL
in	NULL
Lymphoid	NULL
Cells	NULL
SHANNON	NULL
C.	NULL
KENNEY	NULL
,	NULL
**	NULL
ELIZABETH	NULL
HOLLEY-GUTHRIE	NULL
,	NULL
'	NULL
E.	NULL
BYRD	NULL
QUINLIVAN	NULL
,	NULL
'	NULL
DAVID	NULL
GUTSCH	NULL
,	NULL
``	NULL
QIN	NULL
ZHANG	NULL
,	NULL
*	NULL
TIM	NULL
BENDER	NULL
,	NULL
``	NULL
JEAN-FRANCOIS	NULL
GIOT	NULL
,	NULL
``	NULL
anp	NULL
ALAIN	NULL
SERGEANT	NULL
Department	NULL
of	NULL
Medicine	NULL
and	NULL
Lineberger	NULL
Comprehensive	NULL
Cancer	NULL
Research	NULL
Center	NULL
,	NULL
University	NULL
of	NULL
North	NULL
Carolina	NULL
at	NULL
Chapel	NULL
Hill	NULL
,	NULL
Chapel	NULL
Hill	NULL
,	NULL
North	NULL
Carolina	NULL
27599	NULL
``	NULL
;	NULL
University	NULL
of	NULL
Virginia	NULL
,	NULL
Charlottesville	NULL
,	NULL
Virginia	NULL
22903	NULL
and	NULL
Laboratoire	NULL
de	NULL
Virologie	NULL
Moleculaire	NULL
,	NULL
Ecole	NULL
Normale	NULL
Superieure	NULL
de	NULL
Lyon	NULL
,	NULL
Lyon	NULL
,	NULL
France	NULL
Received	NULL
3	NULL
May	NULL
1991/Accepted	NULL
4	NULL
October	NULL
1991	NULL
Regulation	NULL
of	NULL
replicative	NULL
functions	NULL
in	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
genome	NULL
is	NULL
mediated	NULL
through	NULL
activation	NULL
of	NULL
a	NULL
virally	NULL
encoded	NULL
transcription	NULL
factor	NULL
,	NULL
Z	NULL
(	NULL
BZLF1	NULL
)	NULL
.	NULL

We	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
Z	NULL
gene	NULL
product	NULL
,	NULL
which	NULL
binds	NULL
to	NULL
AP-1	NULL
sites	NULL
as	NULL
a	NULL
homodimer	NULL
and	NULL
has	NULL
sequence	NULL
similarity	NULL
to	NULL
c-Fos	NULL
,	NULL
can	NULL
efficiently	NULL
activate	NULL
the	NULL
EBV	NULL
early	NULL
promoter	NULL
,	NULL
BMRF1	NULL
,	NULL
in	NULL
certain	NULL
cell	NULL
types	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
HeLa	NULL
cells	NULL
)	NULL
but	NULL
not	NULL
others	NULL
(	NULL
i.e	NULL
.	NULL

,	NULL
Jurkat	NULL
cells	NULL
)	NULL
.	NULL

Here	NULL
we	NULL
demonstrate	NULL
that	NULL
the	NULL
c-myb	NULL
proto-oncogene	NULL
product	NULL
,	NULL
which	NULL
is	NULL
itself	NULL
a	NULL
DNA-binding	NULL
protein	NULL
and	NULL
transcriptional	NULL
transactivator	NULL
,	NULL
can	NULL
interact	NULL
synergistically	NULL
with	NULL
Z	NULL
in	NULL
activating	NULL
the	NULL
BMRF1	NULL
promoter	NULL
in	NULL
Jurkat	NULL
cells	NULL
(	NULL
a	NULL
T-cell	NULL
line	NULL
)	NULL
or	NULL
Raji	NULL
cells	NULL
(	NULL
an	NULL
EBV-positive	NULL
B-cell	NULL
)	NULL
,	NULL
whereas	NULL
the	NULL
c-myb	NULL
gene	NULL
product	NULL
by	NULL
itself	NULL
has	NULL
little	NULL
effect	NULL
.	NULL

The	NULL
simian	NULL
virus	NULL
40	NULL
early	NULL
promoter	NULL
is	NULL
also	NULL
synergistically	NULL
activated	NULL
by	NULL
the	NULL
Z/c-myb	NULL
combination	NULL
.	NULL

Synergistic	NULL
transactivation	NULL
of	NULL
the	NULL
BMRF1	NULL
promoter	NULL
by	NULL
the	NULL
Z/c-myb	NULL
combination	NULL
appears	NULL
to	NULL
involve	NULL
direct	NULL
binding	NULL
by	NULL
the	NULL
Z	NULL
protein	NULL
but	NULL
not	NULL
the	NULL
c-myb	NULL
protein	NULL
.	NULL

A	NULL
30-bp	NULL
sequence	NULL
in	NULL
the	NULL
BMRF1	NULL
promoter	NULL
which	NULL
contains	NULL
a	NULL
Z	NULL
binding	NULL
site	NULL
(	NULL
a	NULL
consensus	NULL
AP-1	NULL
site	NULL
)	NULL
is	NULL
sufficient	NULL
to	NULL
transfer	NULL
high-level	NULL
lymphoid-specific	NULL
responsiveness	NULL
to	NULL
the	NULL
Z/c-myb	NULL
combination	NULL
to	NULL
a	NULL
heterologous	NULL
promoter	NULL
.	NULL

That	NULL
the	NULL
c-myb	NULL
oncogene	NULL
product	NULL
can	NULL
interact	NULL
synergistically	NULL
with	NULL
an	NULL
EBV-encoded	NULL
member	NULL
of	NULL
the	NULL
leucine	NULL
zipper	NULL
protein	NULL
family	NULL
suggests	NULL
c-myb	NULL
is	NULL
likely	NULL
to	NULL
engage	NULL
in	NULL
similar	NULL
interactions	NULL
with	NULL
cellularly	NULL
encoded	NULL
transcription	NULL
factors	NULL
.	NULL

The	NULL
discovery	NULL
that	NULL
expression	NULL
of	NULL
a	NULL
single	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
immediate-early	NULL
(	NULL
IE	NULL
)	NULL
gene	NULL
product	NULL
,	NULL
BZLF1	NULL
(	NULL
Z	NULL
)	NULL
,	NULL
is	NULL
sufficient	NULL
to	NULL
trigger	NULL
the	NULL
disruption	NULL
of	NULL
viral	NULL
latency	NULL
(	NULL
6	NULL
,	NULL
7	NULL
,	NULL
44	NULL
,	NULL
48	NULL
)	NULL
has	NULL
stimulated	NULL
a	NULL
search	NULL
for	NULL
the	NULL
key	NULL
cellular	NULL
and	NULL
viral	NULL
elements	NULL
needed	NULL
to	NULL
activate	NULL
EBV	NULL
replication	NULL
.	NULL

It	NULL
is	NULL
now	NULL
clear	NULL
that	NULL
the	NULL
Z	NULL
gene	NULL
product	NULL
has	NULL
significant	NULL
sequence	NULL
similarity	NULL
to	NULL
the	NULL
DNA	NULL
binding	NULL
domain	NULL
of	NULL
c-Fos	NULL
(	NULL
11	NULL
)	NULL
.	NULL

The	NULL
Z	NULL
protein	NULL
,	NULL
like	NULL
c-Fos	NULL
,	NULL
can	NULL
bind	NULL
to	NULL
the	NULL
AP-1	NULL
site	NULL
,	NULL
but	NULL
in	NULL
contrast	NULL
to	NULL
c-Fos	NULL
,	NULL
Z	NULL
binds	NULL
as	NULL
a	NULL
homodimer	NULL
and	NULL
can	NULL
also	NULL
bind	NULL
to	NULL
additional	NULL
non-AP-1	NULL
sites	NULL
referred	NULL
to	NULL
as	NULL
Z	NULL
response	NULL
elements	NULL
(	NULL
ZREs	NULL
)	NULL
(	NULL
4	NULL
,	NULL
11	NULL
,	NULL
13	NULL
,	NULL
29	NULL
,	NULL
35	NULL
,	NULL
43	NULL
,	NULL
45	NULL
,	NULL
50	NULL
,	NULL
55	NULL
)	NULL
.	NULL

To	NULL
date	NULL
,	NULL
transcriptional	NULL
activation	NULL
of	NULL
early	NULL
EBV	NULL
promoters	NULL
by	NULL
Z	NULL
has	NULL
been	NULL
associated	NULL
with	NULL
the	NULL
presence	NULL
of	NULL
Z	NULL
binding	NULL
sites	NULL
in	NULL
upstream	NULL
promoter	NULL
elements	NULL
.	NULL

However	NULL
,	NULL
we	NULL
recently	NULL
reported	NULL
that	NULL
the	NULL
EBV	NULL
early	NULL
BMRF1	NULL
promoter	NULL
,	NULL
which	NULL
contains	NULL
a	NULL
consensus	NULL
AP-1	NULL
binding	NULL
site	NULL
,	NULL
is	NULL
transactivated	NULL
efficiently	NULL
by	NULL
Z	NULL
in	NULL
certain	NULL
epithelial	NULL
cell	NULL
lines	NULL
(	NULL
including	NULL
HeLa	NULL
and	NULL
HEp-2	NULL
cells	NULL
)	NULL
but	NULL
not	NULL
in	NULL
several	NULL
lymphoid	NULL
cell	NULL
lines	NULL
(	NULL
including	NULL
the	NULL
Jurkat	NULL
T-cell	NULL
line	NULL
and	NULL
the	NULL
EBV-negative	NULL
B-cell	NULL
line	NULL
Louckes	NULL
)	NULL
(	NULL
21	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
it	NULL
seems	NULL
likely	NULL
that	NULL
cellular	NULL
factors	NULL
,	NULL
as	NULL
well	NULL
as	NULL
Z	NULL
itself	NULL
,	NULL
are	NULL
required	NULL
for	NULL
efficient	NULL
transactivation	NULL
of	NULL
Z-responsive	NULL
promoters	NULL
.	NULL

Here	NULL
we	NULL
report	NULL
the	NULL
first	NULL
evidence	NULL
that	NULL
the	NULL
cellular	NULL
c-myb	NULL
oncogene	NULL
can	NULL
interact	NULL
synergistically	NULL
with	NULL
the	NULL
Z	NULL
transactivator	NULL
in	NULL
lymphoid	NULL
cells	NULL
.	NULL

The	NULL
c-myb	NULL
gene	NULL
is	NULL
the	NULL
cellular	NULL
homolog	NULL
of	NULL
the	NULL
v-myb	NULL
oncogene	NULL
and	NULL
encodes	NULL
a	NULL
75-kDa	NULL
nuclear	NULL
protein	NULL
(	NULL
reviewed	NULL
in	NULL
reference	NULL
38	NULL
)	NULL
.	NULL

The	NULL
v-myb	NULL
oncogene	NULL
is	NULL
carried	NULL
by	NULL
the	NULL
avian	NULL
myeloblastosis	NULL
virus	NULL
and	NULL
transforms	NULL
myeloid	NULL
,	NULL
but	NULL
not	NULL
fibroblast	NULL
,	NULL
cells	NULL
(	NULL
25	NULL
)	NULL
.	NULL

Although	NULL
c-myb	NULL
is	NULL
predominantly	NULL
expressed	NULL
in	NULL
immature	NULL
hematopoietic	NULL
cells	NULL
,	NULL
it	NULL
is	NULL
expressed	NULL
at	NULL
lesser	NULL
levels	NULL
in	NULL
other	NULL
cell	NULL
types	NULL
(	NULL
1	NULL
,	NULL
37	NULL
,	NULL
42	NULL
,	NULL
51	NULL
,	NULL
52	NULL
)	NULL
.	NULL

It	NULL
has	NULL
been	NULL
recently	NULL
shown	NULL
that	NULL
the	NULL
c-myb	NULL
protein	NULL
binds	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

136	NULL
specifically	NULL
to	NULL
the	NULL
nucleotide	NULL
sequence	NULL
pyAACG/TG	NULL
and	NULL
can	NULL
activate	NULL
promoters	NULL
carrying	NULL
multiple	NULL
copies	NULL
of	NULL
this	NULL
sequence	NULL
(	NULL
2	NULL
,	NULL
14	NULL
,	NULL
22	NULL
,	NULL
24	NULL
,	NULL
28	NULL
,	NULL
41	NULL
,	NULL
59	NULL
)	NULL
.	NULL

However	NULL
,	NULL
there	NULL
is	NULL
some	NULL
evidence	NULL
to	NULL
suggest	NULL
that	NULL
transcriptional	NULL
activation	NULL
by	NULL
c-myb	NULL
may	NULL
require	NULL
interaction	NULL
with	NULL
other	NULL
transcriptional	NULL
activators	NULL
.	NULL

Ibanez	NULL
and	NULL
Lipsick	NULL
(	NULL
24	NULL
)	NULL
have	NULL
reported	NULL
that	NULL
v-Myb	NULL
binding	NULL
is	NULL
required	NULL
,	NULL
but	NULL
apparently	NULL
not	NULL
sufficient	NULL
,	NULL
for	NULL
activation	NULL
of	NULL
target	NULL
promoters	NULL
containing	NULL
several	NULL
copies	NULL
of	NULL
the	NULL
consensus	NULL
Myb	NULL
binding	NULL
site	NULL
.	NULL

Furthermore	NULL
,	NULL
v-myb-induced	NULL
transactivation	NULL
of	NULL
certain	NULL
promoters	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
occur	NULL
through	NULL
a	NULL
nonbinding	NULL
mechanism	NULL
(	NULL
27	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
the	NULL
c-myb	NULL
protein	NULL
,	NULL
cDNA	NULL
clones	NULL
of	NULL
two	NULL
closely	NULL
related	NULL
proteins	NULL
,	NULL
A-Myb	NULL
and	NULL
B-Myb	NULL
,	NULL
have	NULL
been	NULL
isolated	NULL
(	NULL
42	NULL
)	NULL
.	NULL

The	NULL
A-myb	NULL
and	NULL
B-myb	NULL
proteins	NULL
,	NULL
which	NULL
are	NULL
expressed	NULL
at	NULL
high	NULL
level	NULL
in	NULL
a	NULL
wider	NULL
variety	NULL
of	NULL
tissues	NULL
than	NULL
is	NULL
c-Myb	NULL
,	NULL
have	NULL
DNA	NULL
binding	NULL
domains	NULL
very	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
c-Myb	NULL
(	NULL
42	NULL
)	NULL
.	NULL

It	NULL
has	NULL
recently	NULL
been	NULL
confirmed	NULL
that	NULL
the	NULL
B-myb	NULL
protein	NULL
,	NULL
like	NULL
c-Myb	NULL
,	NULL
can	NULL
bind	NULL
to	NULL
the	NULL
consensus	NULL
c-myb	NULL
binding	NULL
site	NULL
and	NULL
function	NULL
as	NULL
a	NULL
transcriptional	NULL
activator	NULL
(	NULL
39	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
there	NULL
are	NULL
several	NULL
different	NULL
splicing	NULL
variants	NULL
of	NULL
c-Myb	NULL
,	NULL
some	NULL
of	NULL
which	NULL
affect	NULL
the	NULL
regulatory	NULL
sequences	NULL
of	NULL
the	NULL
protein	NULL
(	NULL
47	NULL
,	NULL
57	NULL
,	NULL
58	NULL
)	NULL
.	NULL

Transcriptional	NULL
regulation	NULL
of	NULL
promoters	NULL
containing	NULL
Myb	NULL
binding	NULL
sites	NULL
is	NULL
therefore	NULL
likely	NULL
to	NULL
be	NULL
cell	NULL
type	NULL
specific	NULL
,	NULL
depending	NULL
on	NULL
the	NULL
relative	NULL
proportions	NULL
of	NULL
the	NULL
different	NULL
myb	NULL
proteins	NULL
in	NULL
each	NULL
cell	NULL
type	NULL
.	NULL

Here	NULL
we	NULL
show	NULL
that	NULL
the	NULL
EBV	NULL
early	NULL
BMRF1	NULL
promoter	NULL
can	NULL
be	NULL
activated	NULL
synergistically	NULL
by	NULL
the	NULL
combination	NULL
of	NULL
Z	NULL
and	NULL
c-myb	NULL
in	NULL
Jurkat	NULL
cells	NULL
(	NULL
a	NULL
T-cell	NULL
line	NULL
)	NULL
or	NULL
Raji	NULL
cells	NULL
(	NULL
an	NULL
EBV-positive	NULL
B-cell	NULL
line	NULL
)	NULL
,	NULL
whereas	NULL
Z	NULL
by	NULL
itself	NULL
efficiently	NULL
activates	NULL
the	NULL
BMRF1	NULL
promoter	NULL
in	NULL
two	NULL
different	NULL
epithelial	NULL
cell	NULL
lines	NULL
.	NULL

We	NULL
map	NULL
the	NULL
region	NULL
of	NULL
the	NULL
BMRF1	NULL
promoter	NULL
required	NULL
for	NULL
maximal	NULL
response	NULL
to	NULL
the	NULL
Z/c-myb	NULL
combination	NULL
to	NULL
a	NULL
30-bp	NULL
stretch	NULL
containing	NULL
a	NULL
consensus	NULL
AP-1	NULL
site	NULL
and	NULL
show	NULL
that	NULL
this	NULL
sequence	NULL
is	NULL
sufficient	NULL
to	NULL
confer	NULL
responsiveness	NULL
to	NULL
the	NULL
Z/c-myb	NULL
combination	NULL
to	NULL
a	NULL
heterologous	NULL
promoter	NULL
.	NULL

The	NULL
simian	NULL
Vor	NULL
.	NULL

12	NULL
,	NULL
1992	NULL
virus	NULL
40	NULL
(	NULL
SV40	NULL
)	NULL
early	NULL
promoter	NULL
,	NULL
which	NULL
contains	NULL
an	NULL
AP-1	NULL
binding	NULL
site	NULL
(	NULL
33	NULL
)	NULL
,	NULL
is	NULL
also	NULL
synergistically	NULL
activated	NULL
by	NULL
the	NULL
Z/c-myb	NULL
combination	NULL
.	NULL

The	NULL
demonstration	NULL
that	NULL
c-myb	NULL
can	NULL
interact	NULL
synergistically	NULL
with	NULL
an	NULL
EBV-encoded	NULL
transactivator	NULL
to	NULL
activate	NULL
two	NULL
different	NULL
promoters	NULL
suggests	NULL
that	NULL
c-myb	NULL
is	NULL
likely	NULL
to	NULL
interact	NULL
in	NULL
a	NULL
similar	NULL
fashion	NULL
with	NULL
as	NULL
yet	NULL
unidentified	NULL
cellular	NULL
transcription	NULL
factors	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
lines	NULL
.	NULL

The	NULL
cell	NULL
lines	NULL
used	NULL
were	NULL
the	NULL
EBV-negative	NULL
T-cell	NULL
line	NULL
Jurkat	NULL
,	NULL
the	NULL
EBV-positive	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
line	NULL
Raji	NULL
,	NULL
the	NULL
cervical	NULL
epithelial	NULL
cell	NULL
line	NULL
HeLa	NULL
,	NULL
and	NULL
an	NULL
EBV-positive	NULL
epithelial	NULL
cell	NULL
line	NULL
,	NULL
NPC-KT	NULL
(	NULL
49	NULL
)	NULL
,	NULL
made	NULL
by	NULL
fusing	NULL
an	NULL
adenoidal	NULL
carcinoma	NULL
line	NULL
with	NULL
a	NULL
nasopharyngeal	NULL
carcinoma	NULL
line	NULL
.	NULL

Lymphoid	NULL
lines	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
.	NULL

Epithelial	NULL
cells	NULL
were	NULL
maintained	NULL
in	NULL
Dulbecco	NULL
modified	NULL
Eagle	NULL
medium	NULL
H	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
.	NULL

DNA	NULL
transfections	NULL
.	NULL

Plasmid	NULL
DNA	NULL
was	NULL
purified	NULL
through	NULL
two	NULL
sequential	NULL
cesium	NULL
chloride	NULL
gradients	NULL
.	NULL

Transfection	NULL
of	NULL
DNA	NULL
into	NULL
both	NULL
lymphoid	NULL
and	NULL
epithelial	NULL
cell	NULL
lines	NULL
was	NULL
accomplished	NULL
by	NULL
using	NULL
electroporation	NULL
(	NULL
54	NULL
)	NULL
.	NULL

For	NULL
each	NULL
condition	NULL
,	NULL
10	NULL
``	NULL
cells	NULL
were	NULL
shocked	NULL
at	NULL
1,500	NULL
V	NULL
,	NULL
using	NULL
the	NULL
Zapper	NULL
electroporation	NULL
unit	NULL
(	NULL
Medical	NULL
Electronics	NULL
Shop	NULL
,	NULL
University	NULL
of	NULL
Wis-consin	NULL
)	NULL
.	NULL

Epithelial	NULL
cells	NULL
were	NULL
harvested	NULL
and	NULL
resuspended	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
for	NULL
electroporation	NULL
.	NULL

EA-CAT	NULL
plasmids	NULL
.	NULL

The	NULL
EA-CAT	NULL
constructs	NULL
used	NULL
in	NULL
this	NULL
study	NULL
(	NULL
some	NULL
of	NULL
which	NULL
have	NULL
been	NULL
previously	NULL
described	NULL
{	NULL
21	NULL
]	NULL
)	NULL
are	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

The	NULL
parent	NULL
construct	NULL
,	NULL
pEA-CAT	NULL
,	NULL
contains	NULL
the	NULL
promoter	NULL
of	NULL
the	NULL
BMRF1	NULL
gene	NULL
from	NULL
sequences	NULL
-331	NULL
to	NULL
+1	NULL
(	NULL
relative	NULL
to	NULL
the	NULL
RNA	NULL
start	NULL
site	NULL
)	NULL
linked	NULL
to	NULL
the	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
gene	NULL
.	NULL

5	NULL
'	NULL
deletions	NULL
of	NULL
EA-CAT	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
were	NULL
made	NULL
by	NULL
cutting	NULL
with	NULL
various	NULL
restriction	NULL
enzymes	NULL
,	NULL
blunt	NULL
ending	NULL
,	NULL
and	NULL
religating	NULL
.	NULL

These	NULL
mutants	NULL
are	NULL
named	NULL
to	NULL
reflect	NULL
the	NULL
promoter	NULL
sequences	NULL
(	NULL
relative	NULL
to	NULL
the	NULL
mRNA	NULL
start	NULL
site	NULL
of	NULL
BMRF1	NULL
)	NULL
contained	NULL
within	NULL
each	NULL
construct	NULL
.	NULL

Plasmid	NULL
pEA-BS-CAT	NULL
(	NULL
used	NULL
for	NULL
site-directed	NULL
mutagenesis	NULL
)	NULL
contains	NULL
the	NULL
BMRF1	NULL
promoter	NULL
sequences	NULL
(	NULL
-331	NULL
to	NULL
+1	NULL
)	NULL
linked	NULL
to	NULL
the	NULL
CAT	NULL
gene	NULL
in	NULL
the	NULL
Stratagene	NULL
m13	NULL
Bluescript	NULL
SK	NULL
+	NULL
phagemid	NULL
vector	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

Site-directed	NULL
mutants	NULL
that	NULL
remove	NULL
the	NULL
AP-1	NULL
site	NULL
,	NULL
another	NULL
Z	NULL
binding	NULL
site	NULL
(	NULL
ZRE	NULL
)	NULL
,	NULL
or	NULL
the	NULL
potential	NULL
c-Myb	NULL
binding	NULL
site	NULL
were	NULL
constructed	NULL
from	NULL
the	NULL
pEA-BS-CAT	NULL
plasmid	NULL
as	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1B	NULL
.	NULL

The	NULL
E1B-EAD-CAT	NULL
plasmid	NULL
was	NULL
made	NULL
by	NULL
ligating	NULL
three	NULL
copies	NULL
of	NULL
the	NULL
30-bp	NULL
BMRF1	NULL
promoter	NULL
sequence	NULL
from	NULL
79801	NULL
to	NULL
79830	NULL
(	NULL
-69	NULL
to	NULL
-39	NULL
relative	NULL
to	NULL
the	NULL
mRNA	NULL
start	NULL
site	NULL
)	NULL
directly	NULL
upstream	NULL
of	NULL
the	NULL
adenovirus	NULL
E1B	NULL
TATA	NULL
box	NULL
in	NULL
the	NULL
E1B-CAT	NULL
construct	NULL
(	NULL
36	NULL
)	NULL
(	NULL
a	NULL
gift	NULL
from	NULL
Katherine	NULL
Martin	NULL
and	NULL
Michael	NULL
Green	NULL
)	NULL
between	NULL
the	NULL
Xbal	NULL
and	NULL
Pst	NULL
restriction	NULL
sites	NULL
.	NULL

EBV	NULL
Z	NULL
transactivator	NULL
plasmids	NULL
.	NULL

Two	NULL
different	NULL
Z	NULL
expression	NULL
vectors	NULL
were	NULL
used	NULL
in	NULL
these	NULL
experiments	NULL
.	NULL

Most	NULL
experiments	NULL
were	NULL
performed	NULL
with	NULL
the	NULL
pEBV-ZIE	NULL
construct	NULL
,	NULL
which	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
21	NULL
)	NULL
contains	NULL
the	NULL
EBV	NULL
genomic	NULL
fragment	NULL
encoding	NULL
the	NULL
Z	NULL
gene	NULL
product	NULL
inserted	NULL
into	NULL
the	NULL
pHD1013	NULL
vector	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
cytomegalovirus	NULL
(	NULL
CMV	NULL
)	NULL
IE	NULL
promoter	NULL
.	NULL

In	NULL
experiments	NULL
using	NULL
pEBV-ZIE	NULL
,	NULL
equal	NULL
amounts	NULL
of	NULL
the	NULL
pHD1013	NULL
vector	NULL
(	NULL
containing	NULL
the	NULL
CMV	NULL
IE	NULL
promoter	NULL
but	NULL
no	NULL
Z	NULL
gene	NULL
)	NULL
versus	NULL
the	NULL
EBV-ZIE	NULL
plasmid	NULL
were	NULL
transfected	NULL
in	NULL
parallel	NULL
to	NULL
control	NULL
for	NULL
promoter	NULL
competition	NULL
effects	NULL
.	NULL

Deletional	NULL
analysis	NULL
of	NULL
the	NULL
Z	NULL
protein	NULL
was	NULL
performed	NULL
by	NULL
using	NULL
a	NULL
series	NULL
of	NULL
deletions	NULL
derived	NULL
from	NULL
the	NULL
parental	NULL
vector	NULL
,	NULL
pKSV41	NULL
.	NULL

As	NULL
previously	NULL
described	NULL
(	NULL
16	NULL
)	NULL
,	NULL
the	NULL
pKSV41	NULL
construct	NULL
is	NULL
a	NULL
pUC18-based	NULL
plasmid	NULL
which	NULL
contains	NULL
the	NULL
Z	NULL
cDNA	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
SV40	NULL
early	NULL
promoter	NULL
and	NULL
enhancer	NULL
.	NULL

c-myb	NULL
AND	NULL
BZLF1	NULL
INTERACT	NULL
SYNERGISTICALLY	NULL
137	NULL
A.	NULL
ff	NULL
,	NULL
2g	NULL
5	NULL
BMRF1	NULL
BomHt	NULL
BstEl	NULL
3	NULL
af	NULL
e	NULL
Sou3A	NULL
Promoter	NULL
T9,537	NULL
T	NULL
=	NULL
‘	NULL
79	NULL
.89e	NULL
a	NULL
4	NULL
<	NULL
Plasmid	NULL
Insert	NULL
BomH1	NULL
pEA	NULL
(	NULL
-331/41	NULL
)	NULL
Rsot	NULL
79,537	NULL
79,870	NULL
BstEH	NULL
Rsot	NULL
pEA	NULL
(	NULL
-265	NULL
/+1	NULL
)	NULL
--	NULL
-79,604	NULL
T9	NULL
,	NULL
a70	NULL
A	NULL
pEA	NULL
(	NULL
-214/+29	NULL
)	NULL
Sous	NULL
T9	NULL
655	NULL
79,898	NULL
BstX1	NULL
__	NULL
Rea	NULL
!	NULL

EA	NULL
(	NULL
-799	NULL
+1	NULL
E	NULL
--	NULL
4	NULL
pEA	NULL
(	NULL
-79/	NULL
+1	NULL
)	NULL
79,790	NULL
79,870	NULL
pEA	NULL
(	NULL
-62/+29	NULL
)	NULL
HinF1__Squsa	NULL
T9,807	NULL
79,8938	NULL
Plasmid	NULL
pEA-BS-CAT	NULL
pEAAAP	NULL
!	NULL

I-CAT	NULL
TGAGCAA	NULL
.	NULL

...	NULL
...	NULL
TGaceTTtcasct6	NULL
pEAAMYB-CAT	NULL
TGAGCAA	NULL
...	NULL
..	NULL
..	NULL
TTCTAGATGAGTCA	NULL
pEAAAP1/106	NULL
TTTICTA	NULL
...	NULL
...	NULL
.	NULL

TGACCTTTCAGCTG	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Construction	NULL
of	NULL
5°	NULL
deletions	NULL
of	NULL
pEA-CAT	NULL
.	NULL

The	NULL
parent	NULL
pEA-CAT	NULL
construct	NULL
contains	NULL
the	NULL
EBV	NULL
BamHI-Rsal	NULL
fragment	NULL
(	NULL
EBV	NULL
nucleotides	NULL
79537	NULL
to	NULL
79870	NULL
)	NULL
linked	NULL
to	NULL
CAT	NULL
.	NULL

A	NULL
series	NULL
of	NULL
5	NULL
'	NULL
deletion	NULL
mutants	NULL
was	NULL
constructed	NULL
by	NULL
cutting	NULL
at	NULL
the	NULL
indicated	NULL
restriction	NULL
endonuclease	NULL
site	NULL
,	NULL
blunt	NULL
ending	NULL
with	NULL
T4	NULL
polymerase	NULL
or	NULL
Klenow	NULL
enzyme	NULL
,	NULL
and	NULL
religating	NULL
.	NULL

The	NULL
sites	NULL
of	NULL
the	NULL
TATA	NULL
box	NULL
and	NULL
potential	NULL
AP-1	NULL
binding	NULL
site	NULL
are	NULL
shown	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Construction	NULL
of	NULL
site-directed	NULL
mutations	NULL
.	NULL

The	NULL
parent	NULL
construct	NULL
,	NULL
pEA-BS-CAT	NULL
,	NULL
contains	NULL
the	NULL
EBV	NULL
BamHI-Rsal	NULL
fragment	NULL
linked	NULL
to	NULL
CAT	NULL
in	NULL
a	NULL
phagemid	NULL
vector	NULL
.	NULL

The	NULL
AP-1	NULL
site	NULL
,	NULL
an	NULL
additional	NULL
upstream	NULL
Z	NULL
binding	NULL
site	NULL
(	NULL
ZRE	NULL
)	NULL
,	NULL
and	NULL
the	NULL
potential	NULL
c-Myb	NULL
binding	NULL
site	NULL
were	NULL
abolished	NULL
by	NULL
using	NULL
the	NULL
Kunkel	NULL
method	NULL
(	NULL
30	NULL
)	NULL
of	NULL
site-directed	NULL
mutagenesis	NULL
as	NULL
shown	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2A	NULL
,	NULL
in-frame	NULL
deletional	NULL
mutants	NULL
of	NULL
Z	NULL
were	NULL
constructed	NULL
by	NULL
cutting	NULL
at	NULL
convenient	NULL
restriction	NULL
enzyme	NULL
locations	NULL
and	NULL
religating	NULL
.	NULL

The	NULL
mutants	NULL
are	NULL
named	NULL
to	NULL
reflect	NULL
the	NULL
location	NULL
of	NULL
the	NULL
Z	NULL
amino	NULL
acids	NULL
that	NULL
were	NULL
deleted	NULL
.	NULL

The	NULL
stability	NULL
and	NULL
cellular	NULL
localization	NULL
of	NULL
these	NULL
mutants	NULL
was	NULL
tested	NULL
by	NULL
transfection	NULL
of	NULL
the	NULL
mutated	NULL
versus	NULL
wild-type	NULL
pKSV41	NULL
plasmids	NULL
into	NULL
COS-7	NULL
cells	NULL
,	NULL
separation	NULL
of	NULL
the	NULL
nuclear	NULL
and	NULL
cytoplasmic	NULL
fractions	NULL
,	NULL
sodium	NULL
dodecyl	NULL
sulfate-polyacryl-amide	NULL
gel	NULL
electrophoresis	NULL
,	NULL
and	NULL
immunoblotting	NULL
.	NULL

This	NULL
analysis	NULL
(	NULL
which	NULL
is	NULL
presented	NULL
in	NULL
detail	NULL
elsewhere	NULL
[	NULL
16	NULL
]	NULL
)	NULL
indicated	NULL
that	NULL
two	NULL
of	NULL
the	NULL
mutant	NULL
proteins	NULL
,	NULL
produced	NULL
from	NULL
plasmids	NULL
ZA42-191	NULL
and	NULL
ZAl40-227	NULL
,	NULL
were	NULL
unstable	NULL
,	NULL
while	NULL
the	NULL
other	NULL
mutant	NULL
proteins	NULL
were	NULL
all	NULL
as	NULL
stable	NULL
as	NULL
the	NULL
wild-type	NULL
protein	NULL
.	NULL

Of	NULL
the	NULL
mutant	NULL
proteins	NULL
that	NULL
were	NULL
shown	NULL
to	NULL
be	NULL
stable	NULL
,	NULL
all	NULL
except	NULL
ZA200-227	NULL
were	NULL
shown	NULL
to	NULL
have	NULL
nuclear	NULL
localization	NULL
.	NULL

Since	NULL
all	NULL
of	NULL
the	NULL
mutations	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2A	NULL
which	NULL
involved	NULL
the	NULL
DNA	NULL
binding	NULL
domain	NULL
of	NULL
the	NULL
Z	NULL
protein	NULL
either	NULL
were	NULL
found	NULL
to	NULL
be	NULL
unstable	NULL
or	NULL
did	NULL
not	NULL
localize	NULL
within	NULL
the	NULL
nucleus	NULL
,	NULL
we	NULL
also	NULL
tested	NULL
a	NULL
mutant	NULL
containing	NULL
a	NULL
site-directed	NULL
mutation	NULL
within	NULL
the	NULL
DNA	NULL
binding	NULL
domain	NULL
of	NULL
Z	NULL
(	NULL
plasmid	NULL
pZ311	NULL
;	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

The	NULL
Z311	NULL
mutant	NULL
produces	NULL
Z	NULL
protein	NULL
which	NULL
is	NULL
stable	NULL
and	NULL
localizes	NULL
to	NULL
the	NULL
nucleus	NULL
,	NULL
although	NULL
the	NULL
protein	NULL
has	NULL
completely	NULL
lost	NULL
DNA	NULL
binding	NULL
activity	NULL
(	NULL
16	NULL
)	NULL
.	NULL

c-myb	NULL
transactivator	NULL
plasmids	NULL
.	NULL

The	NULL
parental	NULL
c-myb	NULL
expression	NULL
vector	NULL
,	NULL
pRmb3SVneo	NULL
,	NULL
which	NULL
has	NULL
been	NULL
previously	NULL
described	NULL
(	NULL
10	NULL
)	NULL
,	NULL
contains	NULL
a	NULL
mouse	NULL
c-myb	NULL
cDNA	NULL
under	NULL
the	NULL
138	NULL
KENNEY	NULL
ET	NULL
AL	NULL
.	NULL

Transactivation	NULL
DNA-Binding	NULL
Dimerization	NULL
A.	NULL
zzz	NULL
°	NULL
___se	NULL
_	NULL
go	NULL
_	NULL
go	NULL
_	NULL
ao	NULL
zs	NULL
0	NULL
,	NULL
|	NULL
in	NULL
+	NULL
P	NULL
+	NULL
'~	NULL
loon	NULL
plasmid	NULL
Nu	NULL
-	NULL
Cyto	NULL
so	NULL
100	NULL
150	NULL
245	NULL
--	NULL
pKSV41	NULL
+	NULL
Coon	NULL
2529	NULL
ZA25-29	NULL
--	NULL
A	NULL
+	NULL
29	NULL
42	NULL
ZA29-42	NULL
t-	NULL
k-	NULL
g-	NULL
+	NULL
93	NULL
_	NULL
132	NULL
ZA93-132	NULL
_	NULL
+	NULL
42	NULL
19	NULL
ZA42-191	NULL
-ma	NULL
-	NULL
40	NULL
ZAI40-227	NULL
o——m———l|	NULL
277—1	NULL
_-	NULL
_	NULL
200	NULL
227	NULL
ZA200-227	NULL
-	NULL
-	NULL
i-	NULL
-	NULL
+	NULL
226	NULL
ZA226-243	NULL
-	NULL
i-tza	NULL
--	NULL
--	NULL
--	NULL
--	NULL
--	NULL
--	NULL
@	NULL
@	NULL
Esss	NULL
+	NULL
-|-	NULL
245	NULL
B.	NULL
NHz	NULL
coon	NULL
176	NULL
194	NULL
Localization	NULL
lasmid	NULL
E	NULL
IKRYKNRVASRKCRAKFK	NULL
Nu	NULL
-	NULL
Cyto	NULL
2311	NULL
E	NULL
IKRYKNRVKSRKCRAKF	NULL
K	NULL
+	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Construction	NULL
of	NULL
the	NULL
EBV	NULL
Z	NULL
transactivator	NULL
plasmids	NULL
.	NULL

The	NULL
parent	NULL
plasmid	NULL
,	NULL
pKSV41	NULL
,	NULL
contains	NULL
the	NULL
Z	NULL
cDNA	NULL
driven	NULL
by	NULL
the	NULL
SV40	NULL
early	NULL
promoter	NULL
and	NULL
enhancer	NULL
in	NULL
a	NULL
pUC18-based	NULL
plasmid	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
16	NULL
)	NULL
.	NULL

In-frame	NULL
deletion	NULL
mutants	NULL
of	NULL
pKSV41	NULL
were	NULL
created	NULL
by	NULL
cutting	NULL
with	NULL
convenient	NULL
restriction	NULL
enzymes	NULL
,	NULL
blunt	NULL
ending	NULL
,	NULL
and	NULL
religating	NULL
as	NULL
shown	NULL
.	NULL

The	NULL
mutants	NULL
are	NULL
named	NULL
to	NULL
reflect	NULL
the	NULL
position	NULL
of	NULL
the	NULL
amino	NULL
acids	NULL
removed	NULL
from	NULL
the	NULL
Z	NULL
protein	NULL
.	NULL

The	NULL
positions	NULL
of	NULL
the	NULL
previously	NULL
mapped	NULL
transactivation	NULL
domain	NULL
,	NULL
DNA	NULL
binding	NULL
domain	NULL
,	NULL
and	NULL
dimerization	NULL
domain	NULL
within	NULL
the	NULL
Z	NULL
protein	NULL
are	NULL
indicated	NULL
.	NULL

Nuclear	NULL
(	NULL
Nu	NULL
)	NULL
versus	NULL
cytoplasmic	NULL
(	NULL
Cy	NULL
)	NULL
localization	NULL
is	NULL
indicated	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Construction	NULL
of	NULL
plasmid	NULL
Z311	NULL
.	NULL

The	NULL
Z311	NULL
plasmid	NULL
contains	NULL
a	NULL
site-directed	NULL
mutation	NULL
in	NULL
the	NULL
DNA	NULL
binding	NULL
domain	NULL
as	NULL
shown	NULL
.	NULL

The	NULL
resultant	NULL
protein	NULL
can	NULL
not	NULL
bind	NULL
DNA	NULL
but	NULL
is	NULL
stable	NULL
and	NULL
localizes	NULL
in	NULL
the	NULL
nucleus	NULL
.	NULL

control	NULL
of	NULL
the	NULL
Rous	NULL
sarcoma	NULL
virus	NULL
long	NULL
terminal	NULL
repeat	NULL
in	NULL
addition	NULL
to	NULL
the	NULL
neomycin	NULL
resistance	NULL
gene	NULL
driven	NULL
by	NULL
the	NULL
SV40	NULL
promoter	NULL
.	NULL

The	NULL
vector	NULL
pJITmyb-fs	NULL
,	NULL
which	NULL
is	NULL
identical	NULL
to	NULL
pRmb3SVneo	NULL
except	NULL
for	NULL
a	NULL
frameshift	NULL
mutation	NULL
within	NULL
the	NULL
c-myb	NULL
coding	NULL
sequence	NULL
(	NULL
10	NULL
)	NULL
(	NULL
a	NULL
gift	NULL
from	NULL
Jenny	NULL
Ting	NULL
)	NULL
,	NULL
was	NULL
used	NULL
to	NULL
control	NULL
for	NULL
vector	NULL
effects	NULL
in	NULL
experiments	NULL
using	NULL
the	NULL
pRmb3SVneo	NULL
plasmid	NULL
.	NULL

MybA2R	NULL
was	NULL
constructed	NULL
by	NULL
removing	NULL
the	NULL
first	NULL
and	NULL
second	NULL
51-	NULL
to	NULL
52-amino-acid	NULL
repeat	NULL
elements	NULL
(	NULL
which	NULL
contain	NULL
the	NULL
DNA	NULL
binding	NULL
domain	NULL
of	NULL
c-Myb	NULL
)	NULL
by	NULL
the	NULL
polymerase	NULL
chain	NULL
reaction	NULL
technique	NULL
and	NULL
recloning	NULL
the	NULL
remainder	NULL
of	NULL
the	NULL
c-myb	NULL
protein	NULL
into	NULL
the	NULL
pHD1013	NULL
vector	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
CMV	NULL
IE	NULL
promoter	NULL
.	NULL

Potential	NULL
CMV	NULL
IE	NULL
promoter	NULL
competition	NULL
effects	NULL
were	NULL
controlled	NULL
for	NULL
by	NULL
including	NULL
a	NULL
transfection	NULL
condition	NULL
with	NULL
the	NULL
pHD1013	NULL
vector	NULL
alone	NULL
(	NULL
without	NULL
c-myb	NULL
)	NULL
as	NULL
a	NULL
control	NULL
in	NULL
all	NULL
experiments	NULL
using	NULL
this	NULL
construct	NULL
.	NULL

CAT	NULL
assays	NULL
.	NULL

Cells	NULL
were	NULL
transfected	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
plasmid	NULL
DNA	NULL
,	NULL
using	NULL
the	NULL
electroporation	NULL
method	NULL
.	NULL

Forty-eight	NULL
hours	NULL
after	NULL
transfection	NULL
,	NULL
a	NULL
cell	NULL
extract	NULL
was	NULL
prepared	NULL
and	NULL
incubated	NULL
at	NULL
37°C	NULL
with	NULL
**C-labelled	NULL
chloramphenicol	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
acetyl	NULL
coenzyme	NULL
A	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
17	NULL
)	NULL
.	NULL

The	NULL
percent	NULL
acetylation	NULL
of	NULL
chloramphenicol	NULL
was	NULL
quantitated	NULL
by	NULL
thin-layer	NULL
chromatography	NULL
followed	NULL
by	NULL
autoradiography	NULL
and	NULL
scintillation	NULL
counting	NULL
.	NULL

Some	NULL
of	NULL
the	NULL
CAT	NULL
assays	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
and	NULL
8	NULL
are	NULL
off-scale	NULL
and	NULL
thus	NULL
represent	NULL
potential	NULL
underestimations	NULL
of	NULL
the	NULL
actual	NULL
Z/c-myb	NULL
synergy	NULL
.	NULL

For	NULL
the	NULL
calculations	NULL
shown	NULL
in	NULL
the	NULL
tables	NULL
and	NULL
Fig	NULL
.	NULL

9	NULL
,	NULL
CAT	NULL
assays	NULL
were	NULL
repeated	NULL
if	NULL
results	NULL
Mort	NULL
.	NULL

CELL	NULL
.	NULL

Bio..	NULL
were	NULL
not	NULL
in	NULL
the	NULL
linear	NULL
range	NULL
(	NULL
less	NULL
than	NULL
80	NULL
%	NULL
chloramphenicol	NULL
acetylation	NULL
)	NULL
,	NULL
using	NULL
smaller	NULL
amounts	NULL
of	NULL
extract	NULL
.	NULL

Western	NULL
immunoblots	NULL
.	NULL

To	NULL
quantitate	NULL
the	NULL
level	NULL
of	NULL
Z	NULL
protein	NULL
expression	NULL
in	NULL
transfected	NULL
cells	NULL
,	NULL
10	NULL
``	NULL
Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
as	NULL
described	NULL
above	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
harvested	NULL
after	NULL
48	NULL
h	NULL
(	NULL
a	NULL
portion	NULL
was	NULL
used	NULL
for	NULL
the	NULL
CAT	NULL
assay	NULL
)	NULL
,	NULL
washed	NULL
with	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
twice	NULL
,	NULL
resuspended	NULL
in	NULL
0.25	NULL
M	NULL
Tris	NULL
(	NULL
pH	NULL
8.0	NULL
)	NULL
,	NULL
lysed	NULL
by	NULL
freeze-thaw	NULL
and	NULL
sonication	NULL
,	NULL
and	NULL
cleared	NULL
by	NULL
centrifugation	NULL
.	NULL

The	NULL
soluble	NULL
proteins	NULL
were	NULL
separated	NULL
by	NULL
electrophoresis	NULL
through	NULL
a	NULL
12.5	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
and	NULL
transferred	NULL
electrophoretically	NULL
to	NULL
nitrocellulose	NULL
.	NULL

The	NULL
preblocked	NULL
nitrocellulose	NULL
filter	NULL
was	NULL
incubated	NULL
for	NULL
1	NULL
h	NULL
at	NULL
37°C	NULL
with	NULL
a	NULL
1:100	NULL
dilution	NULL
of	NULL
pooled	NULL
sera	NULL
from	NULL
patients	NULL
with	NULL
nasopharyngeal	NULL
carcinoma	NULL
(	NULL
a	NULL
gift	NULL
from	NULL
Pierre	NULL
Buisson	NULL
)	NULL
,	NULL
followed	NULL
by	NULL
human	NULL
anti-immunoglobulin	NULL
G-peroxidase	NULL
con-jugate	NULL
.	NULL

The	NULL
coloring	NULL
agent	NULL
was	NULL
developed	NULL
by	NULL
incubation	NULL
in	NULL
3,3'-diaminobenzidine	NULL
and	NULL
hydrogen	NULL
peroxide	NULL
.	NULL

RNA	NULL
analysis	NULL
.	NULL

CAT	NULL
mRNA	NULL
was	NULL
quantitated	NULL
using	NULL
S1	NULL
nuclease	NULL
protection	NULL
(	NULL
12	NULL
)	NULL
.	NULL

Cytoplasmic	NULL
RNA	NULL
was	NULL
prepared	NULL
24	NULL
h	NULL
after	NULL
transfection	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
15	NULL
)	NULL
.	NULL

A	NULL
20-bp	NULL
oligonucleotide	NULL
primer	NULL
homologous	NULL
to	NULL
the	NULL
CAT	NULL
gene	NULL
in	NULL
the	NULL
region	NULL
240	NULL
to	NULL
254	NULL
bp	NULL
downstream	NULL
of	NULL
the	NULL
ATG	NULL
codon	NULL
was	NULL
synthesized	NULL
and	NULL
hybridized	NULL
to	NULL
single-stranded	NULL
DNA	NULL
produced	NULL
from	NULL
the	NULL
EA-PBS-CAT	NULL
phagemid	NULL
construct	NULL
.	NULL

A	NULL
complementary	NULL
single-stranded	NULL
uniformly	NULL
labelled	NULL
DNA	NULL
probe	NULL
was	NULL
subsequently	NULL
synthesized	NULL
by	NULL
extending	NULL
the	NULL
oligonucleotide	NULL
with	NULL
Klenow	NULL
enzyme	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
*°P-labelled	NULL
dCTP	NULL
,	NULL
cutting	NULL
the	NULL
DNA	NULL
with	NULL
Xbal	NULL
(	NULL
located	NULL
directly	NULL
upstream	NULL
of	NULL
the	NULL
332-bp	NULL
BMRF1	NULL
promoter	NULL
element	NULL
)	NULL
,	NULL
and	NULL
isolating	NULL
the	NULL
resultant	NULL
approximately	NULL
600-bp	NULL
single-stranded	NULL
probe	NULL
on	NULL
a	NULL
denaturing	NULL
acrylamide	NULL
gel	NULL
.	NULL

The	NULL
probe	NULL
was	NULL
then	NULL
hybridized	NULL
overnight	NULL
with	NULL
cytoplasmic	NULL
RNA	NULL
in	NULL
a	NULL
solution	NULL
containing	NULL
80	NULL
%	NULL
formamide	NULL
,	NULL
40	NULL
mM	NULL
PIPES	NULL
[	NULL
piperazine-N	NULL
,	NULL
N'-bis	NULL
(	NULL
2-ethanesulfonic	NULL
acid	NULL
)	NULL
)	NULL
,	NULL
400	NULL
mM	NULL
NaCl	NULL
,	NULL
and	NULL
1	NULL
mM	NULL
EDTA	NULL
and	NULL
digested	NULL
with	NULL
S1	NULL
nuclease	NULL
,	NULL
and	NULL
the	NULL
protected	NULL
fragments	NULL
were	NULL
electrophoresed	NULL
on	NULL
a	NULL
6	NULL
%	NULL
acrylamide-7	NULL
M	NULL
urea	NULL
gel	NULL
.	NULL

In	NULL
vitro	NULL
site-directed	NULL
mutagenesis	NULL
.	NULL

Mutants	NULL
were	NULL
made	NULL
by	NULL
using	NULL
the	NULL
Bio-Rad	NULL
Muta-Gene	NULL
phagemid	NULL
in	NULL
vitro	NULL
mutagenesis	NULL
kit	NULL
according	NULL
to	NULL
a	NULL
method	NULL
described	NULL
by	NULL
Kunkel	NULL
(	NULL
30	NULL
)	NULL
.	NULL

Mutants	NULL
were	NULL
made	NULL
by	NULL
using	NULL
a	NULL
synthetic	NULL
oligonucleotide	NULL
complementary	NULL
to	NULL
the	NULL
region	NULL
to	NULL
be	NULL
altered	NULL
except	NULL
for	NULL
a	NULL
limited	NULL
internal	NULL
mismatch	NULL
.	NULL

For	NULL
screening	NULL
possible	NULL
mutants	NULL
,	NULL
synthetic	NULL
oligonucleotides	NULL
were	NULL
designed	NULL
to	NULL
create	NULL
new	NULL
restriction	NULL
sites	NULL
.	NULL

The	NULL
AP-1	NULL
mutation	NULL
has	NULL
been	NULL
previously	NULL
described	NULL
(	NULL
21	NULL
)	NULL
.	NULL

Z	NULL
binding	NULL
studies	NULL
.	NULL

The	NULL
Z	NULL
protein	NULL
was	NULL
in	NULL
vitro	NULL
transcribed	NULL
and	NULL
translated	NULL
by	NULL
using	NULL
wheat	NULL
germ	NULL
lysate	NULL
from	NULL
the	NULL
SP64	NULL
vector	NULL
containing	NULL
Z	NULL
cDNA	NULL
(	NULL
44	NULL
)	NULL
(	NULL
a	NULL
gift	NULL
from	NULL
Paul	NULL
Farrell	NULL
)	NULL
.	NULL

A	NULL
*P-end-labelled	NULL
probe	NULL
containing	NULL
BMRF1l	NULL
promoter	NULL
sequences	NULL
from	NULL
-79	NULL
to	NULL
+128	NULL
was	NULL
incubated	NULL
with	NULL
5	NULL
pl	NULL
of	NULL
in	NULL
vitro-translated	NULL
Z	NULL
protein	NULL
for	NULL
30	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Binding	NULL
reactions	NULL
were	NULL
performed	NULL
in	NULL
buffer	NULL
containing	NULL
100	NULL
mM	NULL
KCI	NULL
,	NULL
20	NULL
mM	NULL
HEPES	NULL
(	NULL
N-2-hydroxyethylpiperazine-N'-	NULL
?	NULL

-ethanesulfonic	NULL
acid	NULL
;	NULL
pH	NULL
7.3	NULL
)	NULL
,	NULL
10	NULL
%	NULL
glycerol	NULL
,	NULL
0.2	NULL
mM	NULL
EDTA	NULL
,	NULL
4	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
5	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
,	NULL
and	NULL
2	NULL
mg	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
-	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
.	NULL

For	NULL
methylation	NULL
protection	NULL
studies	NULL
,	NULL
dimethylsulfate	NULL
(	NULL
1	NULL
pl	NULL
)	NULL
was	NULL
added	NULL
to	NULL
the	NULL
binding	NULL
reaction	NULL
immediately	NULL
prior	NULL
to	NULL
loading	NULL
onto	NULL
a	NULL
5	NULL
%	NULL
polyacrylamide-0.5	NULL
%	NULL
Tris-borate-EDTA	NULL
gel	NULL
.	NULL

Two	NULL
bands	NULL
representing	NULL
the	NULL
bound	NULL
probe	NULL
and	NULL
one	NULL
band	NULL
representing	NULL
the	NULL
free	NULL
probe	NULL
were	NULL
cut	NULL
from	NULL
the	NULL
gel	NULL
and	NULL
transferred	NULL
to	NULL
DEAE	NULL
membrane	NULL
paper	NULL
.	NULL

The	NULL
membrane	NULL
was	NULL
incubated	NULL
with	NULL
1	NULL
M	NULL
piperidine	NULL
at	NULL
90°C	NULL
for	NULL
30	NULL
min	NULL
and	NULL
then	NULL
rinsed	NULL
twice	NULL
with	NULL
sterile	NULL
water	NULL
.	NULL

The	NULL
probe	NULL
fragments	NULL
were	NULL
then	NULL
eluted	NULL
by	NULL
incubating	NULL
the	NULL
membrane	NULL
with	NULL
1	NULL
M	NULL
NaCl-QO.1	NULL
mM	NULL
EDTA-20	NULL
mM	NULL
Tris	NULL
(	NULL
pH	NULL
8.0	NULL
)	NULL
at	NULL
67°C	NULL
.	NULL

Equal	NULL
amounts	NULL
of	NULL
the	NULL
radioactive	NULL
Vor	NULL
.	NULL

12	NULL
,	NULL
1992	NULL
bound	NULL
and	NULL
free	NULL
probes	NULL
were	NULL
then	NULL
analyzed	NULL
on	NULL
a	NULL
6	NULL
%	NULL
poly-acrylamide-7	NULL
M	NULL
urea	NULL
gel	NULL
.	NULL

Myb	NULL
binding	NULL
studies	NULL
.	NULL

Potential	NULL
myb	NULL
protein	NULL
binding	NULL
to	NULL
the	NULL
BMRF1	NULL
promoter	NULL
was	NULL
studied	NULL
by	NULL
using	NULL
a	NULL
bacterial	NULL
fusion	NULL
v-myb	NULL
protein	NULL
(	NULL
14	NULL
)	NULL
(	NULL
a	NULL
gift	NULL
from	NULL
J.	NULL
Lipsick	NULL
)	NULL
which	NULL
has	NULL
been	NULL
previously	NULL
described	NULL
(	NULL
14	NULL
)	NULL
.	NULL

v-Myb	NULL
binding	NULL
to	NULL
the	NULL
BMRF1	NULL
promoter	NULL
was	NULL
analyzed	NULL
by	NULL
using	NULL
a	NULL
synthetic	NULL
double-stranded	NULL
oligonucleotide	NULL
sequence	NULL
(	NULL
oligonucleotide	NULL
EAD	NULL
)	NULL
containing	NULL
the	NULL
BMRF1	NULL
promoter	NULL
sequences	NULL
from	NULL
-50	NULL
to	NULL
-83	NULL
relative	NULL
to	NULL
the	NULL
mRNA	NULL
start	NULL
site	NULL
flanked	NULL
by	NULL
EcoRI	NULL
and	NULL
Sall	NULL
restriction	NULL
sites	NULL
(	NULL
ATGTCGACGAATTCGCTGGTGGTAGATGACCT	NULL
TTGAGTCAGGGTGGCTGTCGACACA	NULL
)	NULL
.	NULL

Oligonucleotide	NULL
sequences	NULL
containing	NULL
mutations	NULL
in	NULL
the	NULL
AP-1	NULL
site	NULL
(	NULL
EAD	NULL
AP-1	NULL
;	NULL
ATGTCGACGAATTCGCTGGTGGTAGATGACCTTTC	NULL
AGCTGGGGTGGCTGTCGACACA	NULL
)	NULL
or	NULL
the	NULL
potential	NULL
c-myh	NULL
site	NULL
(	NULL
EAD	NULL
MYB	NULL
;	NULL
ATGTCGACGAATTCGCTGGTGGTAG	NULL
ATTCTAGATGAGTCAGGGTGGCTGTCGACACA	NULL
)	NULL
were	NULL
also	NULL
analyzed	NULL
.	NULL

An	NULL
oligonucleotide	NULL
containing	NULL
four	NULL
copies	NULL
of	NULL
a	NULL
consensus	NULL
c-Myb	NULL
binding	NULL
site	NULL
(	NULL
CAGTTA	NULL
)	NULL
was	NULL
also	NULL
constructed	NULL
(	NULL
MYB	NULL
;	NULL
CCGAATTCCAGTTAATAGCAG	NULL
TTAATAGCAGTTAATAGCAGTTAATTT	NULL
)	NULL
to	NULL
use	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
for	NULL
Myb	NULL
binding	NULL
.	NULL

Gel	NULL
mobility	NULL
shift	NULL
assays	NULL
were	NULL
performed	NULL
by	NULL
incubating	NULL
the	NULL
renatured	NULL
,	NULL
double-stranded	NULL
synthetic	NULL
oligonucleotides	NULL
(	NULL
after	NULL
end	NULL
labelling	NULL
with	NULL
*P	NULL
by	NULL
Klenow	NULL
reaction	NULL
)	NULL
with	NULL
protein	NULL
extracts	NULL
from	NULL
the	NULL
bacteria	NULL
producing	NULL
v-myb	NULL
protein	NULL
(	NULL
T7MYB	NULL
)	NULL
or	NULL
protein	NULL
extracts	NULL
from	NULL
bacteria	NULL
containing	NULL
the	NULL
negative	NULL
control	NULL
vector	NULL
(	NULL
MYBLESS	NULL
)	NULL
in	NULL
a	NULL
reaction	NULL
buffer	NULL
containing	NULL
10	NULL
mM	NULL
Tris-HCI	NULL
(	NULL
pH	NULL
7.5	NULL
)	NULL
,	NULL
50	NULL
mM	NULL
NaCl	NULL
,	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
5	NULL
%	NULL
glycerol	NULL
,	NULL
and	NULL
80	NULL
ug	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
-	NULL
(	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
per	NULL
ml	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

Free	NULL
and	NULL
bound	NULL
complexes	NULL
were	NULL
then	NULL
resolved	NULL
by	NULL
electrophoresis	NULL
in	NULL
a	NULL
polyacrylamide	NULL
gel	NULL
in	NULL
0.5	NULL
%	NULL
Tris-borate-EDTA	NULL
buffer	NULL
at	NULL
40	NULL
V	NULL
cm~	NULL
'	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4°C	NULL
and	NULL
subjected	NULL
to	NULL
autoradiography	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
anti-myb	NULL
antibody	NULL
on	NULL
bound	NULL
complexes	NULL
was	NULL
determined	NULL
by	NULL
comparing	NULL
the	NULL
results	NULL
of	NULL
mixing	NULL
1	NULL
pl	NULL
of	NULL
preimmune	NULL
rabbit	NULL
serum	NULL
versus	NULL
1	NULL
wl	NULL
of	NULL
rabbit	NULL
polyclonal	NULL
anti-try-myb	NULL
2	NULL
serum	NULL
(	NULL
3	NULL
)	NULL
(	NULL
a	NULL
gift	NULL
from	NULL
J.	NULL
Lipsick	NULL
)	NULL
into	NULL
the	NULL
reaction	NULL
mixture	NULL
30	NULL
min	NULL
before	NULL
adding	NULL
the	NULL
labelled	NULL
probe	NULL
.	NULL

RESULTS	NULL
The	NULL
EBV	NULL
BMRF1	NULL
promoter	NULL
and	NULL
the	NULL
SV40	NULL
early	NULL
promoter	NULL
are	NULL
synergistically	NULL
activated	NULL
by	NULL
the	NULL
combination	NULL
of	NULL
Z	NULL
and	NULL
c-myb	NULL
in	NULL
lymphoid	NULL
cells	NULL
.	NULL

We	NULL
first	NULL
examined	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
c-myb	NULL
oncogene	NULL
to	NULL
complement	NULL
the	NULL
Z	NULL
gene	NULL
product	NULL
in	NULL
transient	NULL
cotransfection	NULL
assays	NULL
in	NULL
which	NULL
the	NULL
BMRF1	NULL
early	NULL
EBV	NULL
promoter	NULL
was	NULL
linked	NULL
to	NULL
the	NULL
heterologous	NULL
CAT	NULL
gene	NULL
.	NULL

Figure	NULL
3	NULL
shows	NULL
the	NULL
results	NULL
of	NULL
representative	NULL
CAT	NULL
assays	NULL
.	NULL

In	NULL
the	NULL
Jurkat	NULL
T-cell	NULL
line	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
,	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
BMRF1	NULL
promoter	NULL
(	NULL
linked	NULL
to	NULL
CAT	NULL
)	NULL
was	NULL
only	NULL
slightly	NULL
increased	NULL
by	NULL
cotransfection	NULL
with	NULL
Z	NULL
alone	NULL
(	NULL
one-	NULL
to	NULL
eightfold	NULL
increase	NULL
in	NULL
multiple	NULL
experiments	NULL
)	NULL
or	NULL
by	NULL
cotransfection	NULL
with	NULL
c-myb	NULL
alone	NULL
(	NULL
one-	NULL
to	NULL
sevenfold	NULL
increase	NULL
)	NULL
.	NULL

Most	NULL
striking	NULL
was	NULL
the	NULL
effect	NULL
of	NULL
Z	NULL
and	NULL
c-myb	NULL
together	NULL
in	NULL
this	NULL
cell	NULL
type	NULL
,	NULL
producing	NULL
increases	NULL
in	NULL
EA-CAT	NULL
activity	NULL
from	NULL
25-	NULL
to	NULL
150-fold	NULL
in	NULL
different	NULL
experiments	NULL
.	NULL

In	NULL
the	NULL
EBV-positive	NULL
B-cell	NULL
line	NULL
Raji	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
,	NULL
the	NULL
effect	NULL
of	NULL
Z	NULL
alone	NULL
is	NULL
more	NULL
efficient	NULL
,	NULL
since	NULL
Z	NULL
activates	NULL
the	NULL
expression	NULL
of	NULL
another	NULL
EBV-encoded	NULL
transactivator	NULL
,	NULL
BRLF1	NULL
,	NULL
and	NULL
we	NULL
have	NULL
previously	NULL
shown	NULL
that	NULL
Z	NULL
and	NULL
BRLF1	NULL
interact	NULL
synergistically	NULL
to	NULL
activate	NULL
the	NULL
BMRF1	NULL
promoter	NULL
in	NULL
lymphoid	NULL
cells	NULL
(	NULL
21	NULL
)	NULL
.	NULL

Nevertheless	NULL
,	NULL
the	NULL
addition	NULL
of	NULL
c-myb	NULL
to	NULL
Z	NULL
in	NULL
Raji	NULL
cells	NULL
consistently	NULL
results	NULL
in	NULL
approximately	NULL
fourfold-higher	NULL
levels	NULL
of	NULL
BMRF1	NULL
promoter	NULL
activation	NULL
than	NULL
seen	NULL
with	NULL
Z	NULL
alone	NULL
,	NULL
even	NULL
though	NULL
the	NULL
c-myb	NULL
transactivator	NULL
by	NULL
itself	NULL
has	NULL
little	NULL
,	NULL
if	NULL
any	NULL
,	NULL
effect	NULL
on	NULL
BMRF1	NULL
promoter	NULL
activity	NULL
in	NULL
this	NULL
cell	NULL
c-myb	NULL
AND	NULL
BZLF1	NULL
INTERACT	NULL
SYNERGISTICALLY	NULL
139	NULL
|	NULL
l	NULL
B	NULL
+	NULL
a	NULL
5	NULL
m	NULL
€	NULL
a	NULL
*A	NULL
§	NULL
£108	NULL
$	NULL
2	NULL
$	NULL
>	NULL
'	NULL
¢	NULL
€	NULL
f	NULL
¥	NULL
.	NULL

E	NULL
#	NULL
r	NULL
<	NULL
N	NULL
0	NULL
N	NULL
G	NULL
q	NULL
N-	NULL
6	NULL
N6	NULL
§	NULL
.	NULL

3	NULL
£	NULL
2C	NULL
ul	NULL
+	NULL
£	NULL
.	NULL

z	NULL
£	NULL
J	NULL
+	NULL
ut	NULL
<	NULL
+	NULL
«	NULL
bits	NULL
s	NULL
#	NULL
<	NULL
li	NULL
#	NULL
6	NULL
8	NULL
8	NULL
t	NULL
&	NULL
a	NULL
``	NULL
*	NULL
%	NULL
2528	NULL
21	NULL
Ser	NULL
%	NULL
OSs	NULL
109	NULL
04	NULL
443	NULL
%	NULL
05	NULL
213	NULL
O7	NULL
185	NULL
``	NULL
_	NULL
g	NULL
S	NULL
<	NULL
.	NULL

E	NULL
:	NULL
&	NULL
a	NULL
a	NULL
9	NULL
T	NULL
E	NULL
o	NULL
2	NULL
2	NULL
<	NULL
o	NULL
NG	NULL
o	NULL
f	NULL
E	NULL
L	NULL
+	NULL
++	NULL
a	NULL
N	NULL
o	NULL
N	NULL
o	NULL
a	NULL
.	NULL

+	NULL
+	NULL
+	NULL
+	NULL
¥	NULL
©	NULL
+-L	NULL
J	NULL
@	NULL
&	NULL
©	NULL
~	NULL
6	NULL
0	NULL
0	NULL
¢	NULL
KOT	NULL
aft	NULL
(	NULL
so	NULL
sss	NULL
%	NULL
2.7	NULL
9	NULL
%	NULL
n	NULL
36	NULL
894	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Evidence	NULL
that	NULL
the	NULL
EBV	NULL
Z	NULL
transactivator/c-myb	NULL
combination	NULL
synergistically	NULL
activates	NULL
the	NULL
EBV	NULL
BMRF1	NULL
and	NULL
SV40	NULL
early	NULL
promoters	NULL
.	NULL

The	NULL
BMRF1	NULL
promoter-CAT	NULL
construct	NULL
(	NULL
EAD-CAT	NULL
)	NULL
was	NULL
transfected	NULL
into	NULL
the	NULL
Jurkat	NULL
T-cell	NULL
line	NULL
(	NULL
A	NULL
)	NULL
,	NULL
the	NULL
EBV-positive	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
cell	NULL
line	NULL
Raji	NULL
(	NULL
B	NULL
)	NULL
,	NULL
HeLa	NULL
cells	NULL
(	NULL
C	NULL
)	NULL
,	NULL
or	NULL
the	NULL
EBV-positive	NULL
epithelial	NULL
cell	NULL
line	NULL
NPC-KT	NULL
(	NULL
D	NULL
)	NULL
.	NULL

The	NULL
EAD-CAT	NULL
plasmid	NULL
was	NULL
cotransfected	NULL
with	NULL
either	NULL
vector	NULL
control	NULL
DNA	NULL
,	NULL
the	NULL
Z	NULL
transactivator	NULL
alone	NULL
,	NULL
the	NULL
c-myb	NULL
transactivator	NULL
alone	NULL
,	NULL
or	NULL
the	NULL
Z	NULL
and	NULL
c-myb	NULL
transactivators	NULL
together	NULL
.	NULL

In	NULL
Jurkat	NULL
and	NULL
Raji	NULL
cells	NULL
,	NULL
the	NULL
combination	NULL
of	NULL
Z	NULL
and	NULL
c-myb	NULL
is	NULL
synergistic	NULL
,	NULL
whereas	NULL
in	NULL
HeLa	NULL
and	NULL
NPC-KT	NULL
cells	NULL
,	NULL
Z	NULL
alone	NULL
is	NULL
as	NULL
effective	NULL
as	NULL
Z	NULL
and	NULL
c-myb	NULL
together	NULL
.	NULL

The	NULL
SV40	NULL
early	NULL
promoter	NULL
(	NULL
pA1OCAT	NULL
)	NULL
(	NULL
31	NULL
)	NULL
is	NULL
also	NULL
synergistically	NULL
activated	NULL
in	NULL
Jurkat	NULL
cells	NULL
by	NULL
the	NULL
combination	NULL
of	NULL
Z	NULL
and	NULL
c-myb	NULL
(	NULL
E	NULL
)	NULL
.	NULL

type	NULL
.	NULL

However	NULL
,	NULL
the	NULL
combination	NULL
of	NULL
Z	NULL
and	NULL
c-myb	NULL
was	NULL
no	NULL
more	NULL
effective	NULL
than	NULL
Z	NULL
alone	NULL
in	NULL
two	NULL
different	NULL
epithelial	NULL
lines	NULL
,	NULL
the	NULL
EBV-negative	NULL
HeLa	NULL
cell	NULL
line	NULL
(	NULL
Fig	NULL
.	NULL

3C	NULL
)	NULL
and	NULL
the	NULL
EBV-positive	NULL
NPC-KT	NULL
cell	NULL
line	NULL
(	NULL
Fig	NULL
.	NULL

3D	NULL
)	NULL
.	NULL

In	NULL
these	NULL
cell	NULL
lines	NULL
,	NULL
Z	NULL
by	NULL
itself	NULL
efficiently	NULL
transactivates	NULL
the	NULL
BMRF1	NULL
promoter	NULL
.	NULL

The	NULL
SV40	NULL
early	NULL
promoter	NULL
(	NULL
pA10CAT	NULL
construct	NULL
)	NULL
(	NULL
31	NULL
)	NULL
,	NULL
which	NULL
contains	NULL
an	NULL
AP-1	NULL
binding	NULL
site	NULL
,	NULL
was	NULL
also	NULL
synergistically	NULL
activated	NULL
by	NULL
the	NULL
combination	NULL
of	NULL
Z	NULL
and	NULL
c-myb	NULL
in	NULL
Jurkat	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

3E	NULL
)	NULL
.	NULL

However	NULL
,	NULL
c-myb	NULL
did	NULL
not	NULL
affect	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
EBV	NULL
BMLFl	NULL
promoter	NULL
(	NULL
with	NULL
or	NULL
without	NULL
Z	NULL
)	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
although	NULL
this	NULL
promoter	NULL
contains	NULL
an	NULL
AP-1	NULL
site	NULL
which	NULL
has	NULL
previously	NULL
been	NULL
shown	NULL
to	NULL
bind	NULL
the	NULL
Z	NULL
protein	NULL
(	NULL
11	NULL
)	NULL
.	NULL

BMRF1I-driven	NULL
CAT	NULL
RNA	NULL
is	NULL
increased	NULL
by	NULL
the	NULL
Z/c-myh	NULL
combination	NULL
.	NULL

In	NULL
previous	NULL
studies	NULL
,	NULL
we	NULL
have	NULL
mapped	NULL
the	NULL
RNA	NULL
start	NULL
site	NULL
of	NULL
the	NULL
BMRFI	NULL
promoter	NULL
to	NULL
EBV	NULL
sequence	NULL
79869	NULL
(	NULL
approximately	NULL
25	NULL
bp	NULL
downstream	NULL
of	NULL
a	NULL
potential	NULL
TATA	NULL
box	NULL
element	NULL
)	NULL
and	NULL
shown	NULL
that	NULL
the	NULL
RNA	NULL
start	NULL
site	NULL
is	NULL
not	NULL
altered	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
Z	NULL
transactivator	NULL
(	NULL
21	NULL
)	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
used	NULL
S1	NULL
nuclease	NULL
analysis	NULL
to	NULL
examine	NULL
the	NULL
effect	NULL
of	NULL
the	NULL
Z/c-myb	NULL
combination	NULL
on	NULL
the	NULL
steady-state	NULL
level	NULL
of	NULL
EA-CAT	NULL
RNA	NULL
.	NULL

In	NULL
the	NULL
experiment	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
5	NULL
ug	NULL
of	NULL
the	NULL
EA-CAT	NULL
construct	NULL
was	NULL
cotransfected	NULL
with	NULL
5	NULL
pg	NULL
of	NULL
either	NULL
vector	NULL
DNA	NULL
alone	NULL
(	NULL
pHD1013	NULL
)	NULL
,	NULL
the	NULL
c-myb	NULL
construct	NULL
alone	NULL
,	NULL
the	NULL
EBV-ZIE	NULL
construct	NULL
(	NULL
a	NULL
vector	NULL
which	NULL
contains	NULL
the	NULL
Z	NULL
gene	NULL
product	NULL
in	NULL
plasmid	NULL
pHD1013	NULL
driven	NULL
by	NULL
the	NULL
CMV	NULL
IE	NULL
promoter	NULL
[	NULL
21	NULL
]	NULL
)	NULL
alone	NULL
,	NULL
or	NULL
the	NULL
combination	NULL
of	NULL
c-myb	NULL
and	NULL
Z.	NULL
Cytoplasmic	NULL
RNA	NULL
was	NULL
harvested	NULL
24	NULL
h	NULL
after	NULL
transfection	NULL
,	NULL
hybridized	NULL
to	NULL
a	NULL
uniformly	NULL
*°P-labelled	NULL
single-stranded	NULL
DNA	NULL
probe	NULL
homologous	NULL
to	NULL
the	NULL
EA-CAT	NULL
gene	NULL
sequences	NULL
extending	NULL
from	NULL
254	NULL
bp	NULL
downstream	NULL
of	NULL
the	NULL
CAT	NULL
ATG	NULL
codon	NULL
to	NULL
331	NULL
bp	NULL
upstream	NULL
of	NULL
the	NULL
presumed	NULL
RNA	NULL
start	NULL
site	NULL
,	NULL
and	NULL
digested	NULL
140	NULL
KENNEY	NULL
ET	NULL
AL	NULL
.	NULL

Probe	NULL
pHD	NULL
1013	NULL
myb	NULL
Z	NULL
+	NULL
myb	NULL
-281	NULL
nt	NULL
-	NULL
271	NULL
nt	NULL
4	NULL
-	NULL
234	NULL
nt	NULL
-	NULL
194	NULL
nt	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

Effect	NULL
of	NULL
the	NULL
Z/c-myb	NULL
transactivator	NULL
combination	NULL
on	NULL
steady-state	NULL
CAT	NULL
mRNA	NULL
level	NULL
.	NULL

The	NULL
BMRF1	NULL
promoter-CAT	NULL
construct	NULL
(	NULL
EAD-CAT	NULL
)	NULL
was	NULL
transfected	NULL
into	NULL
Jurkat	NULL
cells	NULL
with	NULL
either	NULL
control	NULL
vector	NULL
DNA	NULL
,	NULL
the	NULL
Z	NULL
transactivator	NULL
alone	NULL
,	NULL
the	NULL
c-myb	NULL
transactivator	NULL
alone	NULL
,	NULL
or	NULL
the	NULL
combination	NULL
of	NULL
both	NULL
transactivators	NULL
.	NULL

Cytoplasmic	NULL
RNA	NULL
was	NULL
harvested	NULL
24	NULL
h	NULL
after	NULL
transfection	NULL
,	NULL
hybridized	NULL
with	NULL
a	NULL
complementary	NULL
P-labelled	NULL
single-stranded	NULL
DNA	NULL
probe	NULL
extending	NULL
from	NULL
331	NULL
bp	NULL
upstream	NULL
of	NULL
the	NULL
expected	NULL
RNA	NULL
start	NULL
site	NULL
to	NULL
254	NULL
bp	NULL
downstream	NULL
of	NULL
the	NULL
CAT	NULL
ATG	NULL
codon	NULL
,	NULL
and	NULL
digested	NULL
with	NULL
S1	NULL
nuclease	NULL
.	NULL

The	NULL
combination	NULL
of	NULL
the	NULL
Z	NULL
and	NULL
c-myb	NULL
transactivators	NULL
significantly	NULL
increased	NULL
the	NULL
level	NULL
of	NULL
EAD-CAT	NULL
mRNA	NULL
.	NULL

nt	NULL
,	NULL
nucleotides	NULL
.	NULL

with	NULL
S1	NULL
nuclease	NULL
.	NULL

In	NULL
cells	NULL
transfected	NULL
with	NULL
the	NULL
Z/c-myb	NULL
combination	NULL
,	NULL
an	NULL
Sl-protected	NULL
fragment	NULL
of	NULL
the	NULL
expected	NULL
size	NULL
(	NULL
approximately	NULL
260	NULL
bp	NULL
)	NULL
is	NULL
observed	NULL
;	NULL
moreover	NULL
,	NULL
the	NULL
level	NULL
of	NULL
EA-CAT	NULL
mRNA	NULL
is	NULL
clearly	NULL
increased	NULL
.	NULL

Localization	NULL
of	NULL
the	NULL
BMRF1	NULL
promoter	NULL
regions	NULL
required	NULL
for	NULL
response	NULL
to	NULL
the	NULL
Z/c-myb	NULL
combination	NULL
.	NULL

To	NULL
define	NULL
the	NULL
region	NULL
(	NULL
s	NULL
)	NULL
of	NULL
the	NULL
BMRF1	NULL
promoter	NULL
that	NULL
is	NULL
required	NULL
for	NULL
maximal	NULL
responsiveness	NULL
to	NULL
the	NULL
Z/c-myb	NULL
transactivator	NULL
combination	NULL
,	NULL
we	NULL
constructed	NULL
a	NULL
series	NULL
of	NULL
5	NULL
'	NULL
deletions	NULL
of	NULL
the	NULL
BMRF1	NULL
promoter	NULL
(	NULL
linked	NULL
to	NULL
CAT	NULL
)	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
21	NULL
)	NULL
and	NULL
tested	NULL
the	NULL
ability	NULL
of	NULL
each	NULL
construct	NULL
to	NULL
respond	NULL
to	NULL
Z	NULL
alone	NULL
or	NULL
to	NULL
the	NULL
combination	NULL
of	NULL
Z	NULL
plus	NULL
c-myb	NULL
in	NULL
lymphoid	NULL
cells	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

In	NULL
this	NULL
set	NULL
of	NULL
experiments	NULL
,	NULL
the	NULL
parent	NULL
construct	NULL
,	NULL
which	NULL
contains	NULL
BMRF1	NULL
promoter	NULL
sequences	NULL
from	NULL
-331	NULL
to	NULL
+1	NULL
TABLE	NULL
1	NULL
.	NULL

Effects	NULL
of	NULL
the	NULL
Z	NULL
transactivator	NULL
alone	NULL
and	NULL
of	NULL
the	NULL
Z/c-myb	NULL
combination	NULL
on	NULL
pEA-CAT	NULL
deletion	NULL
plasmids	NULL
in	NULL
Jurkat	NULL
cells	NULL
Fold	NULL
increase	NULL
in	NULL
CAT	NULL
activity	NULL
``	NULL
Plasmid	NULL
Z	NULL
transactivator	NULL
Zic-myb	NULL
Avg	NULL
Range	NULL
Avg	NULL
Range	NULL
pEA-CAT	NULL
(	NULL
-331/+1	NULL
)	NULL
2.3	NULL
2.1-2.4	NULL
92.8	NULL
47.6-137.9	NULL
pEA-CAT	NULL
(	NULL
-265/+1	NULL
)	NULL
11.9	NULL
4.0-19.7	NULL
152.5	NULL
152.1-152.8	NULL
pEA-CAT	NULL
(	NULL
-214/+29	NULL
)	NULL
3.4	NULL
2.5-4.2	NULL
37.3	NULL
14.5-50.0	NULL
pEA-CAT	NULL
(	NULL
-79/+1	NULL
)	NULL
1.5	NULL
0.5-2.4	NULL
32.3	NULL
30.2-34.3	NULL
pEA-CAT	NULL
(	NULL
-62/+29	NULL
)	NULL
0.7	NULL
0.7-0.7	NULL
2.2	NULL
1.7-2.6	NULL
``	NULL
Values	NULL
represent	NULL
the	NULL
average	NULL
fold	NULL
increase	NULL
in	NULL
CAT	NULL
activity	NULL
when	NULL
each	NULL
CAT	NULL
plasmid	NULL
was	NULL
cotransfected	NULL
with	NULL
the	NULL
Z	NULL
transactivator	NULL
alone	NULL
(	NULL
pEBV-ZIE	NULL
)	NULL
or	NULL
with	NULL
the	NULL
combination	NULL
of	NULL
Z	NULL
and	NULL
c-myb	NULL
.	NULL

Ranges	NULL
are	NULL
those	NULL
seen	NULL
in	NULL
two	NULL
experiments	NULL
.	NULL

Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

relative	NULL
to	NULL
the	NULL
RNA	NULL
start	NULL
site	NULL
,	NULL
was	NULL
transactivated	NULL
an	NULL
average	NULL
of	NULL
93-fold	NULL
by	NULL
the	NULL
combination	NULL
of	NULL
Z	NULL
and	NULL
c-myb	NULL
,	NULL
versus	NULL
only	NULL
2.3-fold	NULL
by	NULL
Z	NULL
alone	NULL
in	NULL
the	NULL
same	NULL
set	NULL
of	NULL
experiments	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
the	NULL
Z	NULL
transactivator	NULL
alone	NULL
(	NULL
as	NULL
was	NULL
observed	NULL
previously	NULL
[	NULL
21	NULL
]	NULL
)	NULL
could	NULL
be	NULL
significantly	NULL
increased	NULL
by	NULL
deleting	NULL
the	NULL
sequences	NULL
between	NULL
-331	NULL
and	NULL
-265	NULL
,	NULL
although	NULL
even	NULL
with	NULL
this	NULL
construct	NULL
the	NULL
effect	NULL
of	NULL
Z	NULL
and	NULL
c-myb	NULL
together	NULL
was	NULL
still	NULL
much	NULL
greater	NULL
than	NULL
that	NULL
of	NULL
Z	NULL
alone	NULL
(	NULL
152-fold	NULL
transactivation	NULL
versus	NULL
12-fold	NULL
)	NULL
.	NULL

A	NULL
significant	NULL
loss	NULL
in	NULL
the	NULL
response	NULL
of	NULL
the	NULL
promoter	NULL
to	NULL
the	NULL
Z/c-myb	NULL
combination	NULL
occurred	NULL
when	NULL
the	NULL
sequences	NULL
between	NULL
-265	NULL
and	NULL
-214	NULL
were	NULL
deleted	NULL
,	NULL
although	NULL
a	NULL
substantial	NULL
transactivation	NULL
effect	NULL
still	NULL
remained	NULL
(	NULL
37-fold	NULL
transactivation	NULL
)	NULL
.	NULL

The	NULL
most	NULL
precipitous	NULL
drop	NULL
in	NULL
transactivation	NULL
with	NULL
the	NULL
Z/c-myb	NULL
combination	NULL
occurred	NULL
when	NULL
the	NULL
sequences	NULL
between	NULL
-79	NULL
and	NULL
-62	NULL
were	NULL
deleted	NULL
,	NULL
with	NULL
transactivation	NULL
decreasing	NULL
from	NULL
32-fold	NULL
to	NULL
only	NULL
2-fold	NULL
as	NULL
these	NULL
sequences	NULL
were	NULL
re-moved	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
sequences	NULL
between	NULL
-62	NULL
and	NULL
-79	NULL
appear	NULL
to	NULL
be	NULL
most	NULL
important	NULL
for	NULL
response	NULL
of	NULL
the	NULL
EAD	NULL
promoter	NULL
to	NULL
the	NULL
Z/c-myb	NULL
combination	NULL
.	NULL

The	NULL
Z	NULL
protein	NULL
binds	NULL
to	NULL
the	NULL
AP-1	NULL
site	NULL
in	NULL
the	NULL
BMRF1	NULL
promoter	NULL
.	NULL

Although	NULL
the	NULL
BMRF1	NULL
promoter	NULL
contains	NULL
a	NULL
consensus	NULL
AP-1	NULL
binding	NULL
site	NULL
,	NULL
the	NULL
binding	NULL
of	NULL
Z	NULL
protein	NULL
to	NULL
this	NULL
promoter	NULL
has	NULL
not	NULL
been	NULL
previously	NULL
studied	NULL
.	NULL

We	NULL
used	NULL
in	NULL
vitro-transcribed	NULL
and	NULL
-translated	NULL
Z	NULL
protein	NULL
to	NULL
study	NULL
Z	NULL
binding	NULL
to	NULL
the	NULL
BMRF1	NULL
promoter	NULL
.	NULL

In	NULL
gel	NULL
retardation	NULL
assays	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
)	NULL
,	NULL
in	NULL
vitro-translated	NULL
Z	NULL
protein	NULL
produced	NULL
retarded	NULL
bands	NULL
when	NULL
incubated	NULL
with	NULL
a	NULL
**P-labelled	NULL
probe	NULL
encompassing	NULL
the	NULL
BMRF1	NULL
promoter	NULL
sequences	NULL
from	NULL
-79	NULL
to	NULL
+128	NULL
(	NULL
relative	NULL
to	NULL
the	NULL
mRNA	NULL
start	NULL
site	NULL
)	NULL
.	NULL

Z	NULL
binding	NULL
to	NULL
this	NULL
probe	NULL
was	NULL
specifically	NULL
competed	NULL
for	NULL
by	NULL
cold	NULL
competitor	NULL
oligonucleotide	NULL
DNA	NULL
(	NULL
EAD	NULL
)	NULL
encompassing	NULL
the	NULL
BMRF1	NULL
promoter	NULL
sequences	NULL
from	NULL
-50	NULL
to	NULL
-83	NULL
(	NULL
which	NULL
contains	NULL
the	NULL
AP-1	NULL
site	NULL
)	NULL
but	NULL
not	NULL
by	NULL
competitor	NULL
DNA	NULL
(	NULL
AAP-1	NULL
)	NULL
in	NULL
which	NULL
the	NULL
AP-1	NULL
site	NULL
in	NULL
the	NULL
BMRF1	NULL
sequence	NULL
had	NULL
been	NULL
mutated	NULL
.	NULL

Competitor	NULL
DNA	NULL
(	NULL
AMYB	NULL
)	NULL
in	NULL
which	NULL
the	NULL
potential	NULL
c-Myb	NULL
binding	NULL
site	NULL
had	NULL
been	NULL
mutated	NULL
competed	NULL
for	NULL
Z	NULL
binding	NULL
with	NULL
the	NULL
same	NULL
affinity	NULL
as	NULL
did	NULL
the	NULL
wild-type	NULL
sequence	NULL
.	NULL

Methylation	NULL
protection	NULL
studies	NULL
of	NULL
the	NULL
bound	NULL
DNA	NULL
fragments	NULL
confirmed	NULL
that	NULL
the	NULL
Z	NULL
protein	NULL
,	NULL
as	NULL
expected	NULL
,	NULL
binds	NULL
to	NULL
the	NULL
AP-1	NULL
site	NULL
in	NULL
the	NULL
BMRF1	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
.	NULL

Z	NULL
also	NULL
binds	NULL
to	NULL
one	NULL
other	NULL
site	NULL
in	NULL
the	NULL
BMRF1	NULL
promoter	NULL
(	NULL
a	NULL
ZRE	NULL
site	NULL
)	NULL
located	NULL
at	NULL
position	NULL
-106	NULL
relative	NULL
to	NULL
the	NULL
mRNA	NULL
start	NULL
site	NULL
(	NULL
43a	NULL
)	NULL
.	NULL

Roles	NULL
of	NULL
the	NULL
BMRF1	NULL
promoter	NULL
AP-1	NULL
site	NULL
and	NULL
a	NULL
potential	NULL
c-Myb	NULL
binding	NULL
site	NULL
in	NULL
the	NULL
Z/c-myb	NULL
transactivation	NULL
response	NULL
.	NULL

The	NULL
5	NULL
'	NULL
deletional	NULL
analysis	NULL
of	NULL
the	NULL
BMRF1	NULL
promoter	NULL
suggested	NULL
that	NULL
sequences	NULL
located	NULL
between	NULL
-62	NULL
and	NULL
-79	NULL
were	NULL
required	NULL
for	NULL
maximum	NULL
response	NULL
to	NULL
the	NULL
Z/c-myb	NULL
combination	NULL
.	NULL

Examination	NULL
of	NULL
the	NULL
BMRF1	NULL
promoter	NULL
sequence	NULL
from	NULL
-62	NULL
to	NULL
-79	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
reveals	NULL
that	NULL
it	NULL
contains	NULL
a	NULL
consensus	NULL
AP-1	NULL
site	NULL
,	NULL
TGAGTCA	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
overlapping	NULL
the	NULL
AP-1	NULL
site	NULL
is	NULL
the	NULL
sequence	NULL
CCTTTG	NULL
,	NULL
which	NULL
is	NULL
a	NULL
1-bp	NULL
mismatch	NULL
from	NULL
the	NULL
consensus	NULL
c-Myb	NULL
binding	NULL
sequence	NULL
(	NULL
C/T	NULL
)	NULL
AAC	NULL
(	NULL
G/T	NULL
)	NULL
G	NULL
,	NULL
or	NULL
C	NULL
(	NULL
A/C	NULL
)	NULL
GTT	NULL
(	NULL
A/G	NULL
)	NULL
when	NULL
read	NULL
on	NULL
the	NULL
opposite	NULL
strand	NULL
5	NULL
'	NULL
to	NULL
3	NULL
'	NULL
.	NULL

Further	NULL
upstream	NULL
(	NULL
-106	NULL
relative	NULL
the	NULL
mRNA	NULL
start	NULL
site	NULL
)	NULL
is	NULL
another	NULL
Z	NULL
binding	NULL
site	NULL
(	NULL
43a	NULL
)	NULL
homologous	NULL
to	NULL
previously	NULL
reported	NULL
ZREs	NULL
(	NULL
4	NULL
,	NULL
11	NULL
,	NULL
13	NULL
,	NULL
29	NULL
,	NULL
35	NULL
,	NULL
43	NULL
,	NULL
45	NULL
,	NULL
50	NULL
,	NULL
55	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
the	NULL
AP-1	NULL
site	NULL
,	NULL
the	NULL
ZRE	NULL
,	NULL
or	NULL
the	NULL
potential	NULL
c-Myb	NULL
binding	NULL
site	NULL
contributes	NULL
to	NULL
transactivation	NULL
of	NULL
the	NULL
BMRF1	NULL
promoter	NULL
by	NULL
the	NULL
Z/c-myb	NULL
combination	NULL
,	NULL
we	NULL
made	NULL
site-directed	NULL
mutations	NULL
which	NULL
specifically	NULL
abolished	NULL
either	NULL
the	NULL
AP-1	NULL
site	NULL
alone	NULL
,	NULL
the	NULL
AP-1	NULL
site	NULL
and	NULL
the	NULL
ZRE	NULL
simulta-neously	NULL
,	NULL
or	NULL
the	NULL
potential	NULL
c-Myb	NULL
binding	NULL
site	NULL
.	NULL

We	NULL
then	NULL
tested	NULL
these	NULL
mutated	NULL
promoter	NULL
constructs	NULL
for	NULL
the	NULL
ability	NULL
to	NULL
respond	NULL
to	NULL
Z	NULL
alone	NULL
,	NULL
c-myb	NULL
alone	NULL
,	NULL
or	NULL
the	NULL
combination	NULL
of	NULL
Z	NULL
and	NULL
c-myb	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

In	NULL
this	NULL
set	NULL
of	NULL
experiments	NULL
,	NULL
the	NULL
average	NULL
fold	NULL
increase	NULL
in	NULL
Vor	NULL
.	NULL

12	NULL
,	NULL
1992	NULL
A	NULL
7	NULL
as	NULL
as	NULL
22	NULL
i	NULL
=a	NULL
®	NULL
os	NULL
28	NULL
PB	NULL
Po	NULL
4549	NULL
c	NULL
Tol	NULL
R	NULL
-	NULL
'	NULL
40	NULL
«	NULL
4p	NULL
Ep	NULL
E	NULL
190	NULL
<	NULL
6	NULL
COMPETITOR	NULL
mS	NULL
mS	NULL
48	NULL
428	NULL
48	NULL
42	NULL
PROTEIN	NULL
:	NULL
-	NULL
Z	NULL
Lad	NULL
D	NULL
P	NULL
T	NULL
T	NULL
€	NULL
1	NULL
{	NULL
€	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

Binding	NULL
of	NULL
the	NULL
Z	NULL
protein	NULL
to	NULL
the	NULL
AP-1	NULL
site	NULL
in	NULL
the	NULL
BMRF1	NULL
promoter	NULL
.	NULL

(	NULL
A	NULL
)	NULL
In	NULL
vitro-transcribed	NULL
and	NULL
translated	NULL
Z	NULL
protein	NULL
was	NULL
incubated	NULL
with	NULL
a	NULL
*P-labelled	NULL
probe	NULL
containing	NULL
the	NULL
BMRF1	NULL
promoter	NULL
sequences	NULL
from	NULL
-79	NULL
to	NULL
+126	NULL
(	NULL
relative	NULL
to	NULL
the	NULL
mRNA	NULL
start	NULL
site	NULL
)	NULL
at	NULL
23°C	NULL
for	NULL
30	NULL
min	NULL
,	NULL
and	NULL
then	NULL
the	NULL
products	NULL
were	NULL
resolved	NULL
by	NULL
gel	NULL
electrophoresis	NULL
and	NULL
autoradiography	NULL
.	NULL

The	NULL
in	NULL
vitro-translated	NULL
Z	NULL
protein	NULL
produced	NULL
retarded	NULL
complexes	NULL
with	NULL
the	NULL
BMRF1	NULL
promoter	NULL
probe	NULL
that	NULL
were	NULL
not	NULL
seen	NULL
with	NULL
the	NULL
untranslated	NULL
wheat	NULL
germ	NULL
extract	NULL
alone	NULL
(	NULL
last	NULL
lane	NULL
)	NULL
.	NULL

Competition	NULL
studies	NULL
showed	NULL
that	NULL
cold	NULL
competitor	NULL
DNA	NULL
(	NULL
at	NULL
20-	NULL
and	NULL
100-fold	NULL
molar	NULL
excess	NULL
)	NULL
containing	NULL
the	NULL
BMRF1	NULL
promoter	NULL
sequences	NULL
from	NULL
-50	NULL
to	NULL
-83	NULL
(	NULL
oligonucleotide	NULL
EAD	NULL
)	NULL
specifically	NULL
competed	NULL
for	NULL
Z	NULL
binding	NULL
.	NULL

Cold	NULL
competitor	NULL
DNA	NULL
containing	NULL
the	NULL
same	NULL
sequences	NULL
but	NULL
with	NULL
the	NULL
AP-1	NULL
site	NULL
abolished	NULL
(	NULL
oligonucleotide	NULL
AAP-1	NULL
)	NULL
did	NULL
not	NULL
compete	NULL
.	NULL

Competitor	NULL
DNA	NULL
which	NULL
abolished	NULL
the	NULL
potential	NULL
c-Myb	NULL
binding	NULL
site	NULL
(	NULL
oligonucleotide	NULL
AMYB	NULL
)	NULL
competed	NULL
for	NULL
Z	NULL
binding	NULL
with	NULL
the	NULL
same	NULL
efficiency	NULL
as	NULL
did	NULL
the	NULL
wild-type	NULL
sequence	NULL
.	NULL

(	NULL
B	NULL
)	NULL
A	NULL
*P-end-labelled	NULL
probe	NULL
containing	NULL
the	NULL
BMRF1	NULL
promoter	NULL
sequences	NULL
from	NULL
-79	NULL
to	NULL
+126	NULL
was	NULL
incubated	NULL
with	NULL
in	NULL
vitro-translated	NULL
Z	NULL
protein	NULL
and	NULL
then	NULL
treated	NULL
with	NULL
dimethylsulfate	NULL
immediately	NULL
prior	NULL
to	NULL
gel	NULL
electrophoresis	NULL
.	NULL

Two	NULL
different	NULL
retarded	NULL
gel	NULL
complexes	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
3	NULL
,	NULL
with	NULL
lane	NULL
3	NULL
having	NULL
the	NULL
most	NULL
retarded	NULL
complex	NULL
)	NULL
and	NULL
the	NULL
free	NULL
probe	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
were	NULL
removed	NULL
separately	NULL
,	NULL
cut	NULL
with	NULL
piperidine	NULL
,	NULL
and	NULL
then	NULL
analyzed	NULL
on	NULL
a	NULL
6	NULL
%	NULL
polyacrylamide-urea	NULL
gel	NULL
.	NULL

The	NULL
position	NULL
of	NULL
the	NULL
AP-1	NULL
binding	NULL
site	NULL
is	NULL
as	NULL
shown	NULL
.	NULL

Binding	NULL
by	NULL
Z	NULL
to	NULL
the	NULL
BMRF1	NULL
probe	NULL
appears	NULL
to	NULL
protect	NULL
the	NULL
BMRF1	NULL
probe	NULL
from	NULL
methylation	NULL
.	NULL

EA-CAT	NULL
activity	NULL
induced	NULL
by	NULL
Z	NULL
alone	NULL
in	NULL
Jurkat	NULL
cells	NULL
was	NULL
3.8	NULL
,	NULL
the	NULL
average	NULL
fold	NULL
increase	NULL
induced	NULL
by	NULL
c-myb	NULL
alone	NULL
was	NULL
2.5	NULL
,	NULL
and	NULL
the	NULL
average	NULL
fold	NULL
increase	NULL
induced	NULL
by	NULL
both	NULL
transactivators	NULL
together	NULL
was	NULL
32.3	NULL
.	NULL

When	NULL
the	NULL
AP-1	NULL
site	NULL
was	NULL
abolished	NULL
by	NULL
site-directed	NULL
mutation	NULL
,	NULL
the	NULL
effect	NULL
of	NULL
Z	NULL
alone	NULL
decreased	NULL
significantly	NULL
(	NULL
down	NULL
to	NULL
0.9	NULL
)	NULL
,	NULL
as	NULL
did	NULL
the	NULL
effect	NULL
of	NULL
Z	NULL
and	NULL
c-myb	NULL
together	NULL
(	NULL
down	NULL
from	NULL
32.3	NULL
to	NULL
8.5	NULL
)	NULL
.	NULL

The	NULL
residual	NULL
8	NULL
.	NULL

5-fold	NULL
effect	NULL
of	NULL
the	NULL
Z/c-myb	NULL
combination	NULL
on	NULL
this	NULL
mutant	NULL
was	NULL
essentially	NULL
lost	NULL
when	NULL
the	NULL
upstream	NULL
ZRE	NULL
was	NULL
also	NULL
destroyed	NULL
(	NULL
down	NULL
to	NULL
2.4-fold	NULL
effect	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
it	NULL
appears	NULL
that	NULL
at	NULL
least	NULL
one	NULL
Z	NULL
c-myb	NULL
AND	NULL
BZLF1	NULL
INTERACT	NULL
SYNERGISTICALLY	NULL
141	NULL
TABLE	NULL
2	NULL
.	NULL

Effects	NULL
of	NULL
the	NULL
Z	NULL
transactivator	NULL
,	NULL
the	NULL
c-myb	NULL
transactivator	NULL
,	NULL
and	NULL
the	NULL
Z/c-myb	NULL
combination	NULL
on	NULL
pEA-BS-CAT	NULL
site-directed	NULL
mutants	NULL
in	NULL
Jurkat	NULL
cells	NULL
Fold	NULL
increase	NULL
in	NULL
CAT	NULL
activity	NULL
``	NULL
Plasmid	NULL
Z	NULL
alone	NULL
¢-myb	NULL
alone	NULL
ZIC-myb	NULL
Avg	NULL
Range	NULL
Avg	NULL
-	NULL
Range	NULL
-	NULL
Avg	NULL
Range	NULL
pEA-BS-CAT	NULL
3.8	NULL
1.2-5.8	NULL
2.5	NULL
0.9-3.5	NULL
32.3	NULL
22.6-39.8	NULL
pEAAAP-1-CAT	NULL
0.9	NULL
0.6-1.2	NULL
1.7	NULL
1.1-2.2	NULL
8.50	NULL
4.5-15.9	NULL
pEAAAP-1/106	NULL
0.3	NULL
0.1-0.7	NULL
1.7	NULL
Q.4-2.8	NULL
2.4	NULL
1.8-6.0	NULL
pEAAMYB-CAT	NULL
12.9	NULL
6.9-23.5	NULL
3.2	NULL
1.7-4.6	NULL
40.2	NULL
22.8-61.1	NULL
``	NULL
Values	NULL
represent	NULL
the	NULL
average	NULL
fold	NULL
increase	NULL
in	NULL
CAT	NULL
activity	NULL
when	NULL
each	NULL
CAT	NULL
plasmid	NULL
was	NULL
cotransfected	NULL
with	NULL
Either	NULL
Z	NULL
alone	NULL
,	NULL
c-myb	NULL
alone	NULL
,	NULL
or	NULL
the	NULL
combination	NULL
of	NULL
both	NULL
transactivators	NULL
.	NULL

Ranges	NULL
are	NULL
those	NULL
seen	NULL
in	NULL
three	NULL
experiments	NULL
.	NULL

binding	NULL
site	NULL
is	NULL
required	NULL
for	NULL
the	NULL
synergistic	NULL
Z/c-myh	NULL
transactivation	NULL
effect	NULL
.	NULL

.	NULL

When	NULL
the	NULL
potential	NULL
c-Myb	NULL
binding	NULL
site	NULL
was	NULL
abolished	NULL
by	NULL
site-directed	NULL
mutation	NULL
,	NULL
the	NULL
effect	NULL
of	NULL
both	NULL
transactivators	NULL
together	NULL
was	NULL
not	NULL
diminished	NULL
,	NULL
nor	NULL
was	NULL
the	NULL
effect	NULL
of	NULL
c-myb	NULL
alone	NULL
.	NULL

Therefore	NULL
,	NULL
it	NULL
seems	NULL
unlikely	NULL
that	NULL
the	NULL
Z/c-myb	NULL
synergy	NULL
is	NULL
mediated	NULL
through	NULL
binding	NULL
of	NULL
c-Myb	NULL
to	NULL
this	NULL
site	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
it	NULL
would	NULL
be	NULL
somewhat	NULL
surprising	NULL
if	NULL
c-Myb	NULL
were	NULL
to	NULL
bind	NULL
to	NULL
this	NULL
site	NULL
,	NULL
since	NULL
the	NULL
substitution	NULL
of	NULL
C	NULL
to	NULL
A	NULL
in	NULL
the	NULL
fourth	NULL
position	NULL
of	NULL
the	NULL
consensus	NULL
Myb	NULL
binding	NULL
site	NULL
(	NULL
PyAACG/TG	NULL
)	NULL
has	NULL
been	NULL
previously	NULL
shown	NULL
to	NULL
inhibit	NULL
binding	NULL
by	NULL
v-Myb	NULL
(	NULL
23	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
effect	NULL
of	NULL
Z	NULL
alone	NULL
in	NULL
Jurkat	NULL
cells	NULL
was	NULL
unexpectedly	NULL
somewhat	NULL
increased	NULL
(	NULL
from	NULL
3.8-	NULL
to	NULL
12.9-fold	NULL
)	NULL
.	NULL

v-myb	NULL
protein	NULL
does	NULL
not	NULL
bind	NULL
to	NULL
the	NULL
BMRF1	NULL
promoter	NULL
.	NULL

Although	NULL
site-directed	NULL
mutagenesis	NULL
of	NULL
the	NULL
CCTTTG	NULL
sequence	NULL
suggested	NULL
that	NULL
this	NULL
sequence	NULL
itself	NULL
is	NULL
not	NULL
required	NULL
for	NULL
Z/c-myb	NULL
activation	NULL
of	NULL
the	NULL
BMRF1	NULL
promoter	NULL
,	NULL
c-Myb	NULL
could	NULL
potentially	NULL
bind	NULL
elsewhere	NULL
in	NULL
the	NULL
promoter	NULL
,	NULL
using	NULL
a	NULL
novel	NULL
binding	NULL
site	NULL
.	NULL

Since	NULL
the	NULL
bihding	NULL
affinities	NULL
of	NULL
the	NULL
c-myb	NULL
and	NULL
v-myb	NULL
proteins	NULL
are	NULL
thought	NULL
to	NULL
be	NULL
essentially	NULL
identical	NULL
,	NULL
we	NULL
used	NULL
a	NULL
bacterial	NULL
vector	NULL
expressing	NULL
a	NULL
v-myb	NULL
fusion	NULL
protein	NULL
(	NULL
a	NULL
gift	NULL
from	NULL
J.	NULL
Lipsick	NULL
)	NULL
,	NULL
T7MYB	NULL
(	NULL
14	NULL
)	NULL
,	NULL
to	NULL
study	NULL
potential	NULL
myb	NULL
protein	NULL
binding	NULL
to	NULL
the	NULL
BMRF1	NULL
promoter	NULL
.	NULL

Using	NULL
this	NULL
fusion	NULL
protein	NULL
,	NULL
we	NULL
routinely	NULL
observed	NULL
strong	NULL
binding	NULL
to	NULL
a	NULL
control	NULL
probe	NULL
coritaining	NULL
four	NULL
copies	NULL
of	NULL
the	NULL
consensus	NULL
Myb	NULL
binding	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
bindirlg	NULL
by	NULL
v-Myb	NULL
was	NULL
inhibited	NULL
by	NULL
a	NULL
20-fold	NULL
molar	NULL
excess	NULL
of	NULL
competitor	NULL
DNA	NULL
containing	NULL
the	NULL
consensus	NULL
c-Myb	NULL
binding	NULL
site	NULL
.	NULL

However	NULL
,	NULL
two	NULL
different	NULL
oligonucleotides	NULL
containing	NULL
the	NULL
potential	NULL
Myb	NULL
binding	NULL
site	NULL
in	NULL
the	NULL
BMRF1	NULL
promoter	NULL
(	NULL
oligonucleotides	NULL
EAD	NULL
and	NULL
EAD	NULL
AP-1	NULL
)	NULL
were	NULL
unable	NULL
to	NULL
compete	NULL
for	NULL
v-Myb	NULL
binding	NULL
,	NULL
even	NULL
at	NULL
a	NULL
300-fold	NULL
molar	NULL
excess	NULL
.	NULL

Likewise	NULL
,	NULL
a	NULL
**P-labelled	NULL
probe	NULL
containing	NULL
the	NULL
potential	NULL
Myb	NULL
binding	NULL
site	NULL
in	NULL
the	NULL
BMRF1	NULL
promoter	NULL
did	NULL
not	NULL
bind	NULL
the	NULL
v-myb	NULL
protein	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
it	NULL
appears	NULL
unlikely	NULL
that	NULL
c-Myb	NULL
can	NULL
bind	NULL
to	NULL
the	NULL
BMRF1	NULL
promoter	NULL
independently	NULL
.	NULL

However	NULL
,	NULL
since	NULL
c-Myb	NULL
binding	NULL
may	NULL
be	NULL
stabilized	NULL
by	NULL
cellular	NULL
factors	NULL
,	NULL
we	NULL
can	NULL
not	NULL
totally	NULL
exclude	NULL
the	NULL
possibility	NULL
that	NULL
c-Myb	NULL
may	NULL
bind	NULL
to	NULL
the	NULL
BMRF1	NULL
promoter	NULL
in	NULL
vivo	NULL
.	NULL

A	NULL
30-bp	NULL
BMRF1	NULL
promoter	NULL
sequence	NULL
is	NULL
sufficient	NULL
to	NULL
transfer	NULL
Z/c-myb	NULL
responsiveness	NULL
to	NULL
a	NULL
heterologous	NULL
promoter	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
the	NULL
BMRF1	NULL
promoter	NULL
sequences	NULL
containing	NULL
the	NULL
AP-1	NULL
binding	NULL
site	NULL
are	NULL
sufficient	NULL
to	NULL
confer	NULL
Z/c-myb	NULL
responsiveness	NULL
to	NULL
a	NULL
heterologous	NULL
promoter	NULL
,	NULL
we	NULL
inserted	NULL
three	NULL
copies	NULL
of	NULL
the	NULL
30-bp	NULL
BMRF1	NULL
sequence	NULL
(	NULL
ACCTTTGAGTC	NULL
AGGGTGGCTACTTGCTCAG	NULL
)	NULL
located	NULL
from	NULL
-39	NULL
to	NULL
-69	NULL
(	NULL
relative	NULL
to	NULL
the	NULL
mRNA	NULL
start	NULL
site	NULL
)	NULL
upstream	NULL
of	NULL
the	NULL
adenovirus	NULL
E1B	NULL
TATA	NULL
box	NULL
in	NULL
the	NULL
E1B-CAT	NULL
plasmid	NULL
(	NULL
a	NULL
gift	NULL
from	NULL
142	NULL
KENNEY	NULL
ET	NULL
AL	NULL
.	NULL

g*0	NULL
~T	NULL
COMPETITOR	NULL
:	NULL
-	NULL
-	NULL
-	NULL
.	NULL

-	NULL
~	NULL
4	NULL
a.	NULL
s	NULL
E	NULL
i	NULL
«	NULL
<	NULL
3	NULL
*	NULL
<	NULL
.	NULL

t	NULL
a	NULL
€	NULL
serum	NULL
:	NULL
-	NULL
-	NULL
-	NULL
{	NULL
§	NULL
E	NULL
2	NULL
-	NULL
=	NULL
myb-PROTEIN	NULL
:	NULL
-	NULL
legg	NULL
--	NULL
--	NULL
myb-	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

Evidence	NULL
that	NULL
v-myb	NULL
protein	NULL
expressed	NULL
in	NULL
Escherichia	NULL
coli	NULL
does	NULL
not	NULL
bind	NULL
to	NULL
the	NULL
BMRF1	NULL
promoter	NULL
.	NULL

Bacterial	NULL
v-myb	NULL
was	NULL
expressed	NULL
at	NULL
high	NULL
level	NULL
in	NULL
isopropyl-B-o-thiogalactopyranoside	NULL
(	NULL
IPTG	NULL
)	NULL
-induced	NULL
£	NULL
.	NULL

coli	NULL
bearing	NULL
the	NULL
pT7MYB	NULL
vector	NULL
(	NULL
a	NULL
gift	NULL
from	NULL
J.	NULL
Lipsick	NULL
)	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
14	NULL
)	NULL
.	NULL

Equal	NULL
amounts	NULL
of	NULL
protein	NULL
from	NULL
bacterial	NULL
extracts	NULL
containing	NULL
the	NULL
pT7MYB	NULL
vector	NULL
or	NULL
from	NULL
the	NULL
negative	NULL
control	NULL
vector	NULL
pT7MYBLESS	NULL
were	NULL
incubated	NULL
at	NULL
4°C	NULL
for	NULL
30	NULL
min	NULL
with	NULL
a	NULL
P-labelled	NULL
oligonucleotide	NULL
probe	NULL
containing	NULL
four	NULL
copies	NULL
of	NULL
the	NULL
consensus	NULL
Myb	NULL
binding	NULL
site	NULL
.	NULL

The	NULL
products	NULL
were	NULL
then	NULL
resolved	NULL
by	NULL
nondenaturing	NULL
gel	NULL
electrophoresis	NULL
and	NULL
autoradiography	NULL
.	NULL

v-myb	NULL
protein	NULL
was	NULL
shown	NULL
to	NULL
bind	NULL
to	NULL
the	NULL
consensus	NULL
c-Myb	NULL
binding	NULL
site	NULL
as	NULL
expected	NULL
.	NULL

Competition	NULL
studies	NULL
confirmed	NULL
that	NULL
a	NULL
20-fold	NULL
molar	NULL
excess	NULL
of	NULL
cold	NULL
oligonucleotide	NULL
containing	NULL
the	NULL
consensus	NULL
c-Myb	NULL
binding	NULL
site	NULL
(	NULL
oligonucleotide	NULL
MYB	NULL
)	NULL
competed	NULL
for	NULL
binding	NULL
to	NULL
the	NULL
labelied	NULL
myb	NULL
probe	NULL
,	NULL
whereas	NULL
a	NULL
300-fold	NULL
excess	NULL
of	NULL
two	NULL
different	NULL
oligonucleotides	NULL
(	NULL
EAD	NULL
and	NULL
AP-1	NULL
)	NULL
containing	NULL
the	NULL
potential	NULL
c-Myb	NULL
binding	NULL
site	NULL
in	NULL
the	NULL
BMRF1	NULL
promoter	NULL
did	NULL
not	NULL
compete	NULL
.	NULL

The	NULL
myb-specific	NULL
antibody	NULL
(	NULL
3	NULL
)	NULL
,	NULL
as	NULL
expected	NULL
,	NULL
decreased	NULL
v-Myb	NULL
binding	NULL
to	NULL
the	NULL
MYB	NULL
probe	NULL
,	NULL
whereas	NULL
preimmune	NULL
serum	NULL
had	NULL
no	NULL
effect	NULL
.	NULL

A	NULL
labelled	NULL
probe	NULL
containing	NULL
the	NULL
potential	NULL
c-Myb	NULL
binding	NULL
site	NULL
in	NULL
the	NULL
BMRF1	NULL
promoter	NULL
did	NULL
not	NULL
bind	NULL
the	NULL
v-myb	NULL
protein	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Michael	NULL
Green	NULL
and	NULL
Katherine	NULL
Martin	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

7	NULL
,	NULL
the	NULL
-39	NULL
to	NULL
-69	NULL
region	NULL
of	NULL
the	NULL
BMRF1	NULL
promoter	NULL
(	NULL
which	NULL
contains	NULL
the	NULL
AP-1	NULL
binding	NULL
site	NULL
but	NULL
not	NULL
the	NULL
upstream	NULL
ZRE	NULL
binding	NULL
site	NULL
)	NULL
is	NULL
sufficient	NULL
to	NULL
transfer	NULL
high-level	NULL
responsiveness	NULL
to	NULL
the	NULL
Z/c-myb	NULL
combination	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
transferred	NULL
responsiveness	NULL
to	NULL
Z/c-myb	NULL
continues	NULL
to	NULL
be	NULL
lymphoid	NULL
specific	NULL
,	NULL
in	NULL
that	NULL
it	NULL
is	NULL
observed	NULL
in	NULL
Jurkat	NULL
cells	NULL
but	NULL
not	NULL
in	NULL
HeLa	NULL
cells	NULL
.	NULL

c-myb	NULL
does	NULL
not	NULL
increase	NULL
the	NULL
level	NULL
of	NULL
transfected	NULL
Z	NULL
protein	NULL
.	NULL

One	NULL
mechanism	NULL
by	NULL
which	NULL
the	NULL
c-myb	NULL
and	NULL
Z	NULL
transactivator	NULL
plasmids	NULL
might	NULL
interact	NULL
synergistically	NULL
would	NULL
be	NULL
through	NULL
the	NULL
ability	NULL
of	NULL
transfected	NULL
c-myb	NULL
to	NULL
increase	NULL
the	NULL
level	NULL
of	NULL
transfected	NULL
Z	NULL
protein	NULL
.	NULL

To	NULL
exclude	NULL
this	NULL
possibility	NULL
,	NULL
we	NULL
performed	NULL
an	NULL
experiment	NULL
in	NULL
Jurkat	NULL
cells	NULL
in	NULL
which	NULL
the	NULL
level	NULL
of	NULL
Z	NULL
expression	NULL
in	NULL
the	NULL
presence	NULL
and	NULL
absence	NULL
of	NULL
c-myh	NULL
was	NULL
determined	NULL
in	NULL
a	NULL
portion	NULL
of	NULL
the	NULL
cell	NULL
extract	NULL
,	NULL
and	NULL
the	NULL
level	NULL
of	NULL
BMRF1-CAT	NULL
activity	NULL
was	NULL
simultaneously	NULL
determined	NULL
in	NULL
the	NULL
same	NULL
protein	NULL
extracts	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
the	NULL
level	NULL
of	NULL
BMRF1-driven	NULL
CAT	NULL
activity	NULL
is	NULL
much	NULL
higher	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
Z	NULL
and	NULL
c-myb	NULL
together	NULL
than	NULL
with	NULL
Z	NULL
alone	NULL
(	NULL
Fig	NULL
.	NULL

8B	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
level	NULL
of	NULL
transfected	NULL
Z	NULL
(	NULL
determined	NULL
by	NULL
immunoblotting	NULL
)	NULL
is	NULL
similar	NULL
in	NULL
each	NULL
condition	NULL
(	NULL
Fig	NULL
.	NULL

8A	NULL
)	NULL
,	NULL
excluding	NULL
the	NULL
possibility	NULL
that	NULL
the	NULL
increased	NULL
CAT	NULL
activity	NULL
in	NULL
the	NULL
Z/c-myb	NULL
condition	NULL
is	NULL
due	NULL
to	NULL
increased	NULL
Z	NULL
expression	NULL
or	NULL
differences	NULL
in	NULL
transfection	NULL
efficiency	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
we	NULL
found	NULL
that	NULL
the	NULL
level	NULL
of	NULL
transfected	NULL
Z	NULL
tended	NULL
to	NULL
be	NULL
consistently	NULL
higher	NULL
in	NULL
Jurkat	NULL
cells	NULL
than	NULL
in	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

AT	NULL
p	NULL
F	NULL
\	NULL
AD-C	NULL
+A	NULL
+Z	NULL
4	NULL
2.1	NULL
45	NULL
05	NULL
45	NULL
0494806	NULL
1.7	NULL
O6	NULL
25	NULL
FIG	NULL
.	NULL

7	NULL
.	NULL

Evidence	NULL
that	NULL
lymphoid-specific	NULL
responsiveness	NULL
to	NULL
the	NULL
Z/c-myb	NULL
combination	NULL
can	NULL
be	NULL
transferred	NULL
to	NULL
a	NULL
heterologous	NULL
promoter	NULL
by	NULL
a	NULL
30-bp	NULL
BMRF1	NULL
promoter	NULL
sequence	NULL
.	NULL

Three	NULL
copies	NULL
of	NULL
the	NULL
30-bp	NULL
BMRF1	NULL
promoter	NULL
sequence	NULL
from	NULL
-39	NULL
to	NULL
-69	NULL
relative	NULL
to	NULL
the	NULL
mRNA	NULL
start	NULL
site	NULL
were	NULL
inserted	NULL
into	NULL
the	NULL
E1B-CAT	NULL
construct	NULL
upstream	NULL
of	NULL
the	NULL
adenovirus	NULL
ElB	NULL
TATA	NULL
box	NULL
.	NULL

In	NULL
Jurkat	NULL
cells	NULL
(	NULL
A	NULL
)	NULL
,	NULL
the	NULL
parent	NULL
construct	NULL
,	NULL
E1B-CAT	NULL
,	NULL
is	NULL
not	NULL
significantly	NULL
activated	NULL
by	NULL
cotransfection	NULL
with	NULL
Z	NULL
alone	NULL
,	NULL
c-myb	NULL
alone	NULL
,	NULL
or	NULL
the	NULL
combination	NULL
of	NULL
the	NULL
two	NULL
transactivators	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
combination	NULL
of	NULL
Z	NULL
and	NULL
c-myb	NULL
together	NULL
synergistically	NULL
activates	NULL
the	NULL
E1B-EAD-CAT	NULL
construct	NULL
containing	NULL
three	NULL
copies	NULL
of	NULL
the	NULL
BMRF1	NULL
AP-1	NULL
site	NULL
in	NULL
Jurkat	NULL
cells	NULL
(	NULL
B	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
E1B-EAD-CAT	NULL
plasmid	NULL
is	NULL
not	NULL
significantly	NULL
activated	NULL
by	NULL
the	NULL
combination	NULL
of	NULL
Z	NULL
and	NULL
c-myb	NULL
in	NULL
HeLa	NULL
cells	NULL
(	NULL
C	NULL
)	NULL
.	NULL

HeLa	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
further	NULL
ruling	NULL
out	NULL
the	NULL
possibility	NULL
that	NULL
inefficient	NULL
Z	NULL
transactivation	NULL
in	NULL
Jurkat	NULL
cells	NULL
is	NULL
simply	NULL
due	NULL
to	NULL
insufficient	NULL
expression	NULL
of	NULL
the	NULL
Z	NULL
transactivator	NULL
in	NULL
this	NULL
cell	NULL
type	NULL
.	NULL

Defining	NULL
domains	NULL
in	NULL
the	NULL
Z	NULL
protein	NULL
required	NULL
for	NULL
synergy	NULL
with	NULL
e-myb	NULL
.	NULL

To	NULL
determine	NULL
which	NULL
portions	NULL
of	NULL
the	NULL
Z	NULL
protein	NULL
are	NULL
required	NULL
for	NULL
transactivation	NULL
of	NULL
the	NULL
EA-CAT	NULL
plasmid	NULL
in	NULL
cooperation	NULL
with	NULL
c-myb	NULL
,	NULL
we	NULL
tested	NULL
a	NULL
series	NULL
of	NULL
in-frame	NULL
deletion	NULL
mutants	NULL
of	NULL
the	NULL
Z	NULL
protein	NULL
for	NULL
the	NULL
ability	NULL
to	NULL
activate	NULL
EA-CAT	NULL
activity	NULL
with	NULL
and	NULL
without	NULL
the	NULL
c-myb	NULL
protein	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
)	NULL
.	NULL

The	NULL
parental	NULL
construct	NULL
used	NULL
in	NULL
these	NULL
experiments	NULL
contains	NULL
the	NULL
BZLF1	NULL
cDNA	NULL
driven	NULL
by	NULL
the	NULL
SV40	NULL
promoter	NULL
(	NULL
16	NULL
)	NULL
.	NULL

A	NULL
number	NULL
of	NULL
in-frame	NULL
deletions	NULL
were	NULL
constructed	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
which	NULL
delete	NULL
portions	NULL
of	NULL
the	NULL
protein	NULL
important	NULL
for	NULL
transactivation	NULL
,	NULL
DNA	NULL
binding	NULL
,	NULL
or	NULL
dimerization	NULL
(	NULL
4	NULL
,	NULL
11	NULL
,	NULL
16	NULL
)	NULL
.	NULL

The	NULL
to	NULL
B	NULL
o	NULL
o	NULL
a	NULL
O	NULL
5	NULL
Z	NULL
E00	NULL
§	NULL
``	NULL
e	NULL
N	NULL
6	NULL
N	NULL
a	NULL
.	NULL

++	NULL
+	NULL
+	NULL
a	NULL
Q	NULL
we	NULL
aste	NULL
M	NULL
J	NULL
_	NULL
)	NULL
)	NULL
.s	NULL
as	NULL
FIG	NULL
.	NULL

8	NULL
.	NULL

Evidence	NULL
that	NULL
c-myb	NULL
does	NULL
not	NULL
increase	NULL
the	NULL
level	NULL
of	NULL
transfected	NULL
Z	NULL
protein	NULL
.	NULL

To	NULL
exclude	NULL
the	NULL
possibility	NULL
that	NULL
c-myb	NULL
increases	NULL
the	NULL
level	NULL
of	NULL
transfected	NULL
Z	NULL
protein	NULL
,	NULL
immunoblotting	NULL
was	NULL
performed	NULL
(	NULL
using	NULL
sera	NULL
from	NULL
patients	NULL
with	NULL
nasopharyngeal	NULL
carci-noma	NULL
)	NULL
in	NULL
Jurkat	NULL
cells	NULL
on	NULL
a	NULL
portion	NULL
of	NULL
the	NULL
protein	NULL
extract	NULL
simultaneously	NULL
harvested	NULL
for	NULL
CAT	NULL
activity	NULL
.	NULL

The	NULL
level	NULL
of	NULL
Z	NULL
protein	NULL
is	NULL
similar	NULL
when	NULL
Z	NULL
is	NULL
transfected	NULL
alone	NULL
or	NULL
with	NULL
c-myb	NULL
(	NULL
A	NULL
)	NULL
,	NULL
whereas	NULL
the	NULL
EAD-CAT	NULL
activity	NULL
is	NULL
much	NULL
higher	NULL
in	NULL
the	NULL
cells	NULL
transfected	NULL
with	NULL
both	NULL
Z	NULL
and	NULL
c-myb	NULL
(	NULL
B	NULL
)	NULL
.	NULL

Vor	NULL
.	NULL

12	NULL
,	NULL
1992	NULL
FOLD	NULL
ACTIVATION	NULL
EN	NULL
55	NULL
c-myb	NULL
AND	NULL
BZLF1	NULL
INTERACT	NULL
SYNERGISTICALLY	NULL
143	NULL
WT	NULL
MYB	NULL
&	NULL
MYBAIR	NULL
&	NULL
WT	NULL
Z	NULL
FIG	NULL
.	NULL

9	NULL
.	NULL

Effects	NULL
of	NULL
Z	NULL
and	NULL
c-myb	NULL
protein	NULL
deletions	NULL
on	NULL
synergistic	NULL
activation	NULL
of	NULL
the	NULL
BMRF1	NULL
promoter	NULL
.	NULL

The	NULL
EAD-CAT	NULL
construct	NULL
was	NULL
cotransfected	NULL
into	NULL
Jurkat	NULL
cells	NULL
with	NULL
either	NULL
the	NULL
pHD1013	NULL
vector	NULL
alone	NULL
,	NULL
the	NULL
wild-type	NULL
Z	NULL
transactivator	NULL
(	NULL
WT	NULL
Z	NULL
)	NULL
or	NULL
the	NULL
various	NULL
Z	NULL
deletion	NULL
mutants	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
,	NULL
the	NULL
wild-type	NULL
c-myb	NULL
protein	NULL
(	NULL
WT	NULL
MYB	NULL
)	NULL
,	NULL
or	NULL
a	NULL
mutant	NULL
c-myb	NULL
protein	NULL
in	NULL
which	NULL
the	NULL
first	NULL
two	NULL
51-	NULL
to	NULL
52-amino-acid	NULL
repeats	NULL
had	NULL
been	NULL
deleted	NULL
.	NULL

The	NULL
fold	NULL
activation	NULL
of	NULL
EAD-CAT	NULL
activity	NULL
produced	NULL
by	NULL
the	NULL
various	NULL
combination	NULL
of	NULL
wild-type	NULL
and	NULL
mutant	NULL
proteins	NULL
is	NULL
shown	NULL
.	NULL

(	NULL
A	NULL
)	NULL
EAD-CAT	NULL
plasmid	NULL
cotransfected	NULL
with	NULL
wild-type	NULL
Z	NULL
(	NULL
either	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
wild-type	NULL
c-myb	NULL
)	NULL
versus	NULL
various	NULL
Z	NULL
deletion	NULL
mutants	NULL
(	NULL
an	NULL
average	NULL
of	NULL
four	NULL
separate	NULL
experiments	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
EAD-CAT	NULL
plasmid	NULL
cotransfected	NULL
with	NULL
wild-type	NULL
Z	NULL
(	NULL
either	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
wild-type	NULL
c-myb	NULL
)	NULL
versus	NULL
the	NULL
Z311	NULL
site-directed	NULL
mutant	NULL
(	NULL
an	NULL
average	NULL
value	NULL
from	NULL
three	NULL
experiments	NULL
)	NULL
.	NULL

(	NULL
C	NULL
)	NULL
EAD-CAT	NULL
plasmid	NULL
cotransfected	NULL
with	NULL
mutant	NULL
c-myb	NULL
with	NULL
and	NULL
without	NULL
wild-type	NULL
Z	NULL
(	NULL
an	NULL
average	NULL
from	NULL
two	NULL
experiments	NULL
)	NULL
.	NULL

cellular	NULL
localization	NULL
of	NULL
each	NULL
mutant	NULL
protein	NULL
is	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2A	NULL
.	NULL

In	NULL
the	NULL
first	NULL
set	NULL
of	NULL
experiments	NULL
(	NULL
Fig	NULL
.	NULL

9A	NULL
)	NULL
,	NULL
the	NULL
average	NULL
effect	NULL
of	NULL
wild-type	NULL
Z	NULL
alone	NULL
was	NULL
7-fold	NULL
,	NULL
the	NULL
average	NULL
effect	NULL
of	NULL
wild-type	NULL
c-myb	NULL
alone	NULL
was	NULL
6-fold	NULL
,	NULL
and	NULL
the	NULL
average	NULL
effect	NULL
of	NULL
wild-type	NULL
Z	NULL
and	NULL
wild-type	NULL
c-myb	NULL
together	NULL
was	NULL
104-fold	NULL
.	NULL

Deletions	NULL
which	NULL
abolished	NULL
the	NULL
ability	NULL
of	NULL
Z	NULL
to	NULL
bind	NULL
in	NULL
vitro	NULL
(	NULL
either	NULL
through	NULL
deletion	NULL
of	NULL
the	NULL
DNA	NULL
binding	NULL
domain	NULL
or	NULL
through	NULL
deletion	NULL
of	NULL
the	NULL
dimerization	NULL
domain	NULL
)	NULL
all	NULL
essentially	NULL
abolished	NULL
the	NULL
ability	NULL
of	NULL
Z	NULL
to	NULL
interact	NULL
synergistically	NULL
with	NULL
¢-myb	NULL
in	NULL
activating	NULL
EA-CAT	NULL
expression	NULL
.	NULL

However	NULL
,	NULL
all	NULL
of	NULL
the	NULL
deletions	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

9A	NULL
which	NULL
affected	NULL
DNA	NULL
binding	NULL
also	NULL
were	NULL
subsequently	NULL
determined	NULL
to	NULL
affect	NULL
protein	NULL
stability	NULL
or	NULL
nuclear	NULL
localization	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
confirmed	NULL
the	NULL
importance	NULL
of	NULL
the	NULL
Z	NULL
DNA	NULL
binding	NULL
function	NULL
for	NULL
synergy	NULL
with	NULL
c-myb	NULL
by	NULL
testing	NULL
the	NULL
Z311	NULL
plasmid	NULL
,	NULL
which	NULL
contains	NULL
a	NULL
site-directed	NULL
mutation	NULL
in	NULL
Z	NULL
which	NULL
abolishes	NULL
DNA	NULL
binding	NULL
capacity	NULL
but	NULL
does	NULL
not	NULL
affect	NULL
protein	NULL
stability	NULL
or	NULL
nuclear	NULL
localization	NULL
(	NULL
Fig	NULL
.	NULL

9B	NULL
)	NULL
.	NULL

The	NULL
Z311	NULL
mutant	NULL
did	NULL
not	NULL
interact	NULL
synergistically	NULL
with	NULL
c-myb	NULL
,	NULL
confirming	NULL
the	NULL
importance	NULL
of	NULL
Z	NULL
DNA	NULL
binding	NULL
function	NULL
for	NULL
this	NULL
interaction	NULL
.	NULL

Deletions	NULL
which	NULL
affect	NULL
the	NULL
transactivation	NULL
domain	NULL
of	NULL
Z	NULL
also	NULL
significantly	NULL
decreased	NULL
the	NULL
combined	NULL
effect	NULL
of	NULL
Z	NULL
and	NULL
c-myb	NULL
,	NULL
although	NULL
in	NULL
each	NULL
case	NULL
the	NULL
combined	NULL
effect	NULL
was	NULL
still	NULL
slightly	NULL
greater	NULL
than	NULL
the	NULL
additive	NULL
effect	NULL
of	NULL
each	NULL
transactivator	NULL
alone	NULL
(	NULL
Fig	NULL
.	NULL

9A	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
both	NULL
the	NULL
transactivation	NULL
domain	NULL
and	NULL
the	NULL
DNA	NULL
binding	NULL
domain	NULL
of	NULL
Z	NULL
are	NULL
important	NULL
for	NULL
cooperation	NULL
with	NULL
c-myb	NULL
.	NULL

The	NULL
DNA	NULL
binding	NULL
domain	NULL
of	NULL
c-Myb	NULL
is	NULL
also	NULL
important	NULL
for	NULL
synergy	NULL
with	NULL
Z	NULL
.	NULL

The	NULL
DNA	NULL
binding	NULL
domain	NULL
of	NULL
c-Myb	NULL
has	NULL
been	NULL
previously	NULL
localized	NULL
to	NULL
the	NULL
amino-terminal	NULL
portion	NULL
of	NULL
the	NULL
protein	NULL
(	NULL
14	NULL
,	NULL
22	NULL
,	NULL
28	NULL
)	NULL
.	NULL

The	NULL
c-myb	NULL
DNA	NULL
binding	NULL
domain	NULL
is	NULL
contained	NULL
within	NULL
a	NULL
set	NULL
of	NULL
three	NULL
imperfect	NULL
51-	NULL
to	NULL
52-amino-acid	NULL
repeats	NULL
(	NULL
22	NULL
,	NULL
28	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
first	NULL
repeat	NULL
does	NULL
not	NULL
appear	NULL
to	NULL
be	NULL
essential	NULL
for	NULL
binding	NULL
to	NULL
the	NULL
consensus	NULL
c-myb	NULL
response	NULL
element	NULL
,	NULL
the	NULL
second	NULL
and	NULL
third	NULL
repeats	NULL
do	NULL
appear	NULL
to	NULL
be	NULL
required	NULL
for	NULL
binding	NULL
(	NULL
22	NULL
)	NULL
.	NULL

Previous	NULL
investigators	NULL
have	NULL
shown	NULL
that	NULL
transactivation	NULL
of	NULL
the	NULL
heat	NULL
shock	NULL
promoter	NULL
by	NULL
c-myb	NULL
,	NULL
which	NULL
does	NULL
not	NULL
appear	NULL
to	NULL
involve	NULL
a	NULL
DNA	NULL
binding	NULL
mechanism	NULL
,	NULL
is	NULL
still	NULL
efficient	NULL
even	NULL
when	NULL
the	NULL
first	NULL
and	NULL
second	NULL
repeats	NULL
are	NULL
deleted	NULL
together	NULL
(	NULL
27	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
transactivation	NULL
of	NULL
promoters	NULL
linked	NULL
to	NULL
the	NULL
consensus	NULL
c-myb	NULL
response	NULL
element	NULL
,	NULL
which	NULL
does	NULL
require	NULL
c-Myb	NULL
binding	NULL
,	NULL
is	NULL
negligible	NULL
if	NULL
the	NULL
first	NULL
and	NULL
second	NULL
repeats	NULL
together	NULL
are	NULL
deleted	NULL
(	NULL
27	NULL
)	NULL
.	NULL

We	NULL
constructed	NULL
a	NULL
deletion	NULL
of	NULL
c-Myb	NULL
that	NULL
specifically	NULL
removed	NULL
the	NULL
first	NULL
and	NULL
second	NULL
51-	NULL
to	NULL
52-amino-acid	NULL
repeats	NULL
and	NULL
tested	NULL
this	NULL
construct	NULL
for	NULL
the	NULL
ability	NULL
to	NULL
transactivate	NULL
the	NULL
BMRF1	NULL
promoter	NULL
in	NULL
conjunction	NULL
with	NULL
Z	NULL
.	NULL

Previous	NULL
investigators	NULL
have	NULL
shown	NULL
that	NULL
deletion	NULL
of	NULL
the	NULL
first	NULL
and	NULL
second	NULL
repeats	NULL
does	NULL
not	NULL
reduce	NULL
protein	NULL
stability	NULL
or	NULL
impair	NULL
nuclear	NULL
localization	NULL
of	NULL
the	NULL
c-myb	NULL
protein	NULL
(	NULL
22	NULL
,	NULL
27	NULL
)	NULL
(	NULL
although	NULL
there	NULL
is	NULL
some	NULL
evidence	NULL
that	NULL
the	NULL
equivalent	NULL
region	NULL
may	NULL
be	NULL
required	NULL
for	NULL
v-myb	NULL
nuclear	NULL
localization	NULL
in	NULL
avian	NULL
erythroid	NULL
cells	NULL
[	NULL
23	NULL
]	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

9C	NULL
,	NULL
removal	NULL
of	NULL
the	NULL
first	NULL
and	NULL
second	NULL
repeats	NULL
from	NULL
the	NULL
amino-terminal	NULL
end	NULL
of	NULL
the	NULL
c-myb	NULL
protein	NULL
essentially	NULL
abolished	NULL
the	NULL
ability	NULL
of	NULL
c-myb	NULL
to	NULL
interact	NULL
synergistically	NULL
with	NULL
Z	NULL
.	NULL

This	NULL
finding	NULL
suggests	NULL
that	NULL
the	NULL
DNA	NULL
binding	NULL
function	NULL
of	NULL
c-Myb	NULL
is	NULL
required	NULL
for	NULL
the	NULL
observed	NULL
Z/c-myb	NULL
interaction	NULL
.	NULL

However	NULL
,	NULL
since	NULL
we	NULL
have	NULL
not	NULL
yet	NULL
confirmed	NULL
that	NULL
this	NULL
mutant	NULL
stably	NULL
localizes	NULL
to	NULL
the	NULL
nucleus	NULL
in	NULL
Jurkat	NULL
cells	NULL
,	NULL
we	NULL
can	NULL
not	NULL
totally	NULL
exclude	NULL
the	NULL
possibility	NULL
that	NULL
the	NULL
lack	NULL
of	NULL
synergy	NULL
with	NULL
this	NULL
mutant	NULL
is	NULL
secondary	NULL
to	NULL
the	NULL
inability	NULL
of	NULL
this	NULL
mutant	NULL
to	NULL
localize	NULL
in	NULL
the	NULL
nucleus	NULL
.	NULL

144	NULL
KENNEY	NULL
ET	NULL
AL	NULL
.	NULL

DISCUSSION	NULL
The	NULL
EBV	NULL
transactivating	NULL
protein	NULL
Z	NULL
plays	NULL
a	NULL
key	NULL
role	NULL
in	NULL
the	NULL
disruption	NULL
of	NULL
viral	NULL
latency	NULL
.	NULL

The	NULL
Z	NULL
protein	NULL
binds	NULL
to	NULL
AP-1	NULL
sites	NULL
as	NULL
a	NULL
homodimer	NULL
and	NULL
(	NULL
despite	NULL
its	NULL
sequence	NULL
similarity	NULL
with	NULL
c-Fos	NULL
)	NULL
is	NULL
not	NULL
capable	NULL
of	NULL
heterodimerizing	NULL
with	NULL
either	NULL
c-Fos	NULL
or	NULL
c-Jun	NULL
(	NULL
4	NULL
)	NULL
.	NULL

However	NULL
,	NULL
our	NULL
data	NULL
(	NULL
21	NULL
)	NULL
demonstrate	NULL
tissue	NULL
specificity	NULL
in	NULL
the	NULL
ability	NULL
of	NULL
certain	NULL
promoters	NULL
to	NULL
respond	NULL
to	NULL
Z	NULL
,	NULL
suggesting	NULL
that	NULL
Z	NULL
transactivation	NULL
of	NULL
these	NULL
promoters	NULL
is	NULL
likely	NULL
to	NULL
involve	NULL
additional	NULL
cellular	NULL
transcription	NULL
factors	NULL
.	NULL

In	NULL
this	NULL
paper	NULL
,	NULL
we	NULL
report	NULL
the	NULL
first	NULL
evidence	NULL
that	NULL
a	NULL
cellular	NULL
factor	NULL
,	NULL
c-myb	NULL
,	NULL
can	NULL
interact	NULL
synergistically	NULL
with	NULL
the	NULL
Z	NULL
transactivator	NULL
in	NULL
lymphoid	NULL
cells	NULL
.	NULL

There	NULL
are	NULL
several	NULL
lines	NULL
of	NULL
evidence	NULL
to	NULL
suggest	NULL
that	NULL
transcriptional	NULL
activation	NULL
by	NULL
the	NULL
c-myb	NULL
or	NULL
v-myb	NULL
protein	NULL
may	NULL
involve	NULL
interactions	NULL
with	NULL
other	NULL
cellular	NULL
transcription	NULL
factors	NULL
.	NULL

First	NULL
,	NULL
in	NULL
a	NULL
recent	NULL
report	NULL
by	NULL
Ibanez	NULL
and	NULL
Lipsick	NULL
(	NULL
24	NULL
)	NULL
,	NULL
the	NULL
authors	NULL
found	NULL
that	NULL
binding	NULL
of	NULL
the	NULL
viral	NULL
myb	NULL
protein	NULL
to	NULL
consensus	NULL
Myb	NULL
binding	NULL
sites	NULL
was	NULL
required	NULL
but	NULL
not	NULL
sufficient	NULL
for	NULL
activation	NULL
of	NULL
linked	NULL
reporter	NULL
genes	NULL
and	NULL
concluded	NULL
that	NULL
transactivation	NULL
by	NULL
v-myb	NULL
may	NULL
require	NULL
interaction	NULL
with	NULL
another	NULL
DNA-bound	NULL
transcription	NULL
factor	NULL
.	NULL

Second	NULL
,	NULL
the	NULL
Myb-related	NULL
BAS1	NULL
protein	NULL
in	NULL
Saccharomyces	NULL
cerevisiae	NULL
activates	NULL
the	NULL
H1S4	NULL
gene	NULL
only	NULL
in	NULL
cooperation	NULL
with	NULL
a	NULL
second	NULL
transcription	NULL
factor	NULL
,	NULL
BAS2	NULL
(	NULL
a	NULL
homeodomain	NULL
protein	NULL
)	NULL
(	NULL
53	NULL
)	NULL
.	NULL

Third	NULL
,	NULL
the	NULL
transforming	NULL
effects	NULL
of	NULL
v-myb	NULL
are	NULL
highly	NULL
tissue	NULL
specific	NULL
,	NULL
suggesting	NULL
that	NULL
interactions	NULL
with	NULL
tissue-specific	NULL
factors	NULL
are	NULL
likely	NULL
to	NULL
be	NULL
required	NULL
for	NULL
the	NULL
transcriptional	NULL
effects	NULL
of	NULL
the	NULL
myb	NULL
proteins	NULL
.	NULL

Fourth	NULL
,	NULL
at	NULL
least	NULL
one	NULL
promoter	NULL
(	NULL
the	NULL
heat	NULL
shock	NULL
promoter	NULL
)	NULL
can	NULL
be	NULL
activated	NULL
by	NULL
v-myb	NULL
through	NULL
a	NULL
mechanism	NULL
that	NULL
does	NULL
not	NULL
appear	NULL
to	NULL
involve	NULL
direct	NULL
DNA	NULL
binding	NULL
(	NULL
27	NULL
)	NULL
and	NULL
therefore	NULL
is	NULL
likely	NULL
to	NULL
be	NULL
mediated	NULL
through	NULL
interaction	NULL
with	NULL
cellular	NULL
transcription	NULL
factors	NULL
.	NULL

At	NULL
this	NULL
point	NULL
,	NULL
the	NULL
exact	NULL
mechanism	NULL
by	NULL
which	NULL
the	NULL
Z	NULL
and	NULL
c-myb	NULL
proteins	NULL
can	NULL
synergistically	NULL
interact	NULL
to	NULL
stimulate	NULL
BMRF1	NULL
and	NULL
SV40	NULL
promoters	NULL
in	NULL
lymphoid	NULL
cells	NULL
,	NULL
but	NULL
not	NULL
epithelial	NULL
cells	NULL
,	NULL
is	NULL
not	NULL
determined	NULL
.	NULL

Although	NULL
our	NULL
data	NULL
do	NULL
not	NULL
totally	NULL
exclude	NULL
the	NULL
possibility	NULL
that	NULL
this	NULL
effect	NULL
is	NULL
due	NULL
to	NULL
the	NULL
ability	NULL
of	NULL
Z	NULL
to	NULL
enhance	NULL
c-myb-induced	NULL
transactivation	NULL
,	NULL
it	NULL
seems	NULL
much	NULL
more	NULL
likely	NULL
that	NULL
for	NULL
the	NULL
BMRF1	NULL
promoter	NULL
,	NULL
at	NULL
least	NULL
,	NULL
it	NULL
is	NULL
c-myb	NULL
which	NULL
enhances	NULL
Z-induced	NULL
transactivation	NULL
.	NULL

Z	NULL
binding	NULL
to	NULL
the	NULL
BMRF1	NULL
promoter	NULL
appears	NULL
to	NULL
be	NULL
a	NULL
crucial	NULL
element	NULL
in	NULL
this	NULL
interaction	NULL
,	NULL
since	NULL
(	NULL
i	NULL
)	NULL
destruction	NULL
of	NULL
the	NULL
AP-1	NULL
site	NULL
by	NULL
either	NULL
5	NULL
'	NULL
deletion	NULL
or	NULL
site-directed	NULL
mutation	NULL
of	NULL
the	NULL
BMRF1	NULL
promoter	NULL
significantly	NULL
decreases	NULL
the	NULL
combined	NULL
effect	NULL
of	NULL
the	NULL
Z/c-myb	NULL
combination	NULL
on	NULL
BMRF1	NULL
promoter	NULL
activ-ity	NULL
,	NULL
(	NULL
ii	NULL
)	NULL
simultaneous	NULL
destruction	NULL
of	NULL
both	NULL
Z	NULL
binding	NULL
sites	NULL
(	NULL
the	NULL
AP-1	NULL
site	NULL
and	NULL
the	NULL
upstream	NULL
ZRE	NULL
)	NULL
totally	NULL
abolishes	NULL
the	NULL
Z/ic-myb	NULL
effect	NULL
,	NULL
and	NULL
(	NULL
iii	NULL
)	NULL
a	NULL
site-directed	NULL
mutation	NULL
in	NULL
the	NULL
Z	NULL
protein	NULL
which	NULL
impairs	NULL
DNA	NULL
binding	NULL
but	NULL
does	NULL
not	NULL
affect	NULL
protein	NULL
stability	NULL
or	NULL
nuclear	NULL
localization	NULL
also	NULL
abolishes	NULL
the	NULL
ability	NULL
of	NULL
Z	NULL
to	NULL
interact	NULL
synergistically	NULL
with	NULL
c-myb	NULL
.	NULL

The	NULL
mechanism	NULL
by	NULL
which	NULL
c-myb	NULL
contributes	NULL
to	NULL
Z-induced	NULL
transactivation	NULL
of	NULL
the	NULL
BMRF1	NULL
and	NULL
SV40	NULL
promoters	NULL
is	NULL
not	NULL
yet	NULL
clear	NULL
.	NULL

Our	NULL
data	NULL
suggest	NULL
that	NULL
direct	NULL
c-Myb	NULL
binding	NULL
to	NULL
the	NULL
BMRF1	NULL
promoter	NULL
is	NULL
unlikely	NULL
,	NULL
given	NULL
that	NULL
we	NULL
were	NULL
unable	NULL
to	NULL
demonstrate	NULL
binding	NULL
in	NULL
vitro	NULL
,	NULL
and	NULL
mutation	NULL
of	NULL
the	NULL
most	NULL
likely	NULL
potential	NULL
c-Myb	NULL
binding	NULL
in	NULL
the	NULL
promoter	NULL
did	NULL
not	NULL
diminish	NULL
the	NULL
combined	NULL
effect	NULL
of	NULL
Z	NULL
and	NULL
c-myb	NULL
.	NULL

However	NULL
,	NULL
deletion	NULL
of	NULL
the	NULL
DNA	NULL
binding	NULL
domain	NULL
in	NULL
the	NULL
c-myb	NULL
protein	NULL
did	NULL
abolish	NULL
the	NULL
ability	NULL
of	NULL
c-myb	NULL
to	NULL
interact	NULL
synergistically	NULL
with	NULL
Z	NULL
.	NULL

This	NULL
requirement	NULL
for	NULL
the	NULL
c-Myb	NULL
DNA	NULL
binding	NULL
domain	NULL
could	NULL
reflect	NULL
an	NULL
indirect	NULL
mechanism	NULL
involving	NULL
activation	NULL
by	NULL
c-myb	NULL
of	NULL
another	NULL
cellular	NULL
transcription	NULL
factor	NULL
,	NULL
rather	NULL
than	NULL
direct	NULL
c-Myb	NULL
binding	NULL
to	NULL
the	NULL
BMRF1	NULL
promoter	NULL
.	NULL

Alternatively	NULL
,	NULL
the	NULL
amino-terminal	NULL
domain	NULL
of	NULL
c-Myb	NULL
may	NULL
encode	NULL
other	NULL
func-	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

Bloc	NULL
.	NULL

tions	NULL
in	NULL
addition	NULL
to	NULL
DNA	NULL
binding	NULL
.	NULL

The	NULL
latter	NULL
possibility	NULL
is	NULL
suggested	NULL
in	NULL
a	NULL
recent	NULL
report	NULL
by	NULL
Lane	NULL
et	NULL
al	NULL
.	NULL

(	NULL
32	NULL
)	NULL
,	NULL
who	NULL
found	NULL
that	NULL
a	NULL
linker	NULL
insertion	NULL
mutation	NULL
within	NULL
the	NULL
DNA	NULL
binding	NULL
domain	NULL
of	NULL
v-Myb	NULL
,	NULL
which	NULL
did	NULL
not	NULL
affect	NULL
DNA	NULL
binding	NULL
capacity	NULL
or	NULL
nuclear	NULL
localization	NULL
,	NULL
nevertheless	NULL
inhibited	NULL
transactivation	NULL
and	NULL
transformation	NULL
by	NULL
v-myb	NULL
.	NULL

Given	NULL
that	NULL
we	NULL
have	NULL
not	NULL
yet	NULL
confirmed	NULL
that	NULL
our	NULL
particular	NULL
mutant	NULL
localizes	NULL
to	NULL
the	NULL
nucleus	NULL
in	NULL
Jurkat	NULL
cells	NULL
,	NULL
it	NULL
is	NULL
still	NULL
a	NULL
possibility	NULL
that	NULL
inability	NULL
of	NULL
this	NULL
mutant	NULL
c-myb	NULL
protein	NULL
to	NULL
enter	NULL
the	NULL
nucleus	NULL
explains	NULL
our	NULL
results	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
SV40	NULL
early	NULL
promoter	NULL
has	NULL
been	NULL
previously	NULL
found	NULL
to	NULL
contain	NULL
a	NULL
number	NULL
of	NULL
functional	NULL
Myb	NULL
binding	NULL
sites	NULL
(	NULL
40	NULL
)	NULL
.	NULL

One	NULL
of	NULL
the	NULL
weakest	NULL
binding	NULL
sites	NULL
in	NULL
SV40	NULL
,	NULL
designated	NULL
MBS	NULL
II	NULL
,	NULL
is	NULL
present	NULL
within	NULL
the	NULL
pA10CAT	NULL
construct	NULL
used	NULL
in	NULL
these	NULL
experiments	NULL
,	NULL
and	NULL
like	NULL
the	NULL
potential	NULL
Myb	NULL
binding	NULL
site	NULL
in	NULL
the	NULL
BMRF1	NULL
promoter	NULL
,	NULL
the	NULL
MBS	NULL
II	NULL
site	NULL
overlaps	NULL
an	NULL
AP-1	NULL
site	NULL
(	NULL
33	NULL
)	NULL
.	NULL

This	NULL
finding	NULL
suggests	NULL
that	NULL
the	NULL
Z/c-myb	NULL
effect	NULL
on	NULL
the	NULL
SV40	NULL
promoter	NULL
may	NULL
indeed	NULL
be	NULL
mediated	NULL
by	NULL
a	NULL
mechanism	NULL
involving	NULL
binding	NULL
of	NULL
both	NULL
proteins	NULL
to	NULL
this	NULL
promoter	NULL
,	NULL
and	NULL
that	NULL
perhaps	NULL
we	NULL
were	NULL
unable	NULL
to	NULL
detect	NULL
v-Myb	NULL
binding	NULL
to	NULL
the	NULL
BMRF1	NULL
promoter	NULL
because	NULL
binding	NULL
to	NULL
this	NULL
site	NULL
is	NULL
weaker	NULL
than	NULL
binding	NULL
to	NULL
the	NULL
consensus	NULL
site	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
c-Myb	NULL
binding	NULL
to	NULL
sites	NULL
which	NULL
are	NULL
relatively	NULL
weak	NULL
in	NULL
vitro	NULL
(	NULL
such	NULL
as	NULL
the	NULL
MBS	NULL
II	NULL
site	NULL
)	NULL
is	NULL
stabilized	NULL
by	NULL
interactions	NULL
with	NULL
cellular	NULL
factors	NULL
in	NULL
vivo	NULL
.	NULL

However	NULL
,	NULL
the	NULL
MBS	NULL
II	NULL
site	NULL
,	NULL
when	NULL
multimerized	NULL
and	NULL
linked	NULL
to	NULL
a	NULL
heterologous	NULL
promoter	NULL
,	NULL
was	NULL
found	NULL
to	NULL
confer	NULL
negative	NULL
regulation	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
c-myb	NULL
in	NULL
CV1	NULL
cells	NULL
(	NULL
40	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
effect	NULL
of	NULL
a	NULL
particular	NULL
Myb	NULL
binding	NULL
site	NULL
on	NULL
promoter	NULL
activity	NULL
may	NULL
well	NULL
depend	NULL
on	NULL
the	NULL
cell	NULL
type	NULL
tested	NULL
,	NULL
the	NULL
relative	NULL
proportions	NULL
of	NULL
the	NULL
different	NULL
members	NULL
of	NULL
the	NULL
Myb	NULL
family	NULL
of	NULL
proteins	NULL
(	NULL
A-Myb	NULL
versus	NULL
B-Myb	NULL
versus	NULL
c-Myb	NULL
)	NULL
,	NULL
and	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
nearby	NULL
binding	NULL
sites	NULL
for	NULL
other	NULL
transcription	NULL
factors	NULL
.	NULL

Our	NULL
data	NULL
suggest	NULL
the	NULL
possibility	NULL
that	NULL
protein-protein	NULL
interactions	NULL
occur	NULL
between	NULL
c-myb	NULL
and	NULL
Z	NULL
.	NULL

Recent	NULL
reports	NULL
from	NULL
several	NULL
laboratories	NULL
have	NULL
demonstrated	NULL
protein-protein	NULL
interactions	NULL
between	NULL
AP-1	NULL
and	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
(	NULL
9	NULL
,	NULL
60	NULL
)	NULL
,	NULL
and	NULL
these	NULL
interactions	NULL
do	NULL
not	NULL
necessarily	NULL
require	NULL
binding	NULL
sites	NULL
for	NULL
both	NULL
proteins	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
papillomavirus	NULL
E2	NULL
protein	NULL
has	NULL
been	NULL
recently	NULL
shown	NULL
to	NULL
directly	NULL
interact	NULL
with	NULL
the	NULL
Spl	NULL
transcription	NULL
factor	NULL
,	NULL
and	NULL
this	NULL
interaction	NULL
is	NULL
observed	NULL
if	NULL
either	NULL
an	NULL
E2	NULL
binding	NULL
site	NULL
or	NULL
an	NULL
Spl	NULL
binding	NULL
site	NULL
is	NULL
present	NULL
(	NULL
34	NULL
)	NULL
.	NULL

These	NULL
results	NULL
offer	NULL
a	NULL
precedent	NULL
for	NULL
the	NULL
interaction	NULL
observed	NULL
here	NULL
between	NULL
Z	NULL
and	NULL
c-myb	NULL
in	NULL
which	NULL
the	NULL
c-myb	NULL
protein	NULL
does	NULL
not	NULL
appear	NULL
to	NULL
bind	NULL
to	NULL
the	NULL
relevant	NULL
promoter	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
carboxy-terminal	NULL
half	NULL
of	NULL
c-Myb	NULL
,	NULL
which	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
function	NULL
as	NULL
a	NULL
negative	NULL
regulator	NULL
of	NULL
c-myb	NULL
transactivation	NULL
(	NULL
46	NULL
)	NULL
,	NULL
contains	NULL
a	NULL
putative	NULL
leucine	NULL
zipper	NULL
motif	NULL
and	NULL
could	NULL
potentially	NULL
interact	NULL
with	NULL
the	NULL
Z	NULL
protein	NULL
through	NULL
this	NULL
region	NULL
.	NULL

Alternatively	NULL
,	NULL
protein-protein	NULL
interactions	NULL
between	NULL
c-myb	NULL
and	NULL
Z	NULL
might	NULL
involve	NULL
the	NULL
DNA	NULL
binding	NULL
domain	NULL
of	NULL
c-Myb	NULL
,	NULL
which	NULL
was	NULL
found	NULL
in	NULL
this	NULL
study	NULL
to	NULL
be	NULL
required	NULL
for	NULL
synergy	NULL
with	NULL
Z	NULL
.	NULL

At	NULL
this	NULL
point	NULL
,	NULL
however	NULL
,	NULL
we	NULL
have	NULL
no	NULL
evidence	NULL
that	NULL
direct	NULL
protein-protein	NULL
interactions	NULL
between	NULL
Z	NULL
and	NULL
c-myb	NULL
occur	NULL
.	NULL

Specifically	NULL
,	NULL
we	NULL
have	NULL
not	NULL
found	NULL
that	NULL
the	NULL
combination	NULL
of	NULL
Z	NULL
and	NULL
c-myb	NULL
affects	NULL
Z	NULL
or	NULL
c-myb	NULL
protein	NULL
binding	NULL
to	NULL
the	NULL
BMRF1L	NULL
promoter	NULL
in	NULL
vitro	NULL
(	NULL
252	NULL
)	NULL
.	NULL

Regardless	NULL
of	NULL
the	NULL
precise	NULL
mechanism	NULL
,	NULL
our	NULL
demonstration	NULL
that	NULL
the	NULL
c-myb	NULL
protein	NULL
can	NULL
interact	NULL
synergistically	NULL
with	NULL
Z	NULL
to	NULL
activate	NULL
not	NULL
only	NULL
the	NULL
EBV	NULL
BMRF1	NULL
promoter	NULL
but	NULL
also	NULL
the	NULL
SV40	NULL
early	NULL
promoter	NULL
suggests	NULL
that	NULL
c-myb	NULL
is	NULL
likely	NULL
to	NULL
have	NULL
similar	NULL
synergistic	NULL
interactions	NULL
with	NULL
cellular	NULL
transcription	NULL
factors	NULL
.	NULL

Whether	NULL
the	NULL
synergistic	NULL
interaction	NULL
demonstrated	NULL
here	NULL
between	NULL
Z	NULL
and	NULL
c-myb	NULL
is	NULL
important	NULL
in	NULL
EBV	NULL
infection	NULL
remains	NULL
to	NULL
be	NULL
determined	NULL
.	NULL

We	NULL
have	NULL
preliminary	NULL
data	NULL
that	NULL
several	NULL
other	NULL
EBV	NULL
early	NULL
promoters	NULL
are	NULL
transactivated	NULL
more	NULL
Vor	NULL
.	NULL

12	NULL
,	NULL
1992	NULL
efficiently	NULL
in	NULL
lymphoid	NULL
cells	NULL
by	NULL
the	NULL
combination	NULL
of	NULL
Z	NULL
and	NULL
c-myb	NULL
than	NULL
by	NULL
Z	NULL
alone	NULL
(	NULL
25a	NULL
)	NULL
.	NULL

It	NULL
is	NULL
known	NULL
that	NULL
c-myb	NULL
expression	NULL
in	NULL
pre-B	NULL
cells	NULL
is	NULL
much	NULL
higher	NULL
than	NULL
in	NULL
mature	NULL
B	NULL
cells	NULL
(	NULL
1	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
EBV	NULL
infection	NULL
of	NULL
precursor	NULL
B-cell	NULL
lines	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
unusually	NULL
productive	NULL
in	NULL
comparison	NULL
with	NULL
infection	NULL
of	NULL
mature	NULL
B-cell	NULL
lines	NULL
(	NULL
18	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
high	NULL
constitutive	NULL
expression	NULL
of	NULL
c-myb	NULL
in	NULL
precursor	NULL
B	NULL
cells	NULL
might	NULL
facilitate	NULL
productive	NULL
viral	NULL
infection	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
Z	NULL
alone	NULL
to	NULL
function	NULL
efficiently	NULL
in	NULL
HeLa	NULL
cells	NULL
but	NULL
not	NULL
Jurkat	NULL
cells	NULL
is	NULL
somewhat	NULL
paradoxical	NULL
,	NULL
since	NULL
the	NULL
level	NULL
of	NULL
endogenous	NULL
c-myb	NULL
would	NULL
be	NULL
expected	NULL
to	NULL
be	NULL
higher	NULL
in	NULL
Jurkat	NULL
cells	NULL
(	NULL
38	NULL
)	NULL
.	NULL

However	NULL
,	NULL
it	NULL
is	NULL
quite	NULL
possible	NULL
that	NULL
the	NULL
level	NULL
of	NULL
total	NULL
myb	NULL
activity	NULL
(	NULL
including	NULL
A-myb	NULL
and	NULL
B-myb	NULL
)	NULL
is	NULL
higher	NULL
in	NULL
HeLa	NULL
cells	NULL
,	NULL
accounting	NULL
for	NULL
the	NULL
increased	NULL
efficiency	NULL
of	NULL
Z	NULL
in	NULL
this	NULL
cell	NULL
type	NULL
.	NULL

The	NULL
B-myb	NULL
gene	NULL
product	NULL
,	NULL
which	NULL
is	NULL
present	NULL
in	NULL
a	NULL
wide	NULL
variety	NULL
of	NULL
cells	NULL
(	NULL
42	NULL
)	NULL
,	NULL
is	NULL
now	NULL
known	NULL
to	NULL
bind	NULL
to	NULL
c-Myb	NULL
binding	NULL
sites	NULL
and	NULL
function	NULL
as	NULL
a	NULL
transcriptional	NULL
transactivator	NULL
(	NULL
39	NULL
)	NULL
.	NULL

We	NULL
do	NULL
not	NULL
yet	NULL
know	NULL
whether	NULL
B-myb	NULL
,	NULL
like	NULL
c-myb	NULL
,	NULL
can	NULL
interact	NULL
synergistically	NULL
with	NULL
the	NULL
Z	NULL
transactivator	NULL
.	NULL

Since	NULL
HeLa	NULL
cells	NULL
are	NULL
known	NULL
to	NULL
contain	NULL
papillomavirus	NULL
,	NULL
it	NULL
is	NULL
also	NULL
possible	NULL
that	NULL
a	NULL
papillomavirus-encoded	NULL
protein	NULL
can	NULL
substitute	NULL
for	NULL
the	NULL
c-Myb	NULL
function	NULL
.	NULL

Alternatively	NULL
,	NULL
the	NULL
inherent	NULL
differences	NULL
in	NULL
the	NULL
transcriptional	NULL
environment	NULL
in	NULL
Jurkat	NULL
versus	NULL
HeLa	NULL
cells	NULL
may	NULL
dictate	NULL
a	NULL
requirement	NULL
for	NULL
c-myb	NULL
helper	NULL
function	NULL
in	NULL
the	NULL
first	NULL
cell	NULL
type	NULL
which	NULL
is	NULL
unnecessary	NULL
in	NULL
the	NULL
second	NULL
.	NULL

There	NULL
is	NULL
some	NULL
evidence	NULL
that	NULL
an	NULL
EBV-encoded	NULL
IE	NULL
gene	NULL
product	NULL
,	NULL
BRLFI	NULL
(	NULL
R	NULL
)	NULL
(	NULL
19	NULL
,	NULL
20	NULL
)	NULL
,	NULL
may	NULL
provide	NULL
a	NULL
functional	NULL
substitute	NULL
for	NULL
c-myb	NULL
in	NULL
activation	NULL
of	NULL
the	NULL
BMRF1	NULL
promoter	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
shown	NULL
that	NULL
the	NULL
R	NULL
gene	NULL
product	NULL
,	NULL
like	NULL
c-Myb	NULL
,	NULL
can	NULL
interact	NULL
synergistically	NULL
with	NULL
Z	NULL
in	NULL
activating	NULL
the	NULL
BMRF1	NULL
promoter	NULL
in	NULL
lymphoid	NULL
cells	NULL
but	NULL
not	NULL
epithelial	NULL
cells	NULL
(	NULL
21	NULL
)	NULL
.	NULL

We	NULL
have	NULL
also	NULL
found	NULL
that	NULL
the	NULL
R	NULL
transactivator	NULL
effect	NULL
on	NULL
c-myc	NULL
promoter	NULL
regulation	NULL
is	NULL
similar	NULL
to	NULL
the	NULL
previously	NULL
described	NULL
effect	NULL
of	NULL
c-Myb	NULL
(	NULL
10	NULL
,	NULL
19a	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
functional	NULL
similarities	NULL
between	NULL
R	NULL
and	NULL
c-Myb	NULL
are	NULL
clearly	NULL
limited	NULL
,	NULL
in	NULL
that	NULL
we	NULL
have	NULL
been	NULL
unable	NULL
to	NULL
show	NULL
that	NULL
the	NULL
R	NULL
transactivator	NULL
activates	NULL
promoter	NULL
constructs	NULL
containing	NULL
multiple	NULL
copies	NULL
of	NULL
the	NULL
consensus	NULL
myb	NULL
response	NULL
element	NULL
or	NULL
that	NULL
c-Myb	NULL
transactivates	NULL
promoter	NULL
constructs	NULL
containing	NULL
known	NULL
R-responsive	NULL
targets	NULL
(	NULL
5	NULL
,	NULL
8	NULL
,	NULL
25a	NULL
,	NULL
26	NULL
)	NULL
.	NULL

The	NULL
data	NULL
presented	NULL
in	NULL
this	NULL
report	NULL
emphasize	NULL
that	NULL
activation	NULL
of	NULL
responsive	NULL
promoters	NULL
by	NULL
Z	NULL
is	NULL
likely	NULL
to	NULL
involve	NULL
not	NULL
only	NULL
the	NULL
requirement	NULL
for	NULL
Z	NULL
binding	NULL
to	NULL
these	NULL
promoters	NULL
but	NULL
also	NULL
complex	NULL
interactions	NULL
between	NULL
the	NULL
Z	NULL
protein	NULL
and	NULL
cellular	NULL
transcription	NULL
factors	NULL
.	NULL

It	NULL
appears	NULL
that	NULL
the	NULL
cooperative	NULL
interaction	NULL
of	NULL
Z	NULL
with	NULL
other	NULL
transcription	NULL
factors	NULL
(	NULL
either	NULL
the	NULL
virally	NULL
encoded	NULL
R	NULL
transactivator	NULL
or	NULL
the	NULL
cellularly	NULL
encoded	NULL
c-myb	NULL
transactivator	NULL
)	NULL
is	NULL
required	NULL
for	NULL
maximal	NULL
Z	NULL
effect	NULL
on	NULL
the	NULL
BMRF1	NULL
promoter	NULL
in	NULL
lymphoid	NULL
cells	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
Public	NULL
Health	NULL
Service	NULL
grants	NULL
K08-CAQ01229-03	NULL
and	NULL
5-PO1-CA19014-12	NULL
from	NULL
the	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
and	NULL
grant	NULL
MV-532	NULL
from	NULL
the	NULL
American	NULL
Cancer	NULL
Society	NULL
.	NULL

We	NULL
thank	NULL
Gloria	NULL
Majette	NULL
for	NULL
preparation	NULL
of	NULL
the	NULL
manuscript	NULL
and	NULL
Joseph	NULL
Pagano	NULL
for	NULL
reviewing	NULL
the	NULL
manuscript	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Bender	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
M.	NULL
Kuehl	NULL
.	NULL

1987	NULL
.	NULL

Differential	NULL
expression	NULL
of	NULL
the	NULL
c-myb	NULL
proto-oncogene	NULL
marks	NULL
the	NULL
pre-B	NULL
cell/B	NULL
cell	NULL
junction	NULL
in	NULL
murine	NULL
B	NULL
lymphoid	NULL
tumors	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

139:3822-3827	NULL
.	NULL

2	NULL
.	NULL

Biedenkapp	NULL
,	NULL
H.	NULL
,	NULL
U.	NULL
Borgmeyer	NULL
,	NULL
A.	NULL
E.	NULL
Sippel	NULL
,	NULL
and	NULL
K.	NULL
H.	NULL
Kiemp-naver	NULL
.	NULL

1988	NULL
.	NULL

Viral	NULL
myb	NULL
oncogene	NULL
encodes	NULL
a	NULL
sequence-specific	NULL
DNA-binding	NULL
activity	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
335:835-837	NULL
.	NULL

3	NULL
.	NULL

Boyle	NULL
,	NULL
W.	NULL
,	NULL
J.	NULL
Lipsick	NULL
,	NULL
and	NULL
M.	NULL
Baluda	NULL
.	NULL

1986	NULL
.	NULL

Antibodies	NULL
to	NULL
the	NULL
evolutionarily	NULL
conserved	NULL
amino-terminal	NULL
region	NULL
of	NULL
the	NULL
v-myb	NULL
c-myb	NULL
AND	NULL
BZLF1	NULL
INTERACT	NULL
SYNERGISTICALLY	NULL
145	NULL
encoded	NULL
protein	NULL
detect	NULL
the	NULL
c-myb	NULL
protein	NULL
in	NULL
widely	NULL
divergent	NULL
metazoan	NULL
species	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
83:4685-4689	NULL
.	NULL

4	NULL
.	NULL

Chang	NULL
,	NULL
Y.-N.	NULL
,	NULL
D.	NULL
Dong	NULL
,	NULL
G.	NULL
Hayward	NULL
,	NULL
and	NULL
S.	NULL
D.	NULL
Hayward	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
Zta	NULL
transactivator	NULL
:	NULL
a	NULL
member	NULL
of	NULL
the	NULL
bZip	NULL
family	NULL
with	NULL
unique	NULL
DNA-binding	NULL
specificity	NULL
and	NULL
a	NULL
dimerization	NULL
domain	NULL
that	NULL
lacks	NULL
the	NULL
characteristic	NULL
heptad	NULL
leucine	NULL
zipper	NULL
motif	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:3358-3369	NULL
.	NULL

5	NULL
.	NULL

Chevallier-Greco	NULL
,	NULL
A.	NULL
,	NULL
H.	NULL
Gruffat	NULL
,	NULL
E.	NULL
Manet	NULL
,	NULL
A.	NULL
Calender	NULL
,	NULL
and	NULL
A	NULL
.	NULL

Sergeant	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
DR	NULL
enhancer	NULL
contains	NULL
two	NULL
functionally	NULL
different	NULL
domains	NULL
:	NULL
domain	NULL
A	NULL
is	NULL
constitutive	NULL
and	NULL
cell	NULL
specific	NULL
,	NULL
domain	NULL
B	NULL
is	NULL
transactivated	NULL
by	NULL
the	NULL
EBV	NULL
early	NULL
protein	NULL
R.	NULL
J.	NULL
Virol	NULL
.	NULL

63:615-623	NULL
.	NULL

6	NULL
.	NULL

Chevallier-Greco	NULL
,	NULL
A.	NULL
,	NULL
H.	NULL
Gruffat	NULL
,	NULL
E.	NULL
Manet	NULL
,	NULL
P.	NULL
Chavrier	NULL
,	NULL
C.	NULL
Mosnier	NULL
,	NULL
J.	NULL
Daillie	NULL
,	NULL
and	NULL
A	NULL
.	NULL

Sergeant	NULL
.	NULL

1986	NULL
.	NULL

Both	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
-encoded	NULL
transactivators	NULL
,	NULL
EBl	NULL
and	NULL
EB2	NULL
,	NULL
are	NULL
required	NULL
to	NULL
activate	NULL
transcription	NULL
from	NULL
an	NULL
EBV	NULL
early	NULL
promoter	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

5:3243-3249	NULL
.	NULL

7	NULL
.	NULL

Countryman	NULL
,	NULL
J.	NULL
,	NULL
H.	NULL
Jenson	NULL
,	NULL
R.	NULL
Seibl	NULL
,	NULL
H.	NULL
Wolf	NULL
,	NULL
and	NULL
G.	NULL
Miller	NULL
.	NULL

1987	NULL
.	NULL

Polymorphic	NULL
proteins	NULL
encoded	NULL
within	NULL
the	NULL
BZLF1l	NULL
of	NULL
defective	NULL
and	NULL
standard	NULL
Epstein-Barr	NULL
viruses	NULL
disrupt	NULL
latency	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

61:3672-3679	NULL
.	NULL

8	NULL
.	NULL

Cox	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
J.	NULL
Leahy	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Hardwick	NULL
.	NULL

1990	NULL
.	NULL

An	NULL
enhancer	NULL
within	NULL
the	NULL
divergent	NULL
promoter	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
responds	NULL
synergistically	NULL
to	NULL
the	NULL
R	NULL
and	NULL
Z	NULL
transactivators	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:313-321	NULL
.	NULL

9	NULL
.	NULL

Diamond	NULL
,	NULL
M.	NULL
,	NULL
J	NULL
.	NULL

Miner	NULL
,	NULL
S.	NULL
Yoshinaga	NULL
,	NULL
and	NULL
K.	NULL
Yamamoto	NULL
.	NULL

1990	NULL
.	NULL

Transcription	NULL
factor	NULL
interactions	NULL
:	NULL
selectors	NULL
of	NULL
positive	NULL
or	NULL
negative	NULL
regulation	NULL
from	NULL
a	NULL
single	NULL
DNA	NULL
element	NULL
.	NULL

Science	NULL
249:1266-1272	NULL
.	NULL

10	NULL
.	NULL

Evans	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
T.	NULL
L.	NULL
Moore	NULL
,	NULL
W.	NULL
M.	NULL
Kuehl	NULL
,	NULL
T.	NULL
Bender	NULL
,	NULL
and	NULL
J.	NULL
P.-Y	NULL
.	NULL

Ting	NULL
.	NULL

1990	NULL
.	NULL

Functional	NULL
analysis	NULL
of	NULL
c-Myb	NULL
protein	NULL
in	NULL
T-lympho-cytic	NULL
cell	NULL
lines	NULL
shows	NULL
that	NULL
it	NULL
trans-activates	NULL
the	NULL
c-myc	NULL
promoter	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

10:5747-5752	NULL
.	NULL

11	NULL
.	NULL

Farrell	NULL
,	NULL
P.	NULL
,	NULL
D.	NULL
Rowe	NULL
,	NULL
C.	NULL
Rooney	NULL
,	NULL
and	NULL
J.	NULL
T.	NULL
Kouzarides	NULL
.	NULL

1989	NULL
.	NULL

Epstein-Barr	NULL
virus	NULL
BZLF1	NULL
trans-activator	NULL
specifically	NULL
binds	NULL
to	NULL
consensus	NULL
AP-1	NULL
site	NULL
and	NULL
is	NULL
related	NULL
to	NULL
c-fos	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

8:127-132	NULL
.	NULL

12	NULL
.	NULL

Favaloro	NULL
,	NULL
J.	NULL
,	NULL
R.	NULL
Treisman	NULL
,	NULL
and	NULL
R.	NULL
Kamen	NULL
.	NULL

1980	NULL
.	NULL

Transcription	NULL
maps	NULL
of	NULL
polyoma	NULL
virus-specific	NULL
RNA	NULL
;	NULL
analysis	NULL
by	NULL
two	NULL
dimensional	NULL
S1	NULL
gel	NULL
mapping	NULL
.	NULL

Methods	NULL
Enzymol	NULL
.	NULL

65:718-728	NULL
.	NULL

13	NULL
.	NULL

Flemington	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
S.	NULL
H.	NULL
Speck	NULL
.	NULL

1990	NULL
.	NULL

Autoregulation	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
putative	NULL
lytic	NULL
switch	NULL
gene	NULL
BZLF1	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:1227-1232	NULL
.	NULL

14	NULL
.	NULL

Garcia	NULL
,	NULL
A.	NULL
,	NULL
K.	NULL
Montagne	NULL
,	NULL
D.	NULL
Reavis	NULL
,	NULL
U.	NULL
Stober-Grasser	NULL
,	NULL
and	NULL
J.	NULL
Lipsick	NULL
.	NULL

1991	NULL
.	NULL

Determinants	NULL
of	NULL
sequence-specific	NULL
DNA-binding	NULL
by	NULL
p48	NULL
v-myb	NULL
.	NULL

Oncogene	NULL
6:265-273	NULL
.	NULL

15	NULL
.	NULL

Gilman	NULL
,	NULL
M.	NULL
1988	NULL
.	NULL

Preparation	NULL
of	NULL
cytoplasmic	NULL
RNA	NULL
from	NULL
tissue	NULL
culture	NULL
cells	NULL
,	NULL
p.	NULL
4.1.2-4.1.6	NULL
.	NULL

In	NULL
F.	NULL
M.	NULL
Ausubel	NULL
,	NULL
R.	NULL
Brent	NULL
,	NULL
R.	NULL
E.	NULL
Kingston	NULL
,	NULL
D.	NULL
D.	NULL
Moore	NULL
,	NULL
J.	NULL
G.	NULL
Seidman	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Smith	NULL
,	NULL
and	NULL
K.	NULL
Struhl	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Current	NULL
protocols	NULL
in	NULL
molecular	NULL
biology	NULL
.	NULL

Greene	NULL
Publishing	NULL
Associates	NULL
and	NULL
Wiley	NULL
Interscience	NULL
,	NULL
New	NULL
York	NULL
.	NULL

16	NULL
.	NULL

Giot	NULL
,	NULL
J.-F.	NULL
,	NULL
I.	NULL
Mikaelian	NULL
,	NULL
M.	NULL
Buisson	NULL
,	NULL
E.	NULL
Manet	NULL
,	NULL
I.	NULL
Joab	NULL
,	NULL
J.-C.	NULL
Nicolas	NULL
,	NULL
and	NULL
A	NULL
.	NULL

Sergeant	NULL
.	NULL

1991	NULL
.	NULL

Transcriptional	NULL
synergy	NULL
and	NULL
interference	NULL
between	NULL
the	NULL
EBV	NULL
transcription	NULL
factors	NULL
EB1	NULL
and	NULL
R	NULL
require	NULL
both	NULL
the	NULL
basic	NULL
region	NULL
and	NULL
the	NULL
activation	NULL
domain	NULL
2	NULL
of	NULL
EB1	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

19:1251-1258	NULL
.	NULL

17	NULL
.	NULL

Gorman	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
L.	NULL
F.	NULL
Moffat	NULL
,	NULL
and	NULL
B.	NULL
H.	NULL
Howard	NULL
.	NULL

1982	NULL
.	NULL

Recombinant	NULL
genomes	NULL
which	NULL
express	NULL
chloramphenicol	NULL
acetyltransferase	NULL
in	NULL
mammalian	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

2:1044-1051	NULL
.	NULL

18	NULL
.	NULL

Gregory	NULL
,	NULL
C.	NULL
,	NULL
C.	NULL
Kirchgens	NULL
,	NULL
C.	NULL
Edwards	NULL
,	NULL
L.	NULL
Young	NULL
,	NULL
M.	NULL
Rowe	NULL
,	NULL
A.	NULL
Forster	NULL
,	NULL
T.	NULL
Rabbits	NULL
,	NULL
and	NULL
A.	NULL
Rickenson	NULL
.	NULL

1987	NULL
.	NULL

Epstein-Barr	NULL
virus-transformed	NULL
human	NULL
precursor	NULL
B	NULL
cell	NULL
lines	NULL
:	NULL
altered	NULL
growth	NULL
phenotype	NULL
of	NULL
lines	NULL
with	NULL
germ-line	NULL
or	NULL
rearranged	NULL
but	NULL
nonex-pressed	NULL
heavy	NULL
chain	NULL
genes	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

17:1199-1207	NULL
.	NULL

19	NULL
.	NULL

Gruffat	NULL
,	NULL
H.	NULL
,	NULL
E.	NULL
Manet	NULL
,	NULL
A.	NULL
Rigolet	NULL
,	NULL
and	NULL
A	NULL
.	NULL

Sergeant	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
enhancer	NULL
factor	NULL
R	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
is	NULL
a	NULL
sequence-specific	NULL
DNA	NULL
binding	NULL
protein	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

18:6835-6843	NULL
.	NULL

19a.Gutsch	NULL
,	NULL
D.	NULL
Unpublished	NULL
data	NULL
.	NULL

20	NULL
.	NULL

Hardwick	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
P.	NULL
Lieberman	NULL
,	NULL
and	NULL
S.	NULL
D.	NULL
Hayward	NULL
.	NULL

1988	NULL
.	NULL

A	NULL
new	NULL
Epstein-Barr	NULL
virus	NULL
transactivator	NULL
,	NULL
R	NULL
,	NULL
induces	NULL
expression	NULL
of	NULL
a	NULL
cytoplasmic	NULL
early	NULL
antigen	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

62:2274-2284	NULL
.	NULL

21	NULL
.	NULL

Holiey-Guthrie	NULL
,	NULL
E.	NULL
,	NULL
E.	NULL
B.	NULL
Quinlivan	NULL
,	NULL
E.-C.	NULL
Mar	NULL
,	NULL
and	NULL
S.	NULL
Kenney	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
promoter	NULL
for	NULL
early	NULL
antigen	NULL
(	NULL
EA-D	NULL
)	NULL
146	NULL
22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

25a	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

KENNEY	NULL
ET	NULL
AL	NULL
.	NULL

is	NULL
regulated	NULL
by	NULL
the	NULL
EBV	NULL
transactivators	NULL
,	NULL
BRLF1	NULL
and	NULL
BZLF1	NULL
,	NULL
in	NULL
a	NULL
cell-specific	NULL
manner	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:3753-3759	NULL
.	NULL

Howe	NULL
,	NULL
K.	NULL
M.	NULL
,	NULL
C.	NULL
F.	NULL
L.	NULL
Reakes	NULL
,	NULL
and	NULL
R.	NULL
J.	NULL
Watson	NULL
.	NULL

1990	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
sequence-specific	NULL
interaction	NULL
of	NULL
mouse	NULL
c-myb	NULL
protein	NULL
with	NULL
DNA	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

9:161-169	NULL
.	NULL

Ibanez	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
J.	NULL
Lipsick	NULL
.	NULL

1988	NULL
.	NULL

Structural	NULL
and	NULL
functional	NULL
domains	NULL
of	NULL
the	NULL
myb	NULL
oncogene	NULL
:	NULL
requirements	NULL
for	NULL
nuclear	NULL
trans-port	NULL
,	NULL
myeloid	NULL
transformation	NULL
,	NULL
and	NULL
colony	NULL
formation	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

62:1981-1988	NULL
.	NULL

Ibanez	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
J.	NULL
Lipsick	NULL
.	NULL

1990	NULL
.	NULL

Transactivation	NULL
of	NULL
gene	NULL
expression	NULL
by	NULL
v-myb	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

10:2285-2293	NULL
.	NULL

Introna	NULL
,	NULL
M.	NULL
,	NULL
J.	NULL
Golay	NULL
,	NULL
J.	NULL
Frampton	NULL
,	NULL
T.	NULL
Nakano	NULL
,	NULL
S.	NULL
Ness	NULL
,	NULL
and	NULL
T.	NULL
Graf	NULL
.	NULL

1990	NULL
.	NULL

Mutations	NULL
in	NULL
v-myb	NULL
alter	NULL
the	NULL
differentiation	NULL
of	NULL
myelomonocytic	NULL
cells	NULL
transformed	NULL
by	NULL
the	NULL
oncogene	NULL
.	NULL

Cell	NULL
63	NULL
:	NULL
1287-1297	NULL
.	NULL

Kenney	NULL
,	NULL
S.	NULL
Unpublished	NULL
data	NULL
.	NULL

Kenney	NULL
,	NULL
S.	NULL
,	NULL
E.	NULL
Holley-Guthrie	NULL
,	NULL
E.	NULL
C.	NULL
Mar	NULL
,	NULL
and	NULL
M.	NULL
Smith	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
BMLF1	NULL
promoter	NULL
contains	NULL
an	NULL
enhancer	NULL
element	NULL
that	NULL
is	NULL
responsive	NULL
to	NULL
the	NULL
BZLF1	NULL
and	NULL
BRLF1	NULL
transactivators	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:3878-3883	NULL
.	NULL

Klempnauer	NULL
,	NULL
K.-H.	NULL
,	NULL
H.	NULL
Arnold	NULL
,	NULL
and	NULL
H.	NULL
Biedenkapp	NULL
.	NULL

1989	NULL
.	NULL

Activation	NULL
of	NULL
transcription	NULL
by	NULL
v-myb	NULL
:	NULL
evidence	NULL
for	NULL
two	NULL
different	NULL
mechanisms	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

3:1582-1589	NULL
.	NULL

Klempnauer	NULL
,	NULL
K.-H.	NULL
,	NULL
and	NULL
A.	NULL
E.	NULL
Sippel	NULL
.	NULL

1987	NULL
.	NULL

The	NULL
highly	NULL
conserved	NULL
amino-terminal	NULL
region	NULL
of	NULL
the	NULL
protein	NULL
encoded	NULL
by	NULL
the	NULL
v-myb	NULL
oncogene	NULL
functions	NULL
as	NULL
a	NULL
DNA-binding	NULL
domain	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

6:2719-2725	NULL
.	NULL

Kouzarides	NULL
,	NULL
T.	NULL
,	NULL
G.	NULL
Packham	NULL
,	NULL
A.	NULL
Cook	NULL
,	NULL
and	NULL
P.	NULL
Farrell	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
BZLF1	NULL
protein	NULL
of	NULL
EBV	NULL
has	NULL
a	NULL
coiled	NULL
coil	NULL
dimerization	NULL
domain	NULL
without	NULL
a	NULL
heptad	NULL
leucine	NULL
repeat	NULL
but	NULL
homology	NULL
to	NULL
the	NULL
C/EBP	NULL
leucine	NULL
zipper	NULL
.	NULL

Oncogene	NULL
6:195-204	NULL
.	NULL

Kunkel	NULL
,	NULL
T.	NULL
A	NULL
.	NULL

1985	NULL
.	NULL

Rapid	NULL
and	NULL
efficient	NULL
site-specific	NULL
mutagenesis	NULL
without	NULL
phenotypic	NULL
selection	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
82:488-492	NULL
.	NULL

Laimins	NULL
,	NULL
L.	NULL
,	NULL
P.	NULL
Gruss	NULL
,	NULL
R.	NULL
Pozatti	NULL
,	NULL
and	NULL
G.	NULL
Khoury	NULL
.	NULL

1984	NULL
.	NULL

Characterization	NULL
of	NULL
enhancer	NULL
elements	NULL
in	NULL
the	NULL
long	NULL
terminal	NULL
repeat	NULL
of	NULL
Moloney	NULL
murine	NULL
sarcoma	NULL
virus	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

49	NULL
;	NULL
183-189	NULL
.	NULL

Lane	NULL
,	NULL
T.	NULL
,	NULL
C.	NULL
Ibanez	NULL
,	NULL
A.	NULL
Garcia	NULL
,	NULL
T.	NULL
Graf	NULL
,	NULL
and	NULL
J.	NULL
Lipsick	NULL
.	NULL

1990	NULL
.	NULL

Transformation	NULL
by	NULL
v-myb	NULL
correlates	NULL
with	NULL
transactivation	NULL
of	NULL
gene	NULL
expression	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

10:2591-2598	NULL
.	NULL

Lee	NULL
,	NULL
W.	NULL
,	NULL
P.	NULL
Mitchell	NULL
,	NULL
and	NULL
R.	NULL
Tjian	NULL
.	NULL

1987	NULL
.	NULL

Purified	NULL
transcription	NULL
factor	NULL
AP-1	NULL
interacts	NULL
with	NULL
TPA-inducible	NULL
enhancer	NULL
elements	NULL
.	NULL

Cell	NULL
49	NULL
;	NULL
741-752	NULL
.	NULL

Li	NULL
,	NULL
R.	NULL
,	NULL
J.	NULL
Knight	NULL
,	NULL
S.	NULL
Jackson	NULL
,	NULL
R.	NULL
Tjian	NULL
,	NULL
and	NULL
M.	NULL
Botchan	NULL
.	NULL

1991	NULL
.	NULL

Direct	NULL
interaction	NULL
between	NULL
the	NULL
Spl	NULL
and	NULL
the	NULL
BPV	NULL
enhancer	NULL
E2	NULL
protein	NULL
mediates	NULL
synergistic	NULL
activation	NULL
of	NULL
transcription	NULL
.	NULL

Cell	NULL
65:493-505	NULL
.	NULL

Lieberman	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
A.	NULL
Berk	NULL
.	NULL

1990	NULL
.	NULL

In	NULL
vitro	NULL
transcriptional	NULL
activation	NULL
,	NULL
dimerization	NULL
,	NULL
and	NULL
DNA-binding	NULL
specificity	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
Zta	NULL
protein	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:2560-2568	NULL
.	NULL

Lillie	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
M.	NULL
Green	NULL
.	NULL

1989	NULL
.	NULL

Transcription	NULL
activation	NULL
by	NULL
the	NULL
adenovirus	NULL
Ela	NULL
protein	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
338:39-44	NULL
.	NULL

Lipsick	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
and	NULL
W.	NULL
J.	NULL
Boyle	NULL
.	NULL

1987.	NULL
c-myh	NULL
expression	NULL
is	NULL
a	NULL
late	NULL
event	NULL
during	NULL
T-lymphocyte	NULL
activation	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

7:3358-3360	NULL
.	NULL

Luscher	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
B.	NULL
Eisenman	NULL
.	NULL

1990	NULL
.	NULL

New	NULL
light	NULL
on	NULL
myc	NULL
and	NULL
myb	NULL
.	NULL

Part	NULL
II	NULL
.	NULL

Myb	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

4:2235-2241	NULL
.	NULL

Mizuguchi	NULL
,	NULL
G.	NULL
,	NULL
H.	NULL
Nakagoshi	NULL
,	NULL
T.	NULL
Nagase	NULL
,	NULL
N.	NULL
Nomura	NULL
,	NULL
T.	NULL
Date	NULL
,	NULL
Y	NULL
,	NULL
Ueno	NULL
,	NULL
and	NULL
S.	NULL
Ishii	NULL
.	NULL

1990	NULL
.	NULL

DNA	NULL
binding	NULL
activity	NULL
and	NULL
transcriptional	NULL
activator	NULL
function	NULL
of	NULL
the	NULL
human	NULL
B-myb	NULL
protein	NULL
compared	NULL
with	NULL
c-myb	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

265:9280-9284	NULL
.	NULL

Nakagoshi	NULL
,	NULL
H.	NULL
,	NULL
T.	NULL
Nagase	NULL
,	NULL
Y.	NULL
Ueno	NULL
,	NULL
and	NULL
S.	NULL
Ishii	NULL
.	NULL

1989	NULL
.	NULL

Transcriptional	NULL
transrepression	NULL
by	NULL
the	NULL
c-myb	NULL
proto-oncogene	NULL
prod-uct	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

17:7315-7324	NULL
.	NULL

Nishina	NULL
,	NULL
Y.	NULL
,	NULL
H.	NULL
Nakagoshi	NULL
,	NULL
F.	NULL
Imamoto	NULL
,	NULL
T.	NULL
J.	NULL
Gonda	NULL
,	NULL
and	NULL
S.	NULL
Ishii	NULL
.	NULL

1989	NULL
.	NULL

Trans-activation	NULL
by	NULL
the	NULL
c-myb	NULL
proto-oncogene	NULL
.	NULL

Nucleic	NULL
Acid	NULL
Res	NULL
.	NULL

17:107-117	NULL
.	NULL

Nomura	NULL
,	NULL
N.	NULL
,	NULL
M.	NULL
Takahashi	NULL
,	NULL
M.	NULL
Matsui	NULL
,	NULL
S.	NULL
Ishii	NULL
,	NULL
T.	NULL
Date	NULL
,	NULL
S.	NULL
43	NULL
.	NULL

Mor	NULL
.	NULL

CELL	NULL
.	NULL

Bor	NULL
.	NULL

Sasamoto	NULL
,	NULL
and	NULL
R.	NULL
Ishizaki	NULL
.	NULL

1988	NULL
.	NULL

Isolation	NULL
of	NULL
human	NULL
cDNA	NULL
clones	NULL
of	NULL
myb-related	NULL
genes	NULL
,	NULL
A-myb	NULL
and	NULL
B-myb	NULL
.	NULL

Nucleic	NULL
Acid	NULL
Res	NULL
.	NULL

16:11075-11085	NULL
.	NULL

Packham	NULL
,	NULL
G.	NULL
,	NULL
A.	NULL
Economou	NULL
,	NULL
C.	NULL
Rooney	NULL
,	NULL
D.	NULL
Rowe	NULL
,	NULL
and	NULL
P.	NULL
Farrell	NULL
.	NULL

1990	NULL
.	NULL

Structure	NULL
and	NULL
function	NULL
of	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
BZLF1	NULL
protein	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:2110-2116	NULL
.	NULL

43a.Quinlivan	NULL
,	NULL
E.	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Submitted	NULL
for	NULL
publication	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

59	NULL
.	NULL

60	NULL
.	NULL

Rooney	NULL
,	NULL
C.	NULL
,	NULL
N.	NULL
Taylor	NULL
,	NULL
J.	NULL
Countryman	NULL
,	NULL
H.	NULL
Jenson	NULL
,	NULL
J.	NULL
Kolman	NULL
,	NULL
and	NULL
G.	NULL
Miller	NULL
.	NULL

1988	NULL
.	NULL

Genome	NULL
rearrangements	NULL
activate	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
gene	NULL
whose	NULL
product	NULL
disrupts	NULL
latency	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85:9801-9805	NULL
.	NULL

Rooney	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
D.	NULL
T.	NULL
Rowe	NULL
,	NULL
T.	NULL
Ragot	NULL
,	NULL
and	NULL
P.	NULL
J.	NULL
Farrell	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
spliced	NULL
BZLF1	NULL
gene	NULL
of	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
transactivates	NULL
an	NULL
early	NULL
EBV	NULL
promoter	NULL
and	NULL
induces	NULL
the	NULL
virus	NULL
productive	NULL
cycle	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:3109-3116	NULL
.	NULL

Sakura	NULL
,	NULL
H.	NULL
,	NULL
C.	NULL
Kanei-Ishii	NULL
,	NULL
T.	NULL
Nagase	NULL
,	NULL
H.	NULL
Nakagoshi	NULL
,	NULL
T.	NULL
Gonda	NULL
,	NULL
and	NULL
S.	NULL
Ishii	NULL
.	NULL

1989	NULL
.	NULL

Delineation	NULL
of	NULL
three	NULL
functional	NULL
domains	NULL
of	NULL
the	NULL
transcriptional	NULL
activator	NULL
encoded	NULL
by	NULL
the	NULL
c-myb	NULL
proto-oncogene	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86:5758-5762	NULL
.	NULL

Shen-ong	NULL
,	NULL
G.	NULL
,	NULL
B.	NULL
Luscher	NULL
,	NULL
and	NULL
R.	NULL
Eisenman	NULL
.	NULL

1989	NULL
.	NULL

A	NULL
second	NULL
c-myb	NULL
protein	NULL
is	NULL
translated	NULL
from	NULL
an	NULL
alternatively	NULL
spliced	NULL
mRNA	NULL
expressed	NULL
from	NULL
normal	NULL
and	NULL
5	NULL
'	NULL
disrupted	NULL
myb	NULL
loci	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

9:5456-5463	NULL
.	NULL

Takada	NULL
,	NULL
K.	NULL
,	NULL
N.	NULL
Shimuzu	NULL
,	NULL
S.	NULL
Sakuma	NULL
,	NULL
and	NULL
Y.	NULL
Ono	NULL
.	NULL

1986	NULL
.	NULL

Transactivation	NULL
of	NULL
the	NULL
latent	NULL
Epstein-Barr	NULL
virus	NULL
(	NULL
EBV	NULL
)	NULL
genome	NULL
after	NULL
transfection	NULL
of	NULL
the	NULL
EBV	NULL
DNA	NULL
fragment	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

57:1016-1022	NULL
.	NULL

Takimoto	NULL
,	NULL
T.	NULL
,	NULL
H.	NULL
Ogura	NULL
,	NULL
H.	NULL
Sato	NULL
,	NULL
R.	NULL
Umeda	NULL
,	NULL
and	NULL
M.	NULL
Hatano	NULL
.	NULL

1985	NULL
.	NULL

Isolation	NULL
of	NULL
transforming	NULL
and	NULL
early	NULL
antigen-producing	NULL
Epstein-Barr	NULL
virus	NULL
from	NULL
nasopharyngeal	NULL
carcinoma	NULL
hybrid	NULL
cells	NULL
(	NULL
NPC-KT	NULL
)	NULL
.	NULL

J.	NULL
Natl	NULL
.	NULL

Cancer	NULL
Inst	NULL
.	NULL

74	NULL
;	NULL
57-59	NULL
.	NULL

Taylor	NULL
,	NULL
N.	NULL
,	NULL
E.	NULL
Flemington	NULL
,	NULL
J.	NULL
Kolman	NULL
,	NULL
R.	NULL
Baumann	NULL
,	NULL
S.	NULL
Speck	NULL
,	NULL
and	NULL
G.	NULL
Miller	NULL
.	NULL

1991	NULL
.	NULL

ZEBRA	NULL
and	NULL
a	NULL
Fos-GCN4	NULL
chimeric	NULL
protein	NULL
differ	NULL
in	NULL
their	NULL
DNA-binding	NULL
specificities	NULL
for	NULL
sites	NULL
in	NULL
the	NULL
Epstein-Barr	NULL
virus	NULL
BZLF1	NULL
promoter	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

65:4033-4041	NULL
.	NULL

Thiele	NULL
,	NULL
C.	NULL
,	NULL
P.	NULL
S.	NULL
Cohen	NULL
,	NULL
and	NULL
M.	NULL
S.	NULL
Israel	NULL
.	NULL

1988	NULL
.	NULL

Regulation	NULL
of	NULL
c-myb	NULL
expression	NULL
in	NULL
human	NULL
neuroblastoma	NULL
cells	NULL
during	NULL
retinoic	NULL
acid-induced	NULL
differentiation	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

8:1677-1683	NULL
.	NULL

Thompson	NULL
,	NULL
C.	NULL
B.	NULL
,	NULL
P.	NULL
B.	NULL
Challoner	NULL
,	NULL
P.	NULL
E.	NULL
Neiman	NULL
,	NULL
and	NULL
M.	NULL
Groudine	NULL
.	NULL

1986	NULL
.	NULL

Expression	NULL
of	NULL
the	NULL
c-myb	NULL
proto-oncogene	NULL
during	NULL
cellular	NULL
proliferation	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
319:374-380	NULL
.	NULL

Tice-Baldwin	NULL
,	NULL
K.	NULL
,	NULL
G.	NULL
Fink	NULL
,	NULL
and	NULL
K.	NULL
Arndt	NULL
.	NULL

1989	NULL
.	NULL

BAS1	NULL
has	NULL
an	NULL
Myb	NULL
motif	NULL
and	NULL
activates	NULL
HIS4	NULL
transcription	NULL
only	NULL
in	NULL
combination	NULL
with	NULL
BAS2	NULL
.	NULL

Science	NULL
246:931-935	NULL
.	NULL

Tonneguzzo	NULL
,	NULL
F.	NULL
,	NULL
A.	NULL
C.	NULL
Hayday	NULL
,	NULL
and	NULL
A.	NULL
Keating	NULL
.	NULL

1986	NULL
.	NULL

Electric	NULL
field-mediated	NULL
DNA	NULL
transfer	NULL
:	NULL
transient	NULL
and	NULL
stable	NULL
gene	NULL
expression	NULL
in	NULL
human	NULL
and	NULL
mouse	NULL
lymphoid	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

6:703-706	NULL
.	NULL

Trier	NULL
,	NULL
G.	NULL
,	NULL
M.	NULL
Buisson	NULL
,	NULL
P.	NULL
Chambard	NULL
,	NULL
and	NULL
A	NULL
.	NULL

Sergeant	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
Epstein-Barr	NULL
virus	NULL
early	NULL
protein	NULL
EBl	NULL
activates	NULL
transcription	NULL
from	NULL
different	NULL
responsive	NULL
elements	NULL
including	NULL
AP-1	NULL
binding	NULL
sites	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

8:1447-1453	NULL
.	NULL

Vinson	NULL
,	NULL
C.	NULL
R.	NULL
,	NULL
P.	NULL
B.	NULL
Sigler	NULL
,	NULL
and	NULL
S.	NULL
L.	NULL
McKnight	NULL
.	NULL

1989	NULL
.	NULL

Scissors-grip	NULL
model	NULL
for	NULL
DNA	NULL
recognition	NULL
by	NULL
a	NULL
family	NULL
of	NULL
leucine	NULL
zipper	NULL
proteins	NULL
.	NULL

Science	NULL
246:911-916	NULL
.	NULL

Weber	NULL
,	NULL
B.	NULL
,	NULL
E.	NULL
Westin	NULL
,	NULL
and	NULL
M.	NULL
Clarke	NULL
.	NULL

1990	NULL
.	NULL

Differentiation	NULL
of	NULL
mouse	NULL
erythroleukemia	NULL
cells	NULL
enhanced	NULL
by	NULL
alternatively	NULL
spliced	NULL
c-myb	NULL
mRNA	NULL
.	NULL

Science	NULL
249:1291-1293	NULL
.	NULL

Westin	NULL
,	NULL
E.	NULL
,	NULL
K.	NULL
Gorse	NULL
,	NULL
and	NULL
M.	NULL
Clarke	NULL
.	NULL

1990	NULL
.	NULL

Alternative	NULL
splicing	NULL
of	NULL
the	NULL
human	NULL
c-myb	NULL
gene	NULL
.	NULL

Oncogene	NULL
5:1117-1124	NULL
.	NULL

Weston	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Bishop	NULL
.	NULL

1989	NULL
.	NULL

Transcriptional	NULL
activation	NULL
by	NULL
the	NULL
v-myb	NULL
oncogene	NULL
and	NULL
its	NULL
cellular	NULL
progenitor	NULL
,	NULL
c-myb	NULL
.	NULL

Cell	NULL
58:85-93	NULL
.	NULL

Yang-¥en	NULL
,	NULL
H.-F.	NULL
,	NULL
J.-C.	NULL
Chambard	NULL
,	NULL
Y.-L.	NULL
Sun	NULL
,	NULL
T.	NULL
Smeal	NULL
,	NULL
T.	NULL
Schmidt	NULL
,	NULL
J.	NULL
Drouin	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1990	NULL
.	NULL

Transcription	NULL
interference	NULL
between	NULL
c-Jun	NULL
and	NULL
glucocorticoid	NULL
receptor	NULL
:	NULL
mutual	NULL
inhibition	NULL
of	NULL
DNA-binding	NULL
due	NULL
to	NULL
direct	NULL
protein-protein	NULL
interaction	NULL
.	NULL

Cell	NULL
62:1205-1215	NULL
.	NULL

